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Thesis summary 
Given the great potential of porous carrier based drug delivery  for stabilising the 
amorphous form of drugs and enhancing dissolution profiles, this thesis centred on 
investigations into the application of activated carbon (AC) and carbon onion (OLC) as 
porous carriers for oral delivery, using paracetamol (PA) and ibuprofen (IBU) as model 
drugs.  
Initial work was focussed on the toxicity studies of AC followed by preparation and 
characterisation of drug/AC complex. Results showed that AC is a promising drug carrier 
with low toxicity, high loading capacity and ability to stabilise amorphous drug. 
However, loading efficiency and solid state characteristics were different for PA and 
IBU, whilst the drug release from AC was incomplete in the absence of surfactant. 
To investigate the factors affecting drug loading, three different loading methods were 
compared, with solution adsorption followed by centrifugation found to be the optimum 
method to achieve maximum loading with least crystallinity. Initial drug concentration 
in the loading solution was also found to influence the loading, where the optimum 
concentration to achieve maximum loading without any crystallinity differed depending 
on the chemical nature of the drug. Further, the surface chemistry of AC was modified in 
order to achieve complete drug release, and results showed that drug release increased 
with an increase in the surface oxygen content of AC. Also, drug release was found to 
increase with a decrease in the micropore volume fraction.   
The second part of the work was focussed on the synthesis and characterisation of OLC, 
followed by drug loading studies. Results showed that annealing of nano-diamonds (ND) 
at 1100 ºC produced OLC with a diamond core, which is non-toxic. Drug loading studies 
revealed that loadings achieved were lower than those seen with AC, regardless of drug 
solubility.  
Of the both carriers investigated, AC was less expensive and found to be a promising 
carrier with higher loading capacity and lower toxicity. 
 
Keywords: dissolution; loading; factors; release; adsorption; activated carbon; carbon 
onion  
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1.1. Importance of solubility and dissolution profile of drugs 
About 80% of globally marketed drug dosage forms are oral delivery systems, due to low 
manufacturing costs and high patient compliance (Morishita & Peppas 2012). However, 
more than 90% of the active pharmaceutical ingredients (API) are reported to have oral 
bioavailability limitations (Fasinu et al. 2011).  
The effectiveness of an oral dosage form depends on the bioavailability of the drug, which 
in turn depends on the solubility and dissolution rate of the drug; according to the 
Biopharmaceutical Classification System (BCS), a drug is classified as highly soluble, 
when the highest dose (mg) is soluble in ≤ 250 mL of water at 37 oC over the pH range 
1-7.5, and is classified as highly permeable when the fraction of dose absorbed is more 
than 90%  (Lindenberg, Kopp et al. 2004).  
Of the 133 orally administered drugs in the WHO essential drug list, 40% were reported 
to have solubility and dissolution problems and fall under Class II (low solubility and 
high permeability) or class IV (low solubility and low permeability) of BCS (Dahan et 
al. 2013; Douroumis & Fahrenkamp 2012).  
Poor solubility and dissolution of drugs have necessitated the formulation of drugs with 
more than the required dose, leading to economic wastage and an increased risk of 
toxicity. Hence, it is very important for pharmaceutical scientists to develop effective 
techniques to improve the solubility and dissolution behaviour of poorly water-soluble 
drugs. 
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1.2. Drug delivery strategies to improve solubility and dissolution 
Solubility is the maximum amount of drug/solute that can be dissolved in the solvent, 
whereas dissolution is the rate at which this solute dissolves in the solvent. According to 
the Nernst and Brunner equation (Equation 1), dissolution of the drug in a medium is 
affected by various factors, such as solubility, the surface area of the drug, sink conditions 
of the dissolution medium and wettability of the drug (Banker et al. 2002).  
dm
dt
=
DA(Cs-C)
h
                              (Equation 1) 
Where dm/dt is the dissolution rate of the drug (m is the mass of the dissolved drug and 
t is the time); D is the diffusion coefficient of the drug, which depends on several factors, 
such as the viscosity of the dissolution medium; A is the surface area of the drug, which 
in turn depends on the particle size of the drug; Cs is the saturation solubility of the drug 
in the dissolution medium, which depends on many factors, such as intermolecular 
attractions and polarity; C is the concentration of the drug in the medium, which depends 
on the gastric permeability of the compound and volume of the dissolution media; h is 
the thickness of the diffusion layer surrounding the drug particle (Leuner & Dressman 
2000; Limnell et al. 2007; Smith 2016). 
Numerous formulation technologies have been developed to modify the aforementioned 
factors to enhance the solubility and dissolution rate of poorly water-soluble drugs (Table 
1-1); however, such strategies are often associated with limitations with regards to low 
drug loading and poor stability. One of the many solubility enhancing techniques includes 
conversion of crystalline drug to an amorphous state, since the dissolution rate of the 
amorphous form is markedly better than the crystalline form, especially in drugs with 
high crystal energy (Hancock & Zografi 1997; Salonen et al. 2008). 
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Table 1-1: Drug delivery strategies for poorly water-soluble drugs to enhance their oral bioavailability  
Strategies Advantages Limitations Reference 
Physical modification 
Particle size 
reduction 
Simple and cost 
effective. 
 
Potential degradation of 
the drug due to physical 
or thermal stress and 
potential particle 
aggregation. 
(Khadka et al. 
2014; Pouton 
2006) 
Self-emulsifying 
drug delivery 
systems 
Rapid absorption Drug precipitation upon 
dilution and potential 
toxicity of surfactant. 
(He et al. 2010; 
Wang & Zhang 
2013) 
Polymeric micelles-
drugs incorporated 
into the hydrophobic 
core 
Low critical micellar 
concentration 
compared to low 
molecular weight 
surfactants 
Poor stability and low 
solubilisation capacity. 
(Pouton 2006; 
Douroumis & 
Fahrenkamp 
2012; Biswas et 
al. 2013)  
Inclusion complex Can enhance stability 
of drugs 
Difficult large scale 
production of 
cyclodextrin and low drug 
loading efficiency. 
(Loftsson & 
Brewster 2013) 
Solid lipid 
nanoparticles 
Biocompatible, 
Controlled release 
Low drug loading and 
potential lipid aggregation 
(Sonja & Bunjes 
2013; Luo et al. 
2015) 
Amorphous drugs Better compression 
characteristics 
compared to 
crystalline drugs 
Poor stability; converts 
into crystalline form 
(Yu 2001) 
Chemical  modification 
Salt formation Absence of 
excipients 
Poor stability; difficulty 
in the identification of the 
salt form. 
(Serajuddin 2007) 
Prodrugs Simple and cost 
effective 
Reduced drug 
permeability, Poor 
chemical stability 
(Stella & Nti-
Addae 2007) 
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1.3. Amorphous drugs: Preparation methods and stabilising strategies 
Amorphous forms of drugs lack three-dimensional molecular order, resulting in higher 
solubility, unlike crystalline forms that have a long range molecular order (Figure 1-1 :). 
Molecules in an amorphous form are randomly positioned relative to each other and 
possess high free energy, which allows greater motion of molecules, thereby resulting in 
higher solubility compared to crystalline forms (Hancock & Parks 2000). 
 
Figure 1-1 :Schematic diagram of the stages of drug dissolution in amorphous and crystalline drugs 
[Adapted from (Smith 2016)]. 
 
Solubility ratio of the amorphous and crystalline forms of a drug is directly proportional 
to the difference in the Gibbs free energy (Equation 2): 
∆GT=RT ln (
 Solubilitya
Solubilityc
)                           (Equation 2) 
Where ΔG is the difference in the Gibbs free energy, R is the gas constant and T is 
temperature, a is amorphous and c is crystalline.  
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The difference in the Gibbs free energy between amorphous and crystalline form is 
determined from the enthalpy and entropy of the solid forms (Equation-3).  
∆G=∆H-(T∆S)                                         (Equation 3) 
Where ΔG is the difference in the Gibbs free energy, ΔH is the difference in the enthalpy, 
T is temperature and ΔS is the difference in the entropy.  
Amorphous forms possess higher enthalpy and entropy due to their disordered structure 
compared to the crystalline form, resulting in higher Gibbs free energy; the higher the 
difference in the Gibbs free energy between amorphous and crystalline forms, the higher 
will be the solubility of amorphous form compared to its crystalline form (Hughey & 
Williams 2012; Hancock & Parks 2000; Singhal & Curatolo 2004). 
 The amorphous form of drugs can be prepared by various methods (Hancock & Zografi 
1997; Löbmann et al. 2012; Craig et al. 1999):  
1) Melt method, which involves melting the drug followed by rapid cooling using 
liquid nitrogen. 
2) Rotary evaporation, where the drug is dissolved in an organic solvent and the 
solvent is rapidly removed under vacuum using a rotary evaporator. 
3) Spray drying, where the drug is dissolved in a suitable solvent and is sprayed into 
a drying chamber 
4) Cryo-milling, which involves milling the crystalline drug in a ball mill immersed 
in liquid nitrogen. 
5) Freeze drying, which involves freezing the aqueous solution of the drug followed 
by sublimation under vacuum. 
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However, the amorphous form of drugs often have poor stability and tend to convert back 
to crystalline forms, and this tendency is a major drawback in formulations containing 
amorphous drug (Yu 2001). Several studies have been performed to develop stabilising 
strategies for amorphous form of drugs (Table 1-2) and, in recent years, adsorption of 
drugs onto porous materials/adsorbents, to produce stabilised amorphous drugs, has 
gained increasing interest (Laitinen et al. 2013).  
 
Table 1-2: Techniques to stabilise amorphous drugs and their limitations 
Stabilization 
strategies 
Advantages Limitations References 
Solid dispersion  Biocompatibility 
and optimum 
wettability. 
High production costs and low 
drug loading efficiency. 
Carrier is hygroscopic in 
nature leading to poor stability. 
(Kalia & Poddar 
2011; Leuner & 
Dressman 2000) 
Co-amorphous 
mixtures  
Other excipients 
such as 
polymers are not 
required.  
Poor stability, molecular 
interactions, and potential co-
crystal formation. 
(Laitinen et al. 
2013) 
Adsorption/Porous 
carrier based drug 
delivery 
Controlled drug 
release. 
Expensive carrier production, 
High Potential toxicity of 
carriers. 
(Mamaeva et al. 
2013; Preisig et al. 
2014) 
 
 
1.4. Porous carrier based amorphous drug delivery 
Porous carrier based drug delivery involves adsorption of drugs on to the pores of a carrier 
and has shown great potential to produce and stabilise the amorphous form of drugs that 
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tend to convert into the crystalline state during storage. The interactions between the 
carrier and the adsorbed drug, in addition to the small pore size, restrict the crystallisation 
of the drug, resulting in a stable amorphous form. In addition to stabilisation, adsorption 
of drugs onto pores of a carrier increases the effective surface area of the drug that is in 
contact with the dissolution media, resulting in higher solubility (Salonen et al. 2008; 
Vallet-Regi et al. 2001).  
1.4.1. Adsorption  
Adsorption is a spontaneous process, where molecules (adsorbate) in a gaseous or liquid 
medium attach mainly to the surface of a solid (adsorbent), in order to partially restore 
the balance of excess forces on the surface of the adsorbent and to reduce the entropy of 
the adsorbate.  
Adsorption is of two kinds, based on the phase of the solution: 1) Liquid phase adsorption; 
and 2) gas/vapour phase adsorption. Liquid phase adsorption is more complicated than 
gas phase adsorption, since in the former case, the driving force for adsorption could be 
both attraction of solute molecules by the adsorbent and also rejection by the solvent 
(Da̧browski 2001). Adsorption in the liquid phase usually occurs in three stages: 1) 
Transport of solute through the liquid film or hydrodynamic boundary layer to the 
adsorbent surface;  2) Diffusion of solute within the pores of adsorbent; and 3) Adsorption 
of solute particles on to the internal surface of the pores of the adsorbent (Newcombe 
2008). 
Adsorption can be classified into two types based on the interactions between the 
adsorbent and adsorbate: 1) Physical adsorption (physisorption), which involves weak, 
non-specific, short ranged, van der Waals forces between the adsorbent and adsorbate; 
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and 2) Chemical adsorption (chemisorption) which involves chemical bonding between 
the drug and the carrier (Taylor et al. 2010; Da̧browski 2001; Arce et al. 2008).  
Physisorption is the most favourable mechanism of drug loading for amorphous drug 
delivery where immediate drug release is desired, since the drug can readily desorb from 
the carrier and get released into the dissolution medium. The driving force for physical 
adsorption can be electrostatic or non-electrostatic interactions, whereby electrostatic 
interactions are due to the charge densities of the adsorbent and adsorbate and can be 
repulsive or attractive. Aromatic or pi-pi interactions are also a special type of 
electrostatic interactions which only exist between aromatic compounds due to the partial 
positive charge around the periphery or on the edges of an aromatic ring and partial 
negative energy above both aromatic faces (Martinez & Iverson 2012). Non-electrostatic 
interactions include hydrophobic interactions and van der Waals forces, which are 
interactions between neutral atoms/molecules at short distances and are always attractive 
(Radke & Prausnitz 1972; Kaplan 2006).  
Chemisorption is advantageous when controlled drug release is required, since the release 
of the chemically adsorbed drug will depend on the dissolution rate of the carrier. 
However, high drug loading cannot be achieved with chemisorption, since only a 
monolayer of the drug can be adsorbed, thereby limiting the drug loading capacity (Wu 
et al. 2008; Douroumis & Fahrenkamp 2012). 
  
31 
 
1.4.2. Porosity of the carrier 
Porosity is the measure of voids/pores in a material and these pores can be closed or open 
(accessible to the exterior of the material). Porous materials may contain pores of uniform 
size or variable size in their structure and can be arranged in a disordered or ordered 
manner (Figure 1-2 ). These pores can be slit-shaped, which can be seen with micropores 
of activated carbon that originate from spaces between the multiple graphite sheets, or 
can be cylindrical shaped, which can be seen in ordered mesoporous silica. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2 :Illustration showing different types of porosity:  (a) Uniform ordered porosity (b) non-uniform 
disordered porosity (c) Slit-shaped pores-side view (d) slit-shaped pores-front view (e) cylindrical pores- 
side view (f) cylindrical pores- front view 
 
Pores are classified into three types based on their width: 1) micropores with a diameter 
less than 2 nm; 2) mesopores with a diameter in the range of 2 and 50 nm; and 3) 
c) 
b) a) 
d) 
e) f) 
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macropores with a diameter more than 50 nm. Micropores have a width slightly greater 
than most drug molecules (spherical diameters of most small molecule drugs is less than 
1 nm (Knappe et al. 2004; Ehrhardt & Kim 2007)),  which can result in the interaction 
between all the atoms of the pore wall and all the atoms of the drug molecule, thereby 
leading to stronger adsorption and higher stability. In the case of mesopores, the pore 
width is a few times larger than the molecular size of the drug and can accommodate 
multilayer adsorption. Whereas, in macropores, the pore size is much larger and exhibit 
less specific surface area; since the adsorption can only occur on the pore wall, drug 
adsorption in macropores is negligible (Bruce et al. 2010; Da̧browski 2001; Lawrence & 
Jiang 2017). 
1.4.3. Drug loading methods and factors influencing the drug loading 
Several loading methods (Table 1-3), such as solvent evaporation, supercritical CO2 , 
melting and solution adsorption have been studied to allow drugs to be successfully 
adsorbed onto carriers; however, the loaded drug often exists as a mixture of crystalline 
and amorphous drug. Solution adsorption, also called immersion, is the most widely used 
method for drug loading due to ease of reproducibility. Solution adsorption, solvent 
evaporation, and incipient wetness methods use the same principle of dissolving the drug 
in an organic solvent before adding the carrier, followed by removal of the solvent. 
However, these solvent based methods can be challenging when the drug is not soluble 
in any suitable organic solvent. The melt method can be employed in such cases, since it 
does not employ any organic solvents; however, most drugs undergo degradation before 
melting (Salonen, Paski, et al. 2005; Li-hong et al. 2013; Piotto & Bettotti 2017; Ahern 
et al. 2013).  
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Table 1-3: Methods of drug loading into porous carriers: Advantages and limitations 
Loading 
Method 
Conditions Advantages Limitations Reference 
Solution 
adsorption/ 
immersion 
Carrier is added to a   
high-concentrated or 
saturated drug solution 
under sonication or 
continuous stirring. 
Simple and 
reproducible 
Solute–solvent 
interactions can 
reduce the drug 
uptake by the 
carrier; Residual 
solvent toxicity. 
(X. Wang 
et al. 2011; 
Mellaerts et 
al. 2008) 
Melting The molten drug and 
carrier are mixed and 
maintained above the 
melting point of the 
drug for 24 hours. 
High drug 
loading 
compared to 
solution 
adsorption 
Not suitable for 
drugs that are 
unstable at high 
temperatures. 
 
(Ahern et 
al. 2013) 
Solvent 
evaporation 
Carrier is added to the 
drug solution followed 
by removal of solvent 
using a rotary 
evaporator. 
Simple and fast 
technique 
Potential 
crystallisation of 
the drug at the 
surface 
(Preisig et 
al. 2014) 
Super critical 
fluid 
Drug and carrier are 
mixed under constant 
temperature in a high-
pressure reactor vessel 
filled with CO2 until 
the final pressure 
reaches 25-30 MPa 
and is then 
depressurised by 
removing the CO2. 
High loading 
efficiency; 
Absence of 
residual solvents 
 
Involves 
complicated 
procedures 
(Li-hong et 
al. 2013; 
Ahern et al. 
2013) 
Incipient 
wetness/ 
impregnation 
Concentrated drug 
solution is added to the 
carrier drop-wise and 
mixed intensively. The 
sample is then dried 
under vacuum. 
Less wastage of 
drug; Loading 
can be 
determined in 
advance. 
Non-uniform drug 
distribution; Drug 
crystallisation on 
the external 
surface cannot be 
controlled. 
(Xu et al. 
2013; 
Mellaerts et 
al. 2010; 
Lehto et al. 
2013) 
 
Significant research has been undertaken in loading drugs under different loading 
conditions (Table 1-4) and drug loading efficiency was found to depend on several 
factors, such as porosity and surface chemistry of the carrier (Lai et al. 2017; Jarvis et al. 
2012; Li et al. 2002).  
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For the drug to exist in a stable amorphous form inside the carrier, the drug should be 
adsorbed on the pore wall of the carrier and adequate surface area should be available for 
adsorption; therefore, it can be deduced that with an increase in the surface area of the 
carrier, drug loading capacity increases. When it comes to pore width of carrier, it is a 
prerequisite that pore width should be slightly higher than the molecular size of the target 
drug, to be able to fit inside the pore without any steric hindrance. Also, when the pore 
width is sufficiently larger than the molecular size of the drug, multilayer adsorption is 
possible, resulting in higher drug loading. However, drug loading into pores that are too 
wide can lead to crystallisation of the drug, since there is enough space for the drug to 
rearrange into an ordered crystal; therefore, it is important to determine the optimum pore 
size that can result in the maximum drug loading without leading to crystallisation 
(Doadrio et al. 2015; Jarvis et al. 2012). 
In addition to porosity, surface chemistry of the carrier was also found to play a 
significant role in affecting the drug loading capacity, especially when specific drug-
carrier interactions, such as hydrophobic or electrostatic interactions, were involved in 
the adsorption of the drug or when the drug loading method involves use of a solvent 
(Solution adsorption method), where solvent-carrier interactions are possible. For 
example, application of a hydrophilic carrier for drug loading in an aqueous media can 
lead to reduced drug loading, due to the adsorption of water on the hydrophilic carrier 
inhibiting the adsorption of solute/drug (Limnell 2011; Taylor et al. 2010; Li et al. 2002). 
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Table 1-4: Factors affecting drug loading efficiency and solid state characteristics of the loaded drug 
Property Effect on drug loading and 
solid state characteristics 
Drug Carrier Reference 
Pore volume Drug loading increased with 
increase in the pore volume, 
irrespective of the surface 
chemistry. 
Ibuprofen Porous 
silicon (pSi) 
(Jarvis et al. 
2012) 
Surface area Drug loading increased with 
increase in the surface area. 
Ibuprofen MIL-100, 
MIL-101, 
MCM-41, 
SBA-15 
(Vallet-Regi- et 
al. 2007) 
Pore width The crystallinity of the 
loaded drug increased with 
increase in the pore width. 
Ibuprofen Porous 
silicon 
(Jarvis et al. 
2012) 
Microporous carriers 
exhibited lower drug loading 
compared to mesoporous 
carriers; however, no 
dependency on the pore size 
could be observed when two 
mesoporous materials were 
compared. 
Ibuprofen Mesoporous 
SBA-3 and 
microporous 
SBA-3 
(Andersson et 
al. 2004) 
Surface 
chemistry 
Crystallinity of the loaded 
drug is lowest when stronger 
negative charge is used, due 
to stronger interactions 
between the drug and the 
carrier 
Ibuprofen Thermally 
carbonised 
pSi and 
unoxidised 
pSi 
(Jarvis et al. 
2012) 
Loading 
method 
Compared to solvent 
impregnation method and 
supercritical fluid method, 
melting method exhibited 
higher crystallinity in the 
loaded drug. 
Fenofibrate SBA-15 (Ahern et al. 
2013) 
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1.4.4. Factors affecting drug release 
Drug release or desorption from the carrier can be immediate or sustained, depending on 
various factors (Table 1-5), such as porosity of the carrier, surface chemistry of carrier, 
type of adsorption, drug characteristics, etc.  
Drug release was found to decrease with a decrease in the pore size in the range of 2.5-
3.6 nm due to spatially hindered diffusion (Ukmar et al. 2011; Wang 2009). Also, the 
particle size of the carrier was found to affect the drug release rate, with smaller particles 
exhibiting faster drug release due to shorter pore length and less steric diffusion hindrance 
(Y. Zhang, Che, et al. 2014; Zhang et al. 2010; Burguete et al. 2012).  
 Drug release in porous carriers, such as MCM-41 (Mobile crystalline material) and SBA-
15 (Santa Barbara amorphous), with unidirectional pore channels was found to be slower 
when compared with MCM-48 and LP-la3d (Large pore with la3d space group), with 
three-dimensional cubic pore geometry, due to higher molecular accessibility and faster 
transport in the three-dimensional  pore network (Wang 2009; Qu, G Zhu, et al. 2006). 
In addition to porosity, surface chemistry of the carrier was also found to play a 
significant role in affecting drug release, where an increase in the population of 
hydrocarbon chains in the carrier decreased the wettability of the carrier, resulting in 
slower drug release (Izquierdo-Barba et al. 2005). In addition to changing the 
hydrophobicity, functionalisation of the carrier also results in the reduction of pore width, 
which could lead to slower drug release (Wang 2009). 
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Table 1-5: Factors affecting the drug release from porous carriers 
Property Effect on drug release 
rate 
Drug Carrier Reference 
Pore 
diameter 
Drug release was faster 
when loaded into 
mesoporous carrier 
compared to microporous 
carrier 
Ibuprofen Microporous 
and 
mesoporous 
SBA-3 
(Andersson & 
Rosenholm 
2008)  
Carrier 
particle 
shape/pore 
channel 
length 
Spherical particles have 
faster drug release 
compared to fibre-like 
material due to increase 
in the pore channel length 
Vancomycin SBA-15 (Cauda et al. 
2008)  
Captopril MCM-41 (Qu, G Zhu, et 
al. 2006) 
Pore 
arrangement 
Faster for 3D 
interconnected pores than 
2D cylindrical pores. 
Ibuprofen 
 
MCM-41 
(unidirectional 
cylindrical 
pores) and 
MCM-48 (3D 
interconnected 
pores) 
(Qu, 
Guangshan 
Zhu, et al. 
2006)  
Valsartan HPCM (3D 
interconnected 
pores) and 
OMC 
(unidirectional 
cylindrical 
pores) 
(Y. Zhang, 
Che, et al. 
2014) 
Surface 
chemistry 
Drug release decreased 
with increase in 
hydrophobicity of the 
carrier. 
Erythromycin LP-Ia3d 
functionalised 
with octyl 
hydrocarbon 
chain  
(Izquierdo-
Barba et al. 
2005)  
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1.5. Porous materials for amorphous drug delivery 
For the development of porous carrier based amorphous drug delivery system, an ideal 
carrier should exhibit the following properties (Liu et al. 2013; Zhu et al. 2012; Zhu et al. 
2014; Kwon et al. 2013): 
1) Biocompatibility- material that does not undergo dissolution in the gastro-
intestinal environment can pose less risk of toxicity due to the less possibility of 
cellular internalisation. 
2) Chemical inertness to prevent undesired drug-carrier interactions that could lead 
to loss of drug potency. 
3) Low production costs. 
4) Large surface area for high loading. 
5) Chemical and thermal stability- carrier material should not undergo degradation 
during handling or storage. 
6)  Strong adsorption capacity- to prevent crystallisation or loss of drug during 
storage. 
7) Tuneable pore size to control the rate of drug release. 
8) Modifiable surface chemistry to control the rate of drug release. 
Various porous materials have been studied as carriers for drug delivery, resulting in the 
intentional or unintentional conversion of crystalline to amorphous drugs (Figure 1-3), 
amongst which, silicon-based materials were most widely studied for intentional 
development of porous carrier based amorphous drug delivery system, due to their high 
surface area and ordered porous structure. Also,  materials such as calcium carbonate, 
calcium silicate, magnesium alumino- metasilicate, titanium dioxide, porous ceramic and 
calcium phosphate have been studied as porous carriers for amorphous drug delivery 
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(Preisig, Haid et al. 2014). Recently, several carbon-based materials, namely mesoporous 
amorphous carbon, hierarchical porous carbon monolith etc., have gained attention, due 
to their chemical inertness, higher stability and stronger adsorption compared to silicon 
based materials (Zhang, Zhi, et al. 2013; Zhu et al. 2014).  
Despite the extensive research on various types of carriers, several limitations are often 
associated, such as lack of reproducibility, toxicity, poor stability and high production 
costs (Table 1-6), which hinder the commercialisation of this technique. Hence, it is 
important to develop more efficient carriers that can address the aforementioned issues 
(Salonen, Laitinen, et al. 2005; Xu et al. 2013; Limnell 2011; Choudhari et al. 2014).  
 
Figure 1-3: Potential porous carriers for amorphous drug delivery 
Potential porous carriers for drug 
delivery
Materials with internal 
porous structure
Disordered 
porous structure
Eg: porous silicon, calcium 
carbonate, calcium 
phosphate, activated carbon
ordered porous 
structure
Eg: mesoporous carbon 
mesoporous silica, nanoporous 
titanium dioxide, zirconium 
oxide, hierarchial carbon 
monlith
Materials that form porous 
aggregates
Eg: Nanodiamond 
carbon onion, carbon 
nanotubes, fullerenes
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Table 1-6: Advantages and limitations of materials that have been studied previously as drug carriers for 
amorphous drug delivery. 
Porous 
material 
Synthesis 
(Surface area) 
Advantages Limitations Reference 
Porous 
silicon 
Electrochemic
al etching (Up 
to 1000 m2/g) 
 
Biodegradable; 
Ease of 
synthesis and 
fabrication.  
Undergoes atmospheric 
oxidation; Requires 
surface modification for 
stability; Potential 
chemical interactions 
with drugs. Difficult up-
scalability. 
(Salonen, 
Laitinen, et 
al. 2005; 
Jarvis et al. 
2012; 
Limnell 
2011; Xu et 
al. 2013) 
Porous silica Sol-gel 
process (Up to 
800 m2/g) 
Ease of 
synthesis.  
Surface silanol groups 
can chemically interact 
with carboxyl groups of 
drugs via esterification 
resulting in irreversible 
drug adsorption or 
slower drug release; 
Siloxane bridges might 
also undergo hydrolysis.  
(Kinnari et 
al. 2011; Wu 
et al. 2016; 
Zhang & 
Cresswell 
2016; 
Kamarudin 
et al. 2015; 
Choudhari et 
al. 2014; 
Guo et al. 
2013) 
Ordered 
mesoporous 
silica (OMS) 
Surfactant 
templating (Up 
to 1200 m2/g) 
 
Uniform 
porosity; Large 
surface area.  
 
Expensive synthesis; 
Variable toxicity results; 
Chemical interactions 
between drugs and 
surface silanol groups; 
Siloxane bridges might 
undergo hydrolysis; 
Difficult up-scalability. 
(Wang 2009; 
Manzano et 
al. 2008; Ng 
et al. 2013; 
Heikkilä et 
al. 2010) 
Ordered 
mesoporous 
carbon 
Hard 
templating 
method (Up to 
1400 m2/g) 
Uniform 
porosity; 
Chemical 
inertness; 
Insolubility in 
biological 
fluids.  
Synthesis involves the 
use of OMS as a 
template, thereby 
leading to high 
production costs; Poor 
wettability; Difficult up-
scalability. 
(X. Wang et 
al. 2011; 
Zhang, Zhi, 
et al. 2013; 
Zhang, 
Wang, et al. 
2013; Zhao 
et al. 2012) 
 
41 
 
1.5.1. Silicon based materials 
Porous silicon and silicon dioxide (silica) materials have been widely studied as drug 
carriers for amorphous drug delivery, due to their high surface area and tuneable porosity 
(Wang 2009). 
1.5.1.1. Porous silicon 
Porous silicon (pSi) is produced by electrochemical anodisation of silicon crystals in 
hydrofluoric acid solution. The pore diameter of porous silicon produced can vary from 
1 nm to several µm and pore structure can be branched with interconnectivity or columnar 
without any interconnections, depending on the fabrication conditions. pSi produced 
from etching contains Si-Si bonds in the bulk structure and on the surface; the surface 
bonds are weak and react with hydrofluoric acid during synthesis, resulting in Si-H bonds. 
Unfavourably, this hydride (Si-H) surface of pSi is also unstable and undergoes slow 
oxidation on exposure to atmosphere and water vapour, resulting in siloxane (Si-O-Si) 
and silanol (Si-O-H) groups. Also, pSi with hydride surface undergoes degradation and 
converts into silicic acid in the biological media. Since the carrier needs to be inert in the 
process of drug loading and handling, pSi is often stabilised by oxidation, resulting in 
stable surface siloxane (Si-O-Si) and silanol (Si-O-H) groups, which also reduces the rate 
of dissolution in biological media. Stabilisation can also be achieved by carbonisation, 
which results in Si-C bonds, which are more stable than Si-O bonds (Lehto et al. 2013; 
Hecini et al. 2013).  
Faster drug release was achieved when several poorly soluble drugs were loaded into pSi 
materials compared to the pure crystalline drug (Table 1-7); however, porous silicon is 
associated with limitations, such as potential drug-carrier interactions; silanol groups on 
the surface of pSi were found to react with carboxyl groups of drugs, which could be 
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disadvantageous when chemical interactions are not desired. Also, the challenging scale-
up of the production and fabrication of pSi still needs to be addressed (Jarvis et al. 2012; 
Xu et al. 2013; Limnell 2011). 
Table 1-7: Drug loading and release from porous silicon 
Carrier  Surface 
area 
(m2/g) 
Drug (loading 
w/w, %) 
Effect on drug release Reference 
Thermally 
carbonised 
porous 
silicon 
248 Ibuprofen (30.4) At pH 5.5, drug release from 
carrier was complete in 60 min 
whereas the unloaded drug 
required 240 min 
(Salonen, 
Laitinen, 
et al. 
2005) 
253 Itraconazole 
(11.3) 
Drug release (pH 1.2) from the 
carrier was complete in 30 min 
whereas the release was only 
30% for the unloaded drug. 
(Kinnari 
et al. 
2011) 
Thermally 
oxidised 
porous 
silicon  
222.4 Ibuprofen (36.5) Drug release (pH 5.5) from the 
carrier at 160 min was 75% 
whereas the release was only 
55% for the unloaded drug. 
(Limnell 
et al. 
2007) 
226 Itraconazole 
(11.2) 
Drug release (pH 1.2) from the 
carrier was complete in 30 min 
whereas the release was only 
30% for the unloaded drug. 
(Kinnari 
et al. 
2011) 
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1.5.1.2. Porous silica 
Porous silica used in the drug delivery studies is an amorphous form of silicon dioxide, 
which contains siloxane groups (Si-O-Si) in the bulk structure and silanol groups (Si-
OH) on the surface. Porous silica with a disordered porous structure (silica gel) is 
produced from alkoxysilanes via hydrolysis followed by condensation, and are 
commonly used as pharmaceutical excipients (Kinnari et al. 2011; Limnell 2011), 
whereas porous silica with an ordered mesoporous structure (Ordered mesoporous silica) 
is prepared via a template method, using different templates such as alkyl trimethyl 
ammonium ion surfactants or amphiphilic block copolymers; sodium silicate solution is 
added to the template containing solution and is thermally treated, followed by the 
removal of template by either calcination or solvent extraction (Mellaerts et al. 2008; 
Limnell 2011).  
Ordered mesoporous silica (OMS) consists of a narrow pore size distribution in the 
nanometre range and can have a hexagonal unidirectional tube-like pore arrangement 
(Figure 1-4) or a three dimensional cubic pore arrangement, depending on the synthesis 
conditions (Heikkilä et al. 2010; Vallet-Regi- et al. 2007).  
OMS materials prepared using different templates with different pore structures, namely 
MCM-41, SBA-15 and MCM-48, have been extensively studied as drug carriers, since 
they have an ordered pore network and homogenous size for better control on drug 
loading and release, compared to disordered porous silicon and porous silica.  
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Figure 1-4: Cubic (Left) and Hexagonal (Right) type of pore symmetry of ordered mesoporous silica 
materials. 
 
Table 1-8: Drug loading and release from porous silica 
Carrier  Surface area 
in m2/g  
Drug loading 
(w/w, %) 
Effect on drug release Reference 
MCM-41 1200 Ibuprofen (41) Drug release (pH 7.4) from the 
carrier was complete after 10 
hours, whereas the release was 
only 10% for the unloaded drug. 
(Andersson 
et al. 2004) 
1036 Indomethacin 
(33) 
Drug release in water from the 
carrier after 24 hours was 35%, 
whereas the release was only 
28% for the unloaded drug. 
(Ukmar et 
al. 2011) 
SBA-15  550 Indomethacin 
(29.5) 
Drug release (pH 1.2) from the 
carrier was 60% after 60min, 
whereas the release was less 
than 10% for the unloaded drug. 
(Limnell 
2011) 
776 Indomethacin 
(32) 
Drug release in water from the 
carrier after 24 hours was 40%, 
whereas the release was only 
28% for the unloaded drug. 
(Ukmar et 
al. 2011) 
860 Ibuprofen 
(25.6) 
Drug release in PBS was 
complete in 10 hours. 
(Song et al. 
2005) 
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Faster drug release was achieved when several poorly soluble drugs were loaded into 
OMS materials compared to the pure crystalline drug (Table 1-8); however, porous silica 
is also associated with limitations similar to that of pSi, namely potential drug-carrier 
interactions due to reactive surface silanol groups. Few studies have investigated 
functionalisation of surface silanol groups of OMS to achieve controlled release and 
targeted delivery (Table 1-9); surface functionalisation with long carbon chains are able 
to increase the hydrophobicity, thereby reducing the release rate. However, 
functionalisation can significantly decrease the pore diameter, resulting in reduced drug 
loading (Doadrio et al. 2006; Vallet-Regi- et al. 2007; Salonen et al. 2008). 
 
Table 1-9: Functionalisation of porous silica and their potential applications in drug delivery 
Chemical group  Applications in drug delivery Reference 
Aminopropyl folate 
 
Cancer targeting; Overexpression of folate 
receptor on cancer cells may facilitate the uptake 
of the folate-modified silica particles. 
(Slowing et al. 
2006) 
Alkyl chains Controlled release; Hydrophobicity increases with 
increase in chain length, thereby resulting in 
slower drug release. 
(Doadrio et al. 
2006)  
Thiol Mucoadhesive drug delivery; The thiol groups 
covalently bind to glycoproteins in mucin.  
(Q. Zhang et 
al. 2014) 
Poly lysine (PLL) or 
polyethyleneimine 
(PEI) 
RNA delivery; positively charged PLL or PEI 
groups can bind negatively charged nucleic acids. 
(Hom, Lu et 
al. 2010) 
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Despite the extensive research on porous silica, there are still concerns about long-term 
effects of silica materials in-vivo, since exposure to crystalline silica has shown to cause 
adverse effects on the respiratory system and carcinogenic effects. Although porous silica 
investigated for drug delivery applications is amorphous in nature and considered to be 
less toxic unlike the crystalline form, long term effects of these particles still remain a 
debatable issue, due to variable results obtained from different cytotoxicity studies 
(Kwon et al. 2013). In vitro studies reported that cell membrane integrity weakened, 
resulting in reduced metabolism in Caco-2 cells when incubated with high concentrations 
of porous silica microparticles (0.2-14mg/mL) (Heikkilä et al. 2010). However, in-vivo 
studies in mice and rabbits showed no significant toxic effects when porous silica 
microparticles were administered orally (Jaganathan & Godin 2012), indicating that 
studies on bio-safety of porous silica are contradicting and needs further research. 
 
1.5.2. Carbon based materials 
Several porous carbon materials (Figure 1-5) have been studied as carriers for drug 
delivery applications (Table 1-10) due to their high surface area, chemical inertness, and 
high chemical and thermal stability (X. Wang et al. 2011; Chen et al. 2016).  Carbon 
materials that have been studied as drug carriers are usually hydrophobic in nature and 
are insoluble in aqueous media (unless functionalised), which is advantageous for 
application in oral amorphous drug delivery, where dissolution of the carrier is not 
preferred due to potential cellular uptake leading to adverse effects.  
Porosity in these carbon materials can be internal porosity (activated carbon and ordered 
mesoporous carbon) or can be aggregate created porosity (fullerenes, carbon onions, and 
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Fullerene Carbon 
nanotube 
Nanodiamond 
Amorphous carbon with small graphite like crystals 
Carbon onion 
nanodiamonds). Both internal porosity and aggregate created porosity can be found in the 
case of carbon nanotubes (Presser et al. 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
   
   
  
 
 
 
   
 
 
 
 
 
Figure 1-5: Molecular structure of different carbon allotropes that are potential drug carriers [Adapted from 
(Mochida et al. 2006)].   
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Table 1-10: Applications of porous carbon materials in drug delivery. 
Carbon materials Porosity Possible 
adsorption 
mechanism* 
Applications in 
drug delivery 
Reference 
Ordered 
mesoporous carbon 
(amorphous carbon 
with/without sp2 
graphite like 
crystallites) 
Intra-
particle  
Pi-pi interactions 
when graphite 
like crystallites 
are present 
Amorphous drug 
delivery 
(Zhang, Zhi, 
et al. 2013)  
Activated carbon 
(amorphous carbon 
with sp2 graphitic 
crystallites) 
Intra-
particle  
Pi-pi interactions Anticancer drug 
delivery, lymphatic 
targeting  
(Nakase et 
al. 2004; 
Mochida et 
al. 2006) 
Fullerenes (single 
sp2 graphene ring) 
Aggregate 
created  
Pi-pi interactions Anticancer drug 
delivery 
(Montellano 
et al. 2011; 
Blazkova et 
al. 2014)  
Carbon onions 
(multiple sp2 
graphene rings) 
Aggregate 
created  
Pi-pi interactions No specific 
research as drug 
carrier, however the 
ability to cross 
‘Blood brain 
barrier’ was 
investigated. 
(Pakhira et 
al. 2016)  
Nanodiamond (sp3 
diamond core and 
sp2 amorphous 
carbon) 
Aggregate 
created  
Interactions 
between 
functional groups 
and drugs 
Gene delivery, 
Anticancer drug 
delivery 
(Ho et al. 
2010; El-Say 
2011)  
Carbon nanotubes 
(single or multiple 
sp2 graphene 
structures) 
Aggregate 
created and 
intra-
particle 
Pi-pi interactions Anticancer drug 
delivery 
(Bielicka et 
al. 2013; 
Terzyk et al. 
2012; Wong 
et al. 2013) 
* In addition to van der Waals forces 
  
49 
 
1.5.2.1. Activated carbon 
Activated carbon (AC) is a porous material that consists of several small graphitic 
crystallites joined together, but without a long range order. Each graphitic crystallite 
consists of 1-5 layers of hexagonal and pentagonal rings of sp2 carbon arranged in a near 
parallel fashion. AC is produced from carbonisation of a variety of carbon-rich materials 
(e.g. coal, wood, peat etc.), followed by either steam activation or chemical activation. 
Steam activation involves steam treatment of a carbon-rich source, such as wood, at 800-
1100 ºC.  Chemical activation involves carbonisation of carbon-rich material in the 
presence of an activating agent, such as phosphoric acid or zinc chloride, at 600-1000 ºC, 
followed by washing and drying (Olivier 2008; Mochida et al. 2006; Peter et al. 2008; 
Harris et al. 2008). 
AC consists of a disordered three-dimensional interconnected pore structure, with a broad 
pore size distribution of micropores, mesopores, and macropores (Figure 1-6).  
Micropores, which contribute to the major part of the internal surface area, originate from 
the spaces between several randomly arranged small graphitic layers. Unlike graphite, 
where all the layers are arranged in a parallel manner, AC consists of randomly arranged 
layers. Macropores and mesopores of AC act as pathways that lead to micropores. 
Micropores of AC are slit-shaped and can exhibit higher packing density, which can 
result in higher loading compared to cylindrical shaped pores (Harris et al. 2008; 
Rodriguez-Reinso 2007).  
Surface area and pore size distribution of AC depends on the synthesis conditions, and 
pore size distribution can be controlled by changing the type of raw material, activation 
temperature, proportion of activating agent, and duration of the treatment; AC prepared 
from coal was found to contain a wide range of mesopores, whereas coconut shell-based 
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AC showed more microporosity  (Xia et al. 2010; Inagaki 2009; Marsh & Rodriguez-
reinoso 2006).  
 
 
 
 
 
 
 
Figure 1-6: Schematic depiction of the porous structure of activated carbon and origin of micropores from 
the spaces between graphite-like sheets [Adapted from (Mochida et al. 2000; Enoki & Kobayashi 2005)]  
 
1.5.2.1.1. Surface chemistry 
The adsorption on AC is mostly physisorption and the interactions can be simply non-
specific van der Waals forces or structure-specific Pi- Pi interactions that occur between 
the aromatic rings of the adsorbate and aromatic rings of graphene layers of AC (Figure 
1-7). These possible interactions between aromatic drug molecules and AC can 
potentially result in stronger adsorption (Martinez & Iverson 2012; Haghseresht et al. 
2002); however, the aromatic rings in AC are not arranged parallel to the pore wall and 
are present in a random fashion. 
  
Graphite like 
sheets Macropores 
Mesopores 
Micropores 
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a) b) c) 
Cation 
Treatment with HNO3 
 
 
 
 
Figure 1-7: Illustration showing interactions between aromatic ring of adsorbate and the aromatic ring of 
AC: (a) Parallel displaced and (b) T-shaped; (c) interactions between positively charged adsorbate and the 
aromatic ring of AC [Adapted from (Martinez & Iverson 2012)(Matthews et al. 2014)]. 
 
However, adsorption on AC can also be affected by functional groups present on the 
edges (Figure 1-8) of graphene sheets, essentially oxygen-containing groups such as 
carboxyl, since these groups determine the hydrophilicity, which can affect the 
interaction with aqueous media. Acid treatment of AC was found to increase oxygen-
containing functional groups (Table 1-11) and resulted in an increase in the adsorption of 
organic molecules from gaseous phase and a decrease in the adsorption of organic 
molecules from aqueous media (Li et al. 2002). 
 
  
 
 
 
 
 
Figure 1-8: Effect of acid treatment on the surface chemistry of activated carbon. Several hydroxyl or 
carboxyl groups can be imparted resulting in increased hydrophilicity [Adapted from (Mochida et al. 
2006)]. 
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Table 1-11: Effects of surface functionalisation of activated carbon 
Treatment Effect on surface 
chemistry 
Effect on adsorption Reference 
Exposure to oxygen 
at 200-700 oC or 
treatment with H2O2 
or HNO3. 
 
Increase in carboxylic, 
phenolic and hydroxyl 
groups 
Hydrophilicity increases 
with increased number of 
oxygen groups. Adsorption 
of organic compounds in 
aqueous media decreases 
(Li et al. 
2002) 
Heat treatment at 700 
ºC in inert 
atmosphere  
Removes oxygen group 
but might produce free 
radical edge sites 
Hydrophobicity increases. 
Adsorption of organic 
compounds in aqueous 
media increases. 
(Knappe et 
al. 2004; 
Boehm 
2008) 
Exposure to 
ammonia and 
chlorine at 400-900 
ºC 
Increase in pyridine type 
structures and amine 
groups  
Hydrophobicity increases. 
Adsorption of organic 
compounds in aqueous 
media increases. 
(Knappe et 
al. 2004) 
 
1.5.2.1.2. Biological safety and potential applications in drug delivery 
AC is extensively used in water purification and is also clinically used as an antidote to 
remove poisonings (Liang et al. 2013; Olson 2010; Juurlink 2016) AC administered 
orally was not absorbed from the gut and the clinical studies on safety of orally 
administered AC showed no serious adverse effects (Wang, Cui et al. 2012) and minor 
side effects (e.g. constipation, abdominal distention etc.,) were observed on use of AC as 
an antidote (Chang, Kelly et al. 2006). 
AC has also been investigated as a drug carrier for cancer targeting and sustained delivery 
of anticancer drugs; when injected into the tumours in mice, AC loaded with methotrexate 
was found to increase the duration of active exposure period of the drug to the tumour by 
releasing the drug slowly for a prolonged period of time, thereby suppressing the tumour 
growth at a higher rate compared to the unloaded drug (Nakase et al. 2004). Also, AC  
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was found to have an affinity towards the lymph nodes when injected near the tumour 
site (Guo et al. 2011; Yokota et al. 2000).  
Table 1-12: Potential clinical applications of activated carbon 
Potential applications Result Reference 
 
Chemotherapy 
Drugs adsorbed on to AC nano particles were 
selectively delivered to regional lymph nodes 
and retained at the site of injection for a longer 
duration in rats and cancer patients. 
(Guo et al. 
2011; Hagiwara 
& Takahashi 
1987; Shah et al. 
1998) 
 
Antacid 
Calcium carbonate or sodium carbonate 
adsorbed on the activated carbon was able to 
maintain ideal pH and neutralise gastric acidity 
without any rebound effect in vitro. 
(Linares et al. 
2006; Linares et 
al. 2007) 
 
Photo thermal cancer 
therapy 
When exposed to laser radiation, PVP 
dispersed AC nano particles were able to 
convert light into heat energy and resulted in 
tumour growth suppression at the site of 
injection in mice.  
(Chu et al. 
2013) 
 
Lymph node staining 
AC of particle size < 200 nm was readily 
absorbed into regional lymphatics and 
blackened lymph nodes when injected. 
(Yokota et al. 
2000) 
 
Controlled release 
AC containing temperature responsive 
hydrogel was used to increase the drug loading 
capacity and mechanical strength of the 
hydrogel for controlled release.  
(Yun et al. 
2008) 
 
Amorphous drug 
delivery 
AC and crystalline drugs were mixed using a 
mortar and pestle resulted in the loss of 
crystallinity over a period of time. 
(Konno et al. 
1986) 
 
Whilst few studies have explored the use of AC for anticancer drug delivery, as noted in 
Table 1-12, there is not much information on the drug loading efficiency, drug release 
kinetics and application as an amorphous drug carrier. 
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AC is inexpensive, commercially available, non-toxic and has a high surface area to 
volume ratio, which can favour the development of an efficient, cost-effective and safe 
carrier for oral drug delivery. 
 
1.5.2.2. Ordered mesoporous carbon 
Ordered mesoporous carbon (OMC) is an sp2 form of carbon, similar to AC, and can 
contain small graphitised crystallites; however, unlike activated carbon, OMC contains a 
narrow pore size distribution with a uniform pore symmetry and is prepared by a soft 
template or hard template method. The soft template method involves use of surfactants 
as templates to allow self-assembly of carbon molecules to form nanostructures, similar 
to the preparation of OMS, whereas the hard template method involves a physical 
template, such as OMS, on which the carbon source precipitates or polymerises before 
undergoing calcination at high temperatures (Pan et al. 2010; Darmstadt et al. 2008; Niu 
et al. 2013).  
Several studies have been performed using OMC as an amorphous drug carrier due to its 
chemical inertness, low toxicity and stronger adsorption compared to OMS materials. 
OMC was found to be stable in the gastric environment without getting absorbed by 
intestinal cells, which can be advantageous for application in oral drug delivery (Zhang, 
Zhi, et al. 2013). Cytotoxicity studies on Caco-2 cells and gastric irritation tests in mice 
also showed that OMC is non-toxic and did not induce any irritation (Niu et al. 2013; 
Zhao et al. 2012).  
OMC (839 m2/g)  prepared using SBA-15 as a template was studied for ibuprofen loading 
and a loading of 24% could be achieved (X. Wang et al. 2011), which is almost similar 
to the ibuprofen loading (25.6%), achieved when SBA-15 (860 m2/g) was used as a carrier 
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(Song et al. 2005), indicating that there is no significant difference in the drug loading 
capacity between OMC and OMS materials. However, there is no information on the 
fraction of crystallinity in the loaded drug, which could give a better understanding of the 
difference in the ability to produce and stabilise the amorphous drug, between OMS and 
OMC materials.  
OMC was found to be poorly wettable in biological media due to its hydrophobic surface; 
therefore, carboxylation of these materials was performed by treating with a mixture of 
sulphuric and nitric acids, which resulted in an increased wettability (Zhang, Zhi, et al. 
2013). Site-selective release of drug from OMC was also achieved by incorporating Fe 
nanoparticles in the carbon walls (Yuan et al. 2009). OMC functionalised with thermo-
responsive polymer was found to achieve a controlled release of the drug  between 20-25 
ºC (Zhu et al. 2011), indicating the modifiable surface chemistry of amorphous carbon 
for application in controlled drug delivery. However, synthesis of OMC involves the 
application of surfactant template method similar to OMS, which is an expensive and 
complicated process to scale up. 
 
1.5.2.3. Nanodiamond 
Nanodiamonds (ND) are synthesised through detonation of carbon containing explosive 
mixtures, such as trinitrotoluene and hexogen. ND produced from this method are 
spherical in nature in the size range of 2-10 nm and consist of a crystalline diamond core 
surrounded by an amorphous shell of sp3 and sp2 carbons containing several functional 
groups and, therefore, exhibit properties different from that of micro diamonds (El-Say 
2011; Ho et al. 2010). 
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ND particles often aggregate into porous clusters due to strong interactions between the 
surface functional groups, reaching several hundred of nanometres in size. Also, the 
presence of these functional groups was found to be advantageous for drug delivery 
application due to the hydrophilicity imparted and high cellular internalisation since pi-
pi interactions are not present due to the absence of aromatic graphene rings in the 
structure (Chen et al. 2016).  
ND was investigated for application in sustained anticancer drug delivery by 
functionalising with sodium alginate and was found to exhibit less toxic effects in vitro 
compared to the drug alone  (Cui et al. 2016). Furthermore, the surface interaction 
between the drug and ND facilitated slow release of the drug and inhibited the 
precipitation of the poorly water soluble drug. Also, drug adsorbed on to porous ND 
clusters was found to increase the dispersibility of the drug in aqueous media, indicating 
the potential of ND clusters  in improving the solubility of poorly soluble drugs  (Chen 
et al. 2016). However, there is no adequate information on the drug loading capacity or 
drug release kinetics. 
The toxicity of NDs on the respiratory system was studied by the intratracheal 
administration in mice and no toxic effects were found when a concentration of up to 
1mg/kg was used. However, a dose dependent toxicity was observed in several internal 
organs when high concentrations were used (1-20mg/kg) (Zhu et al. 2012). There is no 
clarity about the biocompatibility of ND due to contradicting toxicity studies and needs 
further research on the long-term effects before they can be considered safe for clinical 
use. Also, the application of ND in drug delivery systems is often associated with 
limitations, such as the requirement of incorporating functional groups to improve the 
interaction between the drug and ND (El-Say 2011).  
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1.5.2.4. Carbon nanotubes 
Carbon nanotubes (CNT) are cylindrical graphene tubes of few nanometres in diameter 
and up to several micro metres in length. CNT can be single walled (SWCNT) or 
multiwalled (MWCNT), with an inner tube diameter ranging from 1-3 nm and outer tube 
diameter ranging from 2-100 nm. CNT are synthesised through arc discharge method, 
chemical vapour deposition, and laser ablation method (He et al. 2013). 
Carbon nanotubes have accessible internal porosity and also have high external surface 
area due to their shape; however, internal drug loading is limited due to the restricted 
space in the tube and most of the drug loading studies have been performed by adsorbing 
the drugs on the external surface. Several drugs have been loaded into CNT by 
chemisorption (paclitaxel and cisplatin) and by π-π stacking (doxorubicin) to investigate 
the applications in intracellular delivery, since CNT was found to have an ability to cross 
cell membranes by hydrophobic interactions, π-π stacking interactions, electrostatic 
adsorption and covalent bonding. Despite their higher cellular uptake, application of CNT 
for intracellular delivery is still controversial due to the toxicity concerns associated with 
these nano materials (He et al. 2013; Wong et al. 2013). 
Carbon nanotubes are hydrophobic in nature and insoluble in aqueous solutions and are 
usually functionalised with polyethylene glycol (PEG) to improve their solubility, 
biocompatibility and to reduce their toxicity. PEG-CNT were found to be less toxic 
compared to aggregated unfunctionalised CNT when given intratracheally and 
intraperitoneally, indicated by in-vivo studies in animal models (Liu, Robinson et al. 
2011). No toxicity, mortality or tissue damage was shown when water soluble 
hydroxylated SWCNT were studied for bio distribution in mice through oral, 
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intraperitoneal subcutaneous and intravenous routes (Liu, Robinson et al. 2011); 
however, accumulation was observed in stomach, kidneys, and bone after 30 minutes of 
administration, which were eventually cleared in unchanged form (Yang, Luo et al. 
2012). However, some studies have shown that CNT was broken down by 
myeloperoxidase in the neutrophils of mice (Kagan, Konduru et al. 2010). Also, 
inhalation studies indicated that CNT could lead to inflammation and pulmonary toxicity 
(Bergin & Witzmann 2013). The toxicity and metabolism of CNT were found to depend 
on the surface functionalisation, solubility, shape, aggregation and chemical composition, 
due to which the cytotoxicity results from several studies are contradicting, which makes 
it difficult to generalise the toxicity of the CNT for drug delivery applications. Despite 
the animal studies indicating the safety of oral administration of CNT even at high 
concentrations (Liu et al. 2011), application of these materials for amorphous oral drug 
delivery can be challenging due to their potential pulmonary toxicity and complexity of 
production. 
 
1.5.2.5. Fullerenes 
Fullerenes are hollow molecules with spherically arranged graphene sheets and can be 
produced via arc discharge method which involves an arc discharge between two graphite 
electrodes in water, during which graphite undergoes vapourisation resulting in the 
deposition of carbon soot on the surface of the container. The carbon soot is then scrapped 
and collected followed by boiling with toluene. The toluene carbon mixture is then 
evaporated to produce fullerene crystals (Kyesmen et al. 2016). These fullerene 
aggregates/crystals referred to as fullerites can reach up to 300 µm in size which have 
micropores from molecular defects of fullerenes and may also contain mesopores from 
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point defects and stacking defects in the aggregation (Suárez-García et al. 2008; 
Nikonova et al. 2016). These aggregates can have three preferential adsorption sites: 1) 
between the four fullerene molecules 2) channels formed between two adjacent molecules 
and 3) on the surface of each molecule. Although no drug delivery studies have been 
performed using the fullerites, water-soluble fullerene derivatives were studied as drug 
carriers for intracellular delivery where drugs such as paclitaxel, doxorubicin were 
covalently attached to fullerene molecules (Montellano, Da Ros et al. 2011). 
Fullerenes, when administered orally to rats were excreted in faeces unchanged, while 
trace amounts passed through the gut wall and were observed in urine, indicating the 
uptake by intestinal cells; however, no toxic effects were reported. When given 
intravenously, water-soluble fullerenes were found to be less toxic compared to the 
insoluble fullerenes (Kolosnjaj-Tabi et al. 2012). Few studies have reported that cell 
viability reduced in bovine macrophages and enhanced the production of tumour necrosis 
factor (Mao et al. 2013). Despite few reports on the toxic effects of fullerenes, these are 
considered to be less toxic compared to carbon nanotubes. 
 
1.5.2.6. Carbon onion 
Carbon onion, which is also called onion-like carbon (OLC), consists of spherical closed 
graphene shells that were first observed when carbon soot was exposed to a radiating 
beam of a transmission electron microscope. The layered structure of these shells 
resembles the structure of an onion and can be considered as concentrically arranged 
fullerenes separated by 3-4 Angstroms (Terrones & Terrones 2003; McDonough & 
Gogotsi 2013; Choucair & Stride 2012).  
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OLC has been prepared using several techniques, such as arc discharge, which involves 
discharge between two carbon electrodes in the water; plasma spraying, which involves 
accelerating of ND particles using fast travelling arc plasma; and electron beam 
irradiation, which involves irradiating carbon soot. However, only minute quantities can 
be prepared from the aforementioned methods and larger quantities of OLC can be 
prepared via thermal annealing of detonation nanodiamonds (ND) and the size of each 
onion depends on the size of the nanodiamonds used for the synthesis (Costa et al. 2014; 
Sano et al. 2002; Gubarevich et al. 2003).  
The transformation of ND to OLC (Figure 1-9) involves graphitisation from the surface 
to the core; as the temperature increases, ND undergoes a phase transformation from sp3 
to sp2 carbon, in order to reduce the surface energy, and finally forms completely merged 
graphitised carbon shells. The merging of graphite shells causes a significant decrease in 
the surface energy for the graphitised particles, which could be the driving force for the 
formation of spherical OLC  (Bielicka et al. 2013).  
OLC produced from ND undergo aggregation that can reach up to several µm in size due 
to the van der Waals forces that hold the molecules/onions together, resulting in the 
formation of aggregate created porosity formed by the space between multiple onions, 
which may be used as strong adsorption sites for drug molecules (Zeiger, Jäckel, et al. 
2015; Reinert et al. 2015).  
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Figure 1-9: Illustration of the transformation of sp3 carbon in nanodiamond (ND) from the surface to the 
core with an increase in temperature resulting in the formation of carbon onion (OLC) [Adapted from 
(Cebik et al. 2013)]. 
 
 
OLC contains concentrically arranged graphene layers that are strong potential sites of 
adsorption for drugs (Figure 1-10) due to the possibility of pi-pi interactions between 
aromatic rings of graphene layers of OLC and the aromatic rings of the drug. OLC can 
exhibit much stronger drug adsorption inhibiting crystallisation of the loaded drug 
compared to AC, since the graphitic layers in AC are not arranged parallel to the pore 
wall and are present in a random fashion. (Bielicka et al. 2013; Popov et al. 2012; Enoki 
& Kobayashi 2005; White 2015) 
However, the porous structure of OLC contains aggregate created mesoporosity with 
some microporosity, with a relatively low surface area in the range of 200-600 m2/g 
compared to that of AC, which can exhibit a surface area of up to 2000 m2/g depending 
on the synthesis conditions (Zeiger, Jäckel, et al. 2015). 
  
>1300 °C 900-1300 °C 
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Figure 1-10: Illustration showing the potential adsorption of aromatic molecules on OLC aggregates via 
parallel displaced pi- pi interactions [Adapted from (McDonough et al. 2012)]. 
 
Biocompatibility of OLC has been investigated by few researchers and no significant 
toxicity was observed. Human skin fibroblasts exposed to OLC with a diameter of 30 nm 
produced from arc discharge method showed less toxic effects compared to carbon 
nanotubes. Rat derma fibroblasts were exposed to OLC functionalised with poly ethylene 
glycol and the cell viability was over 80%, even at high concentrations tested (3000 
µg/mL). However, there is limited research on the cytotoxicity studies of OLC, making 
any conclusions on the safety of OLC difficult (Bartelmess & Giordani 2014). 
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No specific research has been performed on the application of OLC as a drug carrier; 
however, the ability of acid treated OLC to cross the blood-brain barrier has been studied 
recently in mice. OLC, when injected into mice were found to enter the brain without 
causing any perfusion and cleared out from the body without depositing for long period, 
indicating the potential of OLC to carry the drug to the brain (Pakhira et al. 2016).  OLC 
was also studied for application in cellular imaging, due to their ability to undergo cellular 
internalisation (Bartelmess & Giordani 2014). 
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1.6.  Thesis aim and objectives 
Although numerous studies about porous carrier based drug delivery have been 
published, there are still many limitations, such as low drug loading efficiency, the 
crystallinity of the loaded drug, poor chemical stability, potential toxicity and high costs 
of production. With the above limitations in mind, the aim of this work is to investigate 
the application of activated carbon and carbon onion as porous drug carriers in order to 
develop safe, efficient, and less expensive porous carriers. 
The main objectives of current work include: 
1. Evaluate cell cytotoxicity of activated carbon and carbon onion micro-particles 
on Caco-2 cells. 
2. Investigate drug loading into activated carbon and carbon onion using 
paracetamol and ibuprofen as model drugs. 
3. Determine drug loading capacities of carbon onion and activated carbon under 
different loading conditions. 
4. Investigate factors affecting drug loading and solid state characteristics of the 
drug loaded. 
5. Investigate drug release behaviour from activated carbon and carbon onion. 
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2.1. Materials 
AC used for drug loading studies in Chapter 3 and 4 was Norit® Darco® G60 type. Three 
other types of activated carbon were used to study the effect of porosity in Chapter 5. All 
four types of AC were purchased from Sigma Aldrich, UK and the information about the 
manufacturing conditions is shown in Table 2-1. Nanodiamond (ND) (particle 
size<10nm, purity ≥97%) used in the preparation of carbon onion was purchased from 
Sigma-Aldrich, UK. Paracetamol powder (purity 98-102%) was purchased from Sigma, 
UK and Ibuprofen powder (purity 99%) was purchased from discovery Fine chemicals, 
UK. Properties of paracetamol and ibuprofen are presented in Table 2-2. Ethanol, sodium 
lauryl sulphate, sodium dihydrogen phosphate, disodium hydrogen phosphate, sulphuric 
acid, nitric acid, dimethyl sulfoxide and sodium hydroxide were purchased from Fisher, 
UK. Caco-2 cells were purchased from ATCC. Dulbecco’s Modified Eagles Medium 
(DMEM, with 4500 mg/L glucose, L-glutamine, sodium pyruvate, sodium bicarbonate, 
amino acids and vitamins), foetal Bovine Serum, trypsin-EDTA solution, anti-mycotic 
solution (with 10,000 units penicillin, 10 mg streptomycin and 25 μg amphotericin B per 
mL), Hank’s balanced salt solution, MTT dye, phosphate buffered saline, trypan blue 
were purchased from Sigma-Aldrich, UK. 
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Table 2-1: Activated carbon specifications, Sigma Aldrich, UK. 
Product name AC Norit® 
Darco® G60 
AC Darco® KB-
G 
AC For Cell 
culture 
AC Meets USP 
testing 
requirements 
Product code 05100 675326 C9157 C7606  
Source   Lignin Wood N/A 100% natural 
origin  
Manufacturing 
conditions 
Steam 
activation  
Chemical 
activation  
Steam 
activation and 
washed with 
hydrochloric 
acid 
Steam activation 
processed to meet 
standards 
required for 
medicinal use 
 
 
Table 2-2: Properties of model drugs 
Model drug Structure Molecular 
weight 
Melting 
point 
(Glass 
transition) 
pKa BCS 
class 
Reference 
Paracetamol 
 
151.16 169 °C 
(22.85)  
9.4 III (Kalantzi et 
al. 2006; 
Sibik et al. 
2014) 
Ibuprofen 
 
206.3 74.8   °C 
(-45.15)  
4.9 II (Limnell 
2011; 
Dudognon 
et al. 2008) 
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2.2. Particle size analysis 
Particle size analysis of carrier was performed using HELOS/BR Laser diffractometer 
(Sympatec GmbH, Germany). 0.5 % (w/v) carrier suspension was prepared in ethanol and 
was analysed for particle size in the measuring range of 0.1 to 500 µm. 
2.3. Cytotoxicity studies 
In vitro cytotoxicity studies of activated carbon and carbon onion were performed with 
human colon carcinoma cells. Caco-2 Cells were cultured in 75 cm2 culture flasks using 
Dulbecco’s modified Eagle’s medium with 10% FBS, 1% L-glutamine and 1% 
antimycotic solution. Cells were incubated at 370C in an atmosphere of 5% CO2 and 95% 
relative humidity, and the growth medium was changed every 2 days.  
Cells between passages 100 and 120 were used in the toxicity studies. Cells were washed 
with HBSS and were harvested using trypsin-EDTA solution. The cell suspension was 
diluted to achieve a density of 104 cells/ml using DMEM and was added to 96 well plates 
at 100 µL per well such that each well has a density of 1000 cells. The cells were 
incubated for 24 hours. The medium was removed after 24 hours and the carrier-DMEM 
suspensions with different concentrations of the carrier (10-800µg/mL) were added to 
96-well plates at 100 µL per well and incubated for 24 h. Caco-2 cells without carrier 
suspension added was used as a control. The medium was removed after 24 hours of 
incubation and the cells were washed with PBS to remove any carrier particles. 100 µL 
of fresh medium and 20 µL of 5mg/mL MTT in PBS solution was added to each well and 
incubated for 4 hours. After 4 hours the medium containing MTT was removed and 
replaced with 100 µL DMSO. The absorbance of the resulting formazan solution was 
determined at 492 nm on a SynergyTM HT microplate reader. Percentage of cell viability 
was calculated using equation -4: 
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Percentage cell viability =  
Absorbance of sample
Absorbance of control
× 100                   (Equation -4)                                                                                                                             
2.4. Drug loading into activated carbon  
2.4.1. Solution adsorption 
1000 mg of AC was added to 10 mL of saturated solution of drug in ethanol (saturation 
solubility of paracetamol and ibuprofen at 20 °C is 150 and 698 mg/mL of ethanol 
respectively) and the suspension was stirred (stirring speed-100 rpm) at 20 °C for 24 
hours. Post loading, the suspension was centrifuged at 1500 rpm, the supernatant was 
removed and the sediment was dried at 40 °C for 24 hours. The concentration of drug in 
the supernatant was determined to estimate the amount of drug adsorbed. The 
unloaded/free drug was found to crystallise as a top layer due to the evaporation of the 
solvent, as shown in Figure 2-1. This top crystalline layer of the sediment was removed 
and analysed for drug content. The bottom layer was collected, sieved (mesh 150-opening 
size 104 µm) to remove any agglomerates and was labelled as drug/AC complex.  
 
Figure 2-1: Schematic representation of solution adsorption method used in the preparation of drug/carrier 
complex and photographic image showing crystallisation of drug after drying the sediment obtained by 
centrifugation. Top white crystalline layer was separated and the bottom layer was labelled as drug/carrier 
complex. 
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2.4.2. Effect of drug loading method 
To understand the effect of loading method on loading efficiency and solid state 
characteristics, three different solvent based loading methods were compared. 
1) Rotary evaporation (RE): 1000 mg of AC was added to a 500 mL round-bottomed 
flask containing 10 mL of the saturated drug-ethanol solution at 25°C (Saturation 
solubility of paracetamol and ibuprofen at 25 °C is 165 and 970 mg/mL of ethanol, 
respectively (Gracin & Rasmuson 2002; Wang et al. 2010)). Ethanol was extracted 
under a vacuum pressure of 5 torr using a rotary-evaporator with a water bath set to 25 
oC, and a runtime of 1 hour. Residual solid was allowed to dry for 24 hours in an oven 
at 40 oC.  
2) Solution adsorption -filtration (SA-F): 1000 mg of AC was added to 10 mL of the 
saturated drug-ethanol solution and the suspension was stirred (100 rpm) at 25 oC for 1 
hour, followed by filtration under vacuum. The residue obtained was allowed to dry for 
24 hours in an oven at 40 oC. 
3) Solution adsorption -centrifugation (SA-C): drug-carrier suspension was prepared 
similar to the SA-F method; however, post stirring, the suspension was centrifuged for 
10 minutes at 1500 rpm. The supernatant was removed and the residue/sediment 
obtained was allowed to dry for 24 hours in an oven at 40 oC. After 24 hours of drying, 
white crystalline drug layer was found on the surface of the sediment, which was 
removed, while the bottom layer was considered as drug/carrier complex, as described 
in the previous chapter. 
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2.4.3. Effect of contact time 
1000 mg of activated carbon was added to 10 mL of saturated drug solution (saturation 
solubility of paracetamol and ibuprofen at 20 °C is 150 and 698 mg/mL of ethanol, 
respectively) and was allowed to undergo stirring (100 rpm) at 20 oC for 1 hour, 4 hours, 
6 hours, 15 hours and 24 hours.  
2.4.4. Effect of temperature 
To understand the effect of temperature on drug loading, drug loading was performed at 
four different temperatures. 1000 mg of AC was added to 10 mL of saturated drug 
solution (concentration of PA: 150 mg/mL of ethanol and concentration of IBU: 690 
mg/mL) and was allowed to undergo stirring for 4 hours at 20, 25, 30, and 35 oC. 
2.4.5. Effect of initial drug concentration 
To determine the effect of concentration of drug in the loading solution on the loading 
efficiency, drug loadings were performed by SA-C method using four different drug 
concentrations (concentrations of 25, 50, 100, 150 mg of PA per mL of ethanol and 
concentrations of 350, 450, 550, 690 mg of IBU per mL of ethanol). 1000 mg of activated 
carbon was added to 10 mL of drug solution and was allowed to undergo stirring (100-
rpm) at 20 oC for 4 hours.  
2.4.6. Drug loading using saturated drug solution at different temperatures 
Saturated PA solutions at four different temperatures were used for loading (saturated 
solubility of PA is 150, 165, 183, 199 mg/mL of ethanol at 20, 25, 30, 35 oC respectively 
(Granberg & Rasmuson 1999)) to determine the maximum PA loading that could be 
achieved without any crystallisation. 
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2.4.7. Effect of carrier dose  
To investigate the effect of quantity of carrier on drug loading efficiency, varying 
amounts of carrier was added to 10 mL of saturated drug solution (concentration of PA: 
150 mg/mL of ethanol and concentration of IBU: 690 mg/mL) and was allowed to 
undergo stirring (100 rpm) at 20 oC for 4 hours. 
2.5. Modification of surface chemistry of activated carbon 
To consider the effects of the surface chemistry of the carrier on drug loading and release, 
AC was treated to modify its surface chemistry with HNO3, NaOH and a mixture of  
H2SO4/HNO3 separately, as reported previously in the literature (Li et al. 2005; Chiang 
et al. 2002; Li et al. 2003). In a typical procedure, 1 g of AC (G60- type) was added to 
100 mL of 3:1- H2SO4(65%)/HNO3(96%) solution and was stirred for 3 hours at room 
temperature. The solution was then decanted and AC was washed with ultrapure water 
until a neutral pH was achieved. The AC was then dried at 70 ºC in an oven for 24 hours 
and was referred to as AC-H2SO4/HNO3.  
Also, 1 g of AC was treated separately with 100 mL of 6N HNO3 solution and 100 mL 
of 2M NaOH solution while stirring at room temperature for 5 hours and 24 hours, 
respectively. Post-treatment with HNO3 and NaOH solution, AC samples were washed 
and dried as described previously and the treated ACs were referred to as AC- HNO3 and 
AC-NaOH, respectively. 
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2.6. Preparation of carbon onions from thermal annealing of detonation 
nanodiamond 
Nanodiamond (ND) powder (primary particle size < 10 nm, ≥ 97% trace metal basis) 
used in the preparation of carbon onions was purchased from Sigma-Aldrich, UK. 
Samples of ND were placed in quartz crucibles and thermally annealed in a carbolite TZF 
furnace under flowing nitrogen atmosphere.  The samples were annealed at a heating rate 
of 5°C/min to three different annealing temperatures: 900; 1000; and 1100°C, with 
holding time of 2 hours. During the process of annealing, all three samples were held for 
0.5 hours when they reached temperatures of 350 and 700°C, to remove adsorbed water 
molecules and acidic groups, respectively (Zeiger, Jäckel, et al. 2015). Approximately 
100 mg of ND sample was annealed at each temperature.  After the thermal treatment, 
the annealed samples were allowed to cool down to room temperature under nitrogen 
atmosphere. The annealed samples are referred to as ND-900, ND-1000 and ND-1100, 
which stand for precursor (nanodiamond) and annealed temperature. 
 
2.7. Drug loading into carbon onion 
2.7.1. Effect of contact time 
Drug loading was performed using solution adsorption-centrifugation method at different 
stirring times. 500 mg of OLC was added to 5 mL of saturated solution of drug in ethanol 
(saturation solubility of paracetamol and ibuprofen at 20 °C is 150 and 698 mg/mL of 
ethanol, respectively) and the suspension was stirred (stirring speed-100 rpm) at 20 °C 
for four different durations (0.25, 0.5, 1, 2, 4 hours). Post loading, the suspension was 
centrifuged at 1500 rpm, the supernatant was removed and the precipitate was dried at 40 
°C for 24 hours. After 24 hours of drying, white crystalline drug layer was found on the 
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surface of the sediment, which was removed, while the bottom layer was considered as 
drug/OLC complex. 
2.7.2. Effect of initial concentration on drug loading 
Drug loadings were performed by SA-C method using three different drug concentrations 
(concentrations of 50, 100, 150 mg of PA per mL of ethanol and concentrations of 300, 
500 and 698 mg of IBU per mL of ethanol). 100 mg of OLC was added to 10 mL of drug 
solution and was allowed to undergo stirring (100-rpm) at 20 oC for 1 hour.  
 
2.8. Determination of drug loading using UV spectroscopy 
50 mg of drug/carrier complex was added to 100 ml of ethanol and was stirred for 24 
hours at 25°C. The solution was filtered using 0.45 µm syringe filters (0.2 µm syringe 
filters were used for samples containing carbon onion) and the concentration of the drug 
in the filtrate was determined by UV spectroscopy (Jenway, UK) at wavelengths of 
257nm and 264nm for paracetamol and ibuprofen respectively. Loading efficiency was 
calculated using equation -5:  
 𝐿𝑜𝑎𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%)  =  
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑐𝑜𝑚𝑝𝑙𝑒𝑥 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓  𝑐𝑜𝑚𝑝𝑙𝑒𝑥
× 100               (Equation-5) 
Calibration curves were constructed for paracetamol and ibuprofen. Stock solutions of 
paracetamol were prepared by dissolving 20 mg in 100 mL ethanol and standards were 
prepared by diluting the stock solution with ethanol to achieve concentrations of 2, 4, 6, 
8 and 10 µg/mL. Calibration curve constructed to relate the absorbance and drug 
concentration is shown in Figure 2-2. 
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Figure 2-2: Calibration curve for paracetamol in ethanol at 257nm. Concentration of the drug in the solution 
was determined by UV spectroscopy. Each experiment was carried out in triplicate with the average mean 
result recorded ± the standard deviation (represented as error bars) 
 
Stock solutions of ibuprofen were prepared by dissolving 100 mg in 100 mL ethanol and 
Standards were prepared by diluting the stock solution with ethanol to achieve 
concentrations of 0.2, 0.3, 0.4, 0.5 and 0.6 mg/mL. Calibration curve constructed to relate 
the absorbance and drug concentration is shown in Figure 2-3. 
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Figure 2-3: Calibration curve for ibuprofen in ethanol at 264nm. Concentration of the drug in the solution 
was determined by UV spectroscopy. Each experiment was carried out in triplicate with the average mean 
result recorded ± the standard deviation (represented as error bars) 
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2.9. Differential Scanning calorimetry (DSC) 
DSC measures the changes in the heat flow as a function of temperature, as the sample is 
being heated. The presence of crystalline drug can be detected from the melting peak of 
DSC curves. The analysis was performed using a Q100 DSC (TA Instruments, UK).   
Sample (2-3 mg) was transferred to Tzero aluminium pan and temperature scan was 
performed at a heating rate of 10oC/min under nitrogen gas. Percentage crystallinity was 
calculated from the melting enthalpy using equation-6 (Kong & Hay 2002):  
𝑋𝑐(%)
𝑋𝑐°(%)
=
∆𝐻𝑚
∆𝐻𝑚°
                                   (Equation-6) 
Where Xc(%)= percentage of crystallinity in the drug/carrier complex and Xc°(%) = 
percentage of crystallinity in physical mixture containing equivalent amount of drug and 
carrier as that of complex and is considered to be 100%. ∆Hm = melting enthalpy of the 
drug/carrier complex and ∆Hm° = melting enthalpy of physical mixture containing 
equivalent amount of drug and carrier as that of complex.  
2.10. Powdered X-ray diffraction analysis (XRD) 
X-ray diffraction is a non-destructive technique used to study the structure of crystalline 
materials. Sample is bombarded with X-rays through a range of angles and the intensity 
of the X-rays diffracted is recorded. To determine the solid state of the drug in the 
drug/carrier complex, XRD diffraction was performed using a Bruker D8 ADVANCE 
diffractometer (Bruker, USA) with a Cu–Kα source operated at 30 kV and 30 mA. The 
angular range (2θ) was 10 to 50° with a step size of 0.02°. Diffraction spectra of carbon 
containing samples were baseline corrected using EVA software. 
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2.11.  Attenuated total reflectance-Fourier transform infra-red (ATR-FTIR) 
spectroscopy 
FTIR involves exposing the sample to Infrared radiation during which the sample absorbs 
radiation at certain wavelengths. The degree of absorption at different wavelengths is 
characteristic of the molecular structure of the sample. FTIR was used to investigate 
possible interactions between the drug and the carrier and was performed using a Nicolet 
iS5 spectrometer (Thermo Fisher Scientific, UK) equipped with an iD5 ATR accessory 
with a laminated diamond crystal at an angle of incidence of 42°. The spectra were 
obtained in the range of 500-4000 cm-1 (wavenumber) at a spatial resolution of 4 cm-1 
and were an average of 16 scans. 
2.12. Nitrogen sorption analysis 
In this technique, the sample is exposed to nitrogen at cryogenic temperature and the 
amount of nitrogen adsorbed at each pressure is calculated from which the surface area 
of the sample can be calculated. The porosity of the carrier before and after drug loading 
was investigated by nitrogen adsorption technique using a Micrometrics ASAP 2420 
(Accelerated surface area and porosimetry system, Micrometrics, USA). Adsorption-
desorption isotherms were obtained at 77 K in the relative pressure range between 0.01 
and 0.9. Prior to analysis, all samples were degassed at 40°C for 24 hours. The specific 
surface area of the sample was determined from adsorption isotherm according to 
Brunauer–Emmett–Teller (BET) model assuming multilayer adsorption. The quantity of 
gas adsorbed as monolayer was determined using equation-7 (Thommes 2010):   
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1
𝑄(
𝑃𝑜
𝑃
−1)
=
1
𝑄𝑚𝐶
+
𝐶−1
𝑄𝑚𝐶
×
𝑃
𝑃𝑜
                                (Equation-7) 
Where P is the partial vapour pressure of adsorbate gas, Po is the saturated pressure of 
adsorbate gas (760 Torr for N2), Q is the total quantity of gas adsorbed at relative pressure 
(P/Po), Qm is the monolayer quantity of gas adsorbed and C is a BET constant. Qm was 
obtained from linear plots of 
1
𝑄(
𝑃0
𝑃
−1)
 vs the relative pressure (
𝑃
𝑃𝑜
) in the linear relative 
pressure range of 0.1-0.3 (Plonska-Brzezinska et al. 2011).  From the value of Qm so 
determined, the BET Specific surface area (BETSSA) was calculated using Equation-8: 
        
𝑆𝑆𝐴 =
𝑄𝑚NA
22400
                                           (Equation-8) 
Where N is the Avogadro constant(6.022 × 1023 𝑚𝑜𝑙−1), A is the cross-sectional area of 
one adsorbate molecule (0.162 nm2 for N2), 22400 is the volume occupied by one mole 
of adsorbate at STP in millilitres.  
Pore size distribution of the sample was computed with the ASAP 2420 software using 
non-local density functional theory (NLDFT) model assuming slit-shaped pores since 
BET model does not take pore morphology into account.  
2.13. Scanning electron microscopy (SEM) 
SEM focuses beams of electrons on the surface of a sample and the interactions between 
the sample surface and beam of electrons are used to obtain images of the surface of the 
sample.  SEM Images presented in chapter 3 were recorded with a VEGA3 SEM 
(TESCAN, Czech Republic) at an acceleration voltage of 15kV. Prior to imaging, 
samples were coated with 10nm gold using a Q150 ES sputter coater (Quorum 
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technologies, UK). SEM images presented in chapter 6 were recorded with an XL30 
ESEM-FEG (Philips, Netherlands) at an acceleration voltage of 10kV.  
2.14. High-resolution transmission electron microscopy (HRTEM) 
In this technique, a thin sample is exposed to high energy beam of electrons which travel 
through the sample and the interactions between the sample and the electrons give 
information about the crystal structure on a molecular level. Transmission electron 
microscope images were recorded using 2010F (JEOL) microscope operating at 200 kV 
and using a Gatan Ultrascan 4K camera. Prior to analysis, the sample powders were 
suspended in ethanol and sonicated for 1 hour to separate agglomerates. 5 µl of the 
suspension was allowed to dry onto lacey carbon grid. 
2.15. Raman spectroscopy 
Raman spectroscopy was used to investigate the transformation of nanodiamond to 
carbon onion (graphitization). This technique involves exposing the sample to laser light 
and detecting the scattered light. Some amount of scattered light is shifted to a different 
energy to that of incident laser rays. Plotting the intensity of shifted light for each energy 
of light results in Raman spectra which can give information on the crystalline structure 
of the sample. Spectra were measured on a Renishaw InVia Raman microscope with a 
532 nm excitation source. The acquisition time was 10 seconds and 3 accumulations were 
recorded. 
2.16. X-ray Photo electron spectroscopy (XPS) and X-ray excited Auger electron 
spectroscopy (XAES) 
XPS provides information about the chemical composition of the surface of materials 
(usually 3-10nm depth). Materials are exposed to X-rays and electrons from the inner 
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shells are emitted. The kinetic energy of the emitted electrons is determined which gives 
the binding energy of the electrons which is characteristic of elements. The chemical 
composition and sp3/sp2 bonding ratio of the samples were determined using a Thermo 
Scientific ESCALAB 250 electron spectrometer. Analysis conditions include X-ray 
source with excitation energy of 15KeV, pass energy of 20 eV with a step size of 0.1 eV, 
dwell time of 50 ms and X-ray spot size of 500 µm. The samples were placed on an 
adhesive copper plate at a chamber pressure of  5 × 10−10 mbar during the analysis. X-
ray excited Auger peaks (C KLL) at higher binding energy were analysed to obtain carbon 
phase information. 
2.17. In vitro drug release studies 
Drug release was studied with a USP Type II dissolution apparatus at 37 °C with paddle 
stirring speed of 100 rpm. Powders were filled in hard gelatin capsules size 000 and 0.1 
M sodium phosphate buffer at different pH, with or without 1% Sodium dodecyl sulphate 
was used as dissolution medium. Samples were withdrawn at specific time intervals and 
replaced with fresh dissolution medium. The samples were filtered using 0.45 µm syringe 
filters (0.2 µm syringe filters were used for samples containing carbon onion) and 
concentration of drug was determined using UV spectrophotometer (Jenway, UK). 
2.18. Statistical analysis 
Each experiment was carried out in triplicate with the average mean result recorded ± the 
standard deviation (represented as error bars).  Statistical analysis was carried out on the 
data by one way ANOVA (analysis of variance) followed by the post-hoc Tukey’s or 
Dunnett’s multiple comparison test using Graph pad prism software (Version 6.0 for 
Windows) unless stated. Statistically significant differences are noted for p <0.05 (p < 
0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001).  
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 - Application of activated carbon as a porous carrier for 
amorphous drug delivery 
 
 
 
 
 
 
 
 
 
 
 
 
 
Some of the results presented in this chapter have been published in the paper:  
Miriyala, N., Ouyang, D., Perrie, Y., Lowry, D., Kirby, D (2017), “Activated carbon as 
a carrier for amorphous drug delivery: Effect of drug characteristics and carrier 
wettability” European Journal of Pharmaceutics and Biopharmaceutics, 115, pp.197–
205.  
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3.1. Introduction 
Application of porous materials, such as porous silica, as carriers to improve the solubility 
or dissolution rate of drugs has been largely demonstrated in various research papers 
(Vallet-Regi et al. 2001; Salonen et al. 2008; Zhang et al. 2010). Drug adsorbed in the 
pores of the carrier is present in an amorphous state and the restricted space in the pores 
inhibits the crystallisation of the drug. The amorphous form of drugs have disordered 
molecular packing and higher internal energy compared to the crystalline form, leading 
to improved solubility and dissolution, especially in drugs with high crystal energy 
(Salonen, Laitinen, et al. 2005; Yu 2001; Preisig et al. 2014). In addition, adsorption of 
the drug to the carrier can also improve the dissolution due to the higher surface area 
exposed to the dissolution medium. However, most of the carriers investigated so far are 
often associated with limitations, such as expensive synthesis, low loading efficiency, 
poor stability, reactivity with drugs and safety concerns (Salonen, Laitinen, et al. 2005; 
Jarvis et al. 2012; Xu et al. 2013; Kinnari et al. 2011). Hence, it is crucial to develop more 
efficient carriers that can overcome these limitations.  
Of interest during this study is the application of activated carbon as a porous carrier to 
study mechanisms of drug loading and release, since this material has several properties 
such as high porosity, commercial availability, low cost and chemical inertness, 
qualifying it for oral drug delivery. AC consists of a three-dimensional interconnected 
pore structure, with micropores (pore width <2 nm), mesopores (pore width 2-50 nm) and 
macropores (pore width >50 nm). AC is extensively used in drinking water treatment and 
is also clinically used as an antidote to remove poisonings. Despite, the favourable 
properties, the literature on the application of activated carbon for drug delivery is sparse. 
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Various drug loading methods such as solvent evaporation, supercritical CO2 , melting 
and solution adsorption have been studied previously for drug loading into porous 
carriers, however, solution adsorption also called as immersion is the most widely used 
method. Solution adsorption involves drug loading by immersing the carrier in a saturated 
or high concentrated drug solution and stirring for a specific duration followed by 
separating the drug-loaded carrier complex by filtration or centrifugation (Salonen, Paski, 
et al. 2005; Li-hong et al. 2013; Piotto & Bettotti 2017).  
3.2. Aims and Objectives 
The aim of this chapter is to investigate the application of activated carbon (AC) as a 
porous carrier for amorphous drug delivery using paracetamol and ibuprofen as model 
drugs. To achieve this, the main objectives were to: 
1. Investigate the particle size of AC (Norit® Darco® G60 type) and study the 
cytotoxicity of AC using Caco-2 cells. 
2. Perform drug loading using solution adsorption method and determine the drug 
loading efficiency 
3. Study the solid state characteristics of the drug loaded in to AC and investigate the 
interactions between drugs and AC in order to understand if the drug loading was 
due to physical adsorption or chemical interaction.  
4. Investigate if the drug loading is reversible and to understand the kinetics of drug 
desorption.  
5. Identify the sites of adsorption of the drug and analyse the porosity of AC before and 
after drug loading. 
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3.2.1. Characterisation of activated carbon 
Cellular uptake of microparticles is much lower compared to nanoparticles, therefore the 
risk of toxicity associated with microparticles can be much lower. However, studies 
(Desai et al. 1996; Heikkilä et al. 2010; Desai et al. 1997; He & Park 2016) have shown 
uptake of microparticles of size up to 10 µm by intestinal epithelium, with particles of 
size < 5 µm transported through lymphatics and particles of size > 5 µm retained in the 
Peyer’s patches, suggesting the importance of considering the toxicity of microparticles 
of size < 10 µm. Also, the particle size of the carrier may affect the drug release rate; 
smaller particles can exhibit faster drug release due to higher surface to volume ratio and 
shorter pore length (Y. Zhang, Wang, et al. 2014; Burguete et al. 2012). Therefore, the 
particle size of activated carbon used in this study was determined by laser diffraction. 
 AC used in this study has a particle size in the range of 0.55- 87.5 µm, with nearly 40% 
of the particles ≤ 10 µm in size (Figure 3-1 and Table 3-1), indicating the possibility of 
internalisation by cells.  Hence, toxicity studies were performed on Caco-2 cells to 
determine the feasibility of application of AC in oral drug formulations.  
Caco-2 cells were incubated with media containing AC in concentrations of 10-
800µg/mL, with cell survival rate subsequently evaluated by MTT assay (Figure 3-2). 
There was a statistically significant difference in the survival rate between cells exposed 
to different concentrations of AC (p < 0.0001, one-way ANOVA). A post hoc test showed 
that there was no statistically significant difference (p > 0.05, Dunnett’s multiple 
comparison test),  for AC in concentrations of 10-200 µg/mL; however, for the 
concentrations ≥ 400 µg/mL, significant toxicity was observed (p < 0.01, Dunnett’s 
multiple comparison test), which could be attributed to adsorption of nutrients in the 
culture medium by activated carbon (Fröhlich 2012; Baeza-Squiban et al. 2011). 
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Nevertheless, even at the highest concentration (800 µg/mL) tested, the cell viability was 
still over 80%, suggesting that application of AC with a particle size above 0.45 µm could 
be safe for oral drug delivery. 
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Figure 3-1: Particle size distribution of activated carbon. 25 mg of carrier was dispersed in 200 mL of 
ethanol and then analysed for particle size using laser diffraction (HELOS, Sympatec GmbH, Germany) in 
the measuring range of 0.1 to 500 µm. 
 
Table 3-1: Particle size characteristics of activated carbon from laser diffraction analysis. 
Material X90a (µm) X50b (µm) X10c (µm) Volume mean 
diameter (µm) 
Span 
Activated 
carbon 
40.59 ± 0.53 12.62 ± 0.09 3.92 ± 0.02 17.85 ± 0.15 2.91 ± 0.02 
a Particle dimension corresponding to 90% of the cumulative undersize distribution 
b Median particle dimension 
c Particle dimension corresponding to 10% of the cumulative undersize distribution 
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Figure 3-2. Cytotoxicity of activated carbon against Caco-2 cells. MTT assay was used to analyse the 
survival rate of Caco-2 cells incubated with different concentrations of activated carbon. Statistically 
significant differences compared to control (0 µg/mL) are noted for p < 0.05 (**p < 0.01; *** p < 0.001; **** 
p < 0.0001, one-way ANOVA and Dunnett’s multiple comparison test). 
 
3.2.2. Determination of drug loading efficiency 
Drug loading was performed as described in section-2.4.1. The sediment obtained after 
centrifugation was allowed to dry for 24 hours, during which residual ethanol was 
evaporated, leaving a crystalline layer of the drug on the top of the sediment. Also, due 
to the tight packing of particles in the sediment, the evaporation process was slowed 
down, which can give enough time for the drug to be diffused into the deeper pores 
(Preisig et al. 2014). The quantity of drug present in the supernatant, crystalline layer of 
the sediment and complex are presented in Table 3-2. The loading efficiency was found 
to be 20.7 % and 44.4 % for paracetamol (PA) and ibuprofen (IBU), respectively. The 
higher drug loading of IBU is attributed to the higher initial concentration of IBU in the 
loading solution, due to its higher maximum solubility in ethanol compared to PA. 
Although the loading efficiency was higher, the fraction of adsorbed to the unadsorbed 
drug was lower for IBU compared to that of PA, which could be due to better interstitial 
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accommodation with the ethanol leading to stronger interactions between IBU and 
ethanol (Domańska et al. 2009) since among many aspects,  adsorption depends on the 
solubility of the adsorptive (drug) and solution chemistry (Radke & Prausnitz 1972).  It 
was also found that analysis of free drug in the supernatant solution can give a false 
estimation of drug loading capacity, since it does not consider the top crystalline layer of 
the sediment.  
Table 3-2: Comparison of ibuprofen and paracetamol loading in activated carbon 
Drug Initial quantity 
of drug a (mg) 
Quantity of 
drug in the 
complex (mg) 
% Loading 
efficiency 
(drug/complex)  
Quantity of drug (mg) 
Supernatant 
b 
Crystalline 
layer c 
PA 1500 208 ± 12.5 20.7 ± 1 985.5 ± 12  320.5 ± 6  
IBU 6900 643 ± 77.7 44.4 ± 4 5592.4  ± 
159  
662.3 ± 174  
a per 10mL of Ethanol 
b supernatant obtained from centrifugation 
c  top crystalline layer of the sediment. 
 
3.2.3. Solid-state analysis of drug 
DSC and XRD techniques were used to detect any crystalline drug in the complex. Pure 
paracetamol exhibited a melting peak at 169 °C, characteristic of monoclinic Form I 
crystalline paracetamol (Qi et al. 2008). In the case of PA/AC phy mix containing an 
equivalent amount of PA and AC as that of complex, a melting peak at 169 °C similar to 
that of pure PA was observed. However PA/AC complex did not show any crystallinity, 
suggesting that the paracetamol is completely amorphous in the complex (Figure 3-3). 
Pure ibuprofen and a physical mixture containing an equivalent amount of IBU and AC 
as that of complex exhibited a melting peak at 74.8 °C indicative of crystalline drug (Cano 
et al. 2001; Xu et al. 2004). However, unlike PA/AC complex, IBU/AC complex 
exhibited a melting peak at 74.8 °C, suggesting the presence of crystallinity (Figure 3-4). 
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To determine the amount of crystallinity, melting enthalpies of IBU/AC phy mix and 
IBU/AC complex were compared (Table 3-3) and the percentage crystallinity in the 
IBU/AC complex, was found to be about 19% of the total drug present in the IBU/AC 
complex (which is equivalent to 122 mg of IBU, since the total IBU present in IBU/AC 
complex is 643 mg). This suggests that the true loading efficiency for IBU is 39% and 
loading higher than this could lead to crystallisation of ibuprofen. To obtain IBU/AC 
complex with no crystallinity, the concentration of IBU in the loading solution needs to 
be adjusted, suggesting that saturated drug solution for loading is not suitable in all cases, 
especially for drugs with high solubility in the loading solvent, which could result in 
higher loading leading to crystallisation. Hence, it is important to optimise drug loading 
conditions to obtain drug/carrier complexes with 100% amorphous drug and will be 
investigated in the next chapter. Also, melting enthalpies of both PA/AC phy mix and 
IBU/AC phy mix were not equivalent to that of pure PA and IBU respectively. Possible 
reasons for such differences could be: (1) drug-AC interactions leading to reduced 
intermolecular forces in the drug and; (2) adsorption of drug into the pores of AC during 
the process of melting (Wang et al. 2012; Chen et al. 2012). The exact mechanism on 
how these can lead to changes in melting enthalpy requires further investigation. 
  
  
89 
 
Table 3-3: Melting enthalpies and melting temperatures obtained from DSC thermograms of pure drugs, 
drug/carrier complexes, and drug/carrier physical mixtures. 
Sample Drug 
carrier 
ratio (w/w) 
Melting 
Enthalpy (J/g) 
Melting 
temperature 
(°C) 
% Crystallinity  
IBU 1:0 130.3 74.8 100 
IBU/AC phy mix 0.8:1 83.4 74.8 100* 
IBU/AC 
complex 
0.8:1 15.78 72 19 
PA 1:0 181 169.2 100 
PA/AC phy mix 0.25:1 27.1 169.2 100* 
PA/AC complex 0.25:1 - - 0 
* Crystallinity in the physical mixture is considered as 100% to calculate the crystallinity in the complex 
relative to that of physical mixture.  
 
Figure 3-3: DSC curves of paracetamol (PA), activated carbon (AC), paracetamol loaded activated carbon 
(PA/AC complex) and physical mixture of paracetamol and activated carbon (PA/AC phy mix). No melting 
peak was found in PA/AC complex indicating that the drug loaded was completely amorphous. Note that 
the heat flow scale is arbitrary. 
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Figure 3-4: DSC thermograms of ibuprofen (IBU), activated carbon (AC), ibuprofen-loaded activated 
carbon (IBU/AC complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy mix). 
IBU/AC complex exhibited a melting peak and from the melting enthalpy, percentage crystallinity was 
found to be 19% of the total drug loaded. Note that the heat flow scale is arbitrary. 
 
The results from DSC were confirmed by X-ray diffraction studies (Figure 3-6 and Figure 
3-5). PA and PA/AC Phy mix showed characteristic diffraction peaks at 15.4°, 18.1°, 
20.3°, 23.3°, 24.2° and 26.4°, corresponding to crystalline PA (I.-C. Wang et al. 2011). 
XRD patterns of pure IBU and IBU/AC phy mix showed characteristic peaks at 11.8°, 
16.4°, 17.4°, 20° and 22° (2θ), corresponding to crystalline IBU (Liu et al. 2014; Martín 
et al. 2009).  
In the case of drug/carrier complexes, XRD patterns of PA/AC complex did not show 
any peaks corresponding to crystalline PA, suggesting that the drug was completely 
present in an amorphous form. However, IBU/AC complex exhibited diffraction patterns 
corresponding to crystalline IBU; however, the peaks at 20° and 22° were less intense, 
suggesting reduced crystallinity of IBU.  
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Figure 3-5: XRD patterns of paracetamol (PA), activated carbon (AC), paracetamol loaded activated carbon 
(PA/AC complex) and physical mixture of paracetamol and activated carbon (PA/AC phy mix). No 
diffraction pattern was found in PA/AC complex corresponding to crystalline PA indicating that the drug 
loaded was completely amorphous. Note that the intensity scale is arbitrary. 
 
 
Figure 3-6: XRD patterns of ibuprofen (IBU), activated carbon (AC), ibuprofen-loaded activated carbon 
(IBU/AC complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy mix). IBU/AC 
complex exhibited a diffraction pattern corresponding to crystalline IBU however, the peaks at 20° and 22° 
were less intense. Note that the intensity scale is arbitrary. 
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Results from DSC and XRD studies suggest, in the case of PA/AC complex, PA was 
effectively loaded into the pores of AC in an amorphous state. However, with IBU/AC 
complex, the loaded drug was not completely amorphous, which could be attributed to 
the higher loading, which in turn is a result of higher concentration of drug in the loading 
solution compared to PA. This indicates the effect of initial drug concentration on the 
loading efficiency and solid state characteristics and will be investigated in the next 
chapter. Nevertheless, both PA and IBU loaded into AC were successfully converted into 
the amorphous form. 
3.2.4. Drug carrier interactions 
It is important to consider possible chemical interactions between the drugs and AC, since 
these interactions can affect the chemical nature and stability of the drugs loaded. FTIR 
spectra of AC did not show any significant peaks (Figure 3-7 and Figure 3-8), whilst the 
sloping of the spectra towards the right in samples containing AC is due to an increase in 
the absorption by carbon with an increase in wavelength (decrease in wavenumber), since 
the depth of penetration of radiation increases at higher wavelengths (Wilhelm 1996).  
FTIR spectra of PA and PA/AC phy mix (Figure 3-7) showed a strong peak at 3310cm-1 
and a broad peak at 3200 cm-1, corresponding to secondary amide N-H stretching and 
phenol O-H stretching, respectively. Also, a sharp peak corresponding to carbonyl C=O 
stretching at 1645 cm-1 was found. Spectra of IBU and IBU/AC phy mix (Figure 3-8) 
showed a sharp peak corresponding to carboxylic acid (C=O) stretching at 1710 cm-1  and 
characteristic three peaks between 2960-2860 cm-1, corresponding to C-H stretching.(Lai 
et al. 2017) 
No significant peaks corresponding to PA were found in the case of PA/AC complex 
(Figure 3-7) and could be due to the absence of PA on the surface or in the superficial 
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pores. Since the depth of penetration of IR into the samples is only about 0.2 - 5 µm, drug 
deposited in the deeper pores may not be detected (Kazarian & Chan 2013).  PA/AC 
complex with higher drug loading could help study about possible chemical interactions 
between PA and AC and will be discussed in the next chapter.  
Spectra of IBU/AC complex was found to be similar to that of IBU, with no significant 
shift in the existing peaks and no new peaks found, indicating the absence of any chemical 
interactions (Figure 3-8). The presence of peaks in the spectrum of IBU/AC complex 
unlike that of PA/AC complex, could also indicate the presence of IBU as separate drug 
crystals or as a layer adsorbed on the external surface of AC, further supporting results 
from DSC and XRD.  
 
Figure 3-7: FTIR spectra of paracetamol (PA), activated carbon (AC), paracetamol-loaded activated carbon 
(PA/AC complex) and physical mixture of paracetamol and activated carbon (PA/AC phy mix). No 
chemical interactions could be detected between PA and AC. Note that the transmittance scale is arbitrary. 
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Figure 3-8: FTIR spectra of ibuprofen (IBU), activated carbon (AC), ibuprofen-loaded activated carbon 
(IBU/AC complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy mix). No 
chemical interactions could be detected between IBU and AC. Note that the transmittance scale is arbitrary. 
 
3.2.5. Surface morphology 
The above studies demonstrate that, in the case of PA/AC complex, PA is completely 
amorphous, loaded into the pores and is absent on the surface of AC, while IBU/AC 
complex contained crystalline and possibly surface adsorbed IBU. To examine the 
surface morphology and to identify sites of adsorption of the drug in the complex, SEM 
images were obtained (Figure 3-9). However, in IBU/AC complex, small particles of 
approximately 2 µm in size adsorbed on the surface could be seen, indicated by an arrow 
in Figure 3-10 (c). When this particular area in IBU/AC complex with adsorbed particles 
was magnified, the surface morphology looked completely different to that of pure AC 
(Figure 3-10 (d)), and the presence of these particles could be due to the surface 
crystallisation of IBU as previously indicated by DSC, XRD and FTIR studies. 
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Figure 3-9: SEM images of (a) and (b) activated carbon, (c) and (d) paracetamol, (e) and (f) paracetamol 
loaded activated carbon with 25% loading.     
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Figure 3-10: SEM images of (a) and (b) ibuprofen, (c) and (d) ibuprofen loaded activated carbon with 44% 
loading showing surface crystallised ibuprofen. 
 
3.2.6. In vitro drug release studies 
The dissolution profiles of pure drug and drug/carrier complex are presented in Figure 
3-11 and Figure 3-12. Phosphate buffer at pH 5.8 and pH 7.2 was used as dissolution 
medium for paracetamol and ibuprofen, respectively, according to BP specifications 
(Pharmacopoeia 2016). Prior to the study, all the samples were put in hard gelatin 
capsules, which took approximately 3 minutes to disintegrate; hence, drug release has 
commenced at 3 min in all the samples.  
Compared to crystalline PA, the dissolution rate of PA/AC complex was slightly higher 
until 10 min, after which drug release from the complex slowed down and reached an end 
point at 20 min with an incomplete release (54 %). No further drug release was observed 
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even after 72 hours and this incomplete PA release from the complex could be attributed 
to poor wettability of AC (powder samples floating on the surface of the dissolution 
medium could be observed), leading to inaccessibility of dissolution medium to deeper 
pores. Therefore, sodium phosphate buffer with 1% SDS was used as dissolution medium 
to improve the wettability of carbon. Indeed, the complete release was achieved for 
PA/AC complex in the presence of SDS. There was a statistically significant difference 
in the drug release between pure crystalline PA and PA/AC complex (p < 0.0001, two-
way ANOVA), which could be due to the amorphous nature of PA loaded into porous 
AC. Compared to pure crystalline drug, amorphous drug present in the pores of AC has 
a higher surface area in contact with the dissolution media, which can result in faster 
release; thus, the drug loaded into AC, compared to the pure crystalline drug, favoured 
faster release. 
                 
Figure 3-11: Dissolution profiles of paracetamol (PA) and paracetamol loaded activated carbon (PA/AC 
complex) determined at pH 5.8. Curves PA-SDS and PA/AC complex-SDS represent dissolution profiles 
determined in media containing 1% SDS. Statistically significant differences are noted for p < 0.05, (**** p 
≤ 0.0001, two-way ANOVA and Bonferroni’s multiple comparison test). 
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In the absence of SDS, similar to PA/AC complex, drug release from IBU/AC complex 
was incomplete (no further release was observed even after 72 hours) with 61% release 
(Figure 3-12 (a)); however, was higher than PA/AC complex (total release was 56%), 
and could be due to the presence of higher amount of IBU in the superficial pores of AC 
or due to the presence of crystalline ibuprofen outside the pores of AC.   
In the presence of SDS, drug release from IBU/AC complex was complete, reaching an 
endpoint within 15 minutes; however, there was no statistically significant difference in 
the drug release between crystalline IBU and IBU/AC complex (p > 0.5, two-way 
ANOVA), which could be due to the higher solubility of IBU at pH 7.2. IBU is a weak 
acid with pKa 4.9 and its solubility is lower at acidic pH (Rivera-Leyva et al. 2012). 
Therefore, sodium phosphate buffer at pH 5.5 with and without SDS (Figure 3-12 (b)), 
was used as dissolution medium to reduce the solubility of IBU. In the absence of SDS, 
drug release from IBU/AC complex was incomplete similar to that at pH 7.2, indicating 
that pH did not have any effect on the wettability of carbon. It was observed that 
disintegration of gelatin capsules at pH 5.5 was faster compared to pH 7.2, due to which 
a higher initial release (within 5 min) was observed at pH 5.5 compared to pH 7.2 (Zhao 
et al. 2004). 
In the presence of SDS, there was a statistically significant difference in the drug release 
between pure crystalline IBU and IBU/AC complex (p < 0.0001, two-way ANOVA); 
however, when drug release data from IBU/AC complex at pH 7.2 was compared with 
IBU/AC complex at pH 5.5 (Figure 3-13), no statistically significant difference was 
found (p > 0.5, two-way ANOVA), indicating that: (1) the difference observed in the 
drug release between IBU and IBU/AC complex at pH 5.5 is due to reduction in the drug 
release rate of pure crystalline IBU and not due to increase in the drug release from 
IBU/AC complex; (2) that drug release from IBU/AC complex was less pH dependent. 
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Nevertheless, compared to the pure crystalline IBU, IBU/AC complex favoured faster 
release (at pH 5.5), further supporting results from PA/AC complex release studies.  
 
 
Figure 3-12: Dissolution profiles in sodium phosphate buffer determined at (a) pH 7.2 and (b) pH 5.5. 
Curves IBU and IBU/AC complex represent pure ibuprofen and ibuprofen-loaded activated carbon. Curves 
IBU-SDS and IBU/AC complex-SDS represent dissolution profiles determined in media containing 1% 
SDS. Statistically significant differences are noted for p < 0.05 (****p < 0.0001, two-way ANOVA and 
Bonferroni’s multiple comparison test). 
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Figure 3-13: Comparison of dissolution profiles of ibuprofen-loaded activated carbon complex determined 
at pH 7.2 and pH 5.5 in sodium phosphate buffer with 1% SDS. Statistically significant differences are 
noted for p < 0.05 (two-way ANOVA). 
 
Drug release profiles obtained in the presence of SDS for PA and IBU were fitted with 
simplified Higuchi model which describes drug release based on Fick’s law of diffusion 
(equation-9) which can be used to describe diffusion controlled system where drug 
release is from an insoluble matrix (Costa et al. 2001; Izquierdo-Barba et al. 2005): 
𝑓𝑡 = 𝐾𝐻𝑡
1/2                         (Equation-9) 
Where 𝐾𝐻 is the Higuchi constant and 𝑓𝑡 is the fraction of drug released at time t 
Higuchi square root of time plots for both drug loaded complexes (Figure 3-14), display 
a two-step release with an initial burst effect, which could be attributed to the drug release 
from superficial macropores and mesopores followed by slow release which could be 
attributed to drug release from deeper micropores. Results also show that kinetic 
  
101 
 
constants for PA and IBU are different indicating the influence of the chemical nature of 
drug (Table 3-4).  
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Figure 3-14: Two step regression linear utilising Higuchi’s square root of time plot for drug release from 
complex in the presence of SDS. In brackets pH of the dissolution medium. Each point represents the mean 
of n=3 determinations. 
 
Table 3-4: Kinetic parameters of drug release from paracetamol and ibuprofen loaded activated carbon 
Sample Higuchi diffusion two step 
Duration Rate constant Linear regression 
coefficient 
PA/AC complex at 
pH 5.8 
3-10 min 
10-20 min 
47.54 
16.88 
1 
0.8854 
IBU/AC complex at 
pH 5.5 
3-10 min 
10-20 min 
54.75 
3.87 
0.9342 
0.9202 
IBU/AC complex at 
pH 7.2 
3-10 min 
10-20 min 
55.22 
5.72 
0.9994 
0.7913 
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3.2.7. Porosity analysis to determine the sites of adsorption 
Adsorption isotherms and pore size distribution curves of AC before and after drug 
loading are shown in Figure 3-15 and Figure 3-16, with the data from N2 sorption studies 
summarised in Table 3-5. The adsorption/desorption isotherm of AC exhibited a typical 
type IV isotherm and a hysteresis loop, characteristic of microporous materials with 
significant mesoporosity (Chen et al. 2010). The pore size distribution of pure AC shows 
the presence of pores in the range of 2-14 nm. For PA/AC physical mixture, reduction in 
surface area and pore volume was observed, but the pore size distribution was similar to 
that of AC indicating that the drug was not present inside the pores of AC. However, for 
IBU/AC physical mixture, pore size distribution became broader and the exact reason for 
this is not clear, however could be due to adsorption of IBU on AC due to hydrophobic 
interactions. 
Table 3-5: Surface areas and pore volumes obtained from Nitrogen sorption of pure activated carbon (AC), 
ibuprofen loaded activated carbon (IBU/AC complex) and paracetamol loaded activated carbon (PA/AC 
complex)  
Sample Specific surface areaa 
(m2/g) 
Total pore volume b 
(cm3/g) 
Micropore volume b 
(cm3/g) 
AC-untreated 1027.4 0.81 0.33 
AC-Post 
treatment 
994.6 0.77 0.32 
PA/AC complex 127 0.31 0.016 
IBU/AC complex 101.8 0.23 0.014 
PA/AC phy mix 673.5 0.57 0.21 
IBU/AC phy mix 30.9 0.17 0 
a Calculated  by BET method 
b Calculated by NLDFT method  
 
 
  
103 
 
A C
R e la t iv e  p r e s s u r e  ( P / P o )
Q
u
a
n
ti
ty
 A
d
s
o
r
b
e
d
 (
c
m
³
/
g
 S
T
P
)
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
0
2 0 0
4 0 0
6 0 0
P A / A C  c o m p le x - 2 0 .5 %
P A / A C  p h y  m ix - 2 0 .5 %
( a )
 
A C
R e la t iv e  p r e s s u r e  ( P / P o )
Q
u
a
n
ti
ty
 A
d
s
o
r
b
e
d
 (
c
m
³
/
g
 S
T
P
)
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
0
2 0 0
4 0 0
6 0 0
I B U / A C  c o m p le x - 4 4 .5 %
IB U / A C  p h y  m ix -4 4 .5 %
( b )
 
Figure 3-15: Nitrogen adsorption/desorption isotherms at 77 K of activated carbon (AC) before and after 
drug loading showing, (a) paracetamol loaded activated carbon (PA/AC complex) and physical mixture of 
paracetamol and activated carbon (PA/AC phy mix); (b) ibuprofen-loaded activated carbon (IBU/AC 
complex) and physical mixture of ibuprofen and activated carbon (IBU/AC phy mix). 
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Figure 3-16: (a) Nitrogen adsorption/desorption isotherms at 77 K (b) Pore size distribution (2-14nm) 
calculated using NLDFT slit-shaped pore model, of pure activated carbon (AC), ibuprofen-loaded activated 
carbon (IBU/AC complex) and paracetamol loaded activated carbon (PA/AC complex).  
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3.3.Conclusion  
The potential for activated carbon as an amorphous drug carrier was investigated, using 
paracetamol and ibuprofen as model drugs. Solution adsorption is the most commonly 
used method for drug loading into a porous carrier. Hence, drug loaded AC (drug/AC) 
complex was prepared by solution adsorption where AC was immersed in saturated drug 
solution at 20C and stirred for 24 hours. UV analysis revealed that drug loading of 20.7 
± 1 and 44.4 ± 4 % (w/w) was achieved for PA and IBU, respectively. Higher loading of 
IBU is attributed to the higher concentration of IBU in the loading solution, indicating 
the effect of concentration in the loading solution on the loading efficiency. Solid-state 
analysis showed that PA present in the PA/AC complex was completely amorphous, 
whereas 19% of the IBU in IBU/AC complex was found to be crystalline. FTIR studies 
could not detect any drug in PA/AC complex, which could be due to the absence of 
surface adsorbed drug in PA/AC complex, since the depth of penetration is < 5 µm and 
drug deposited in the deeper pores could not be detected. Whereas, FTIR was able to 
detect IBU in IBU/AC complex, which could be attributed to the higher loading and 
presence of surface adsorbed drug or crystalline drug particles. However, no chemical 
interactions could be detected between IBU and AC, confirming physical adsorption. The 
higher loading of IBU and presence of crystallinity in the IBU/AC complex indicated that 
using saturated drug solution for drug loading is not applicable to all drugs, and optimum 
concentration of drug in the loading solution needs to be determined for every drug due 
to the difference in the solubility and chemical characteristics of the drug. Therefore, 
optimisation of drug loading method is necessary and will be discussed in chapter 4. 
In vitro release studies were performed in phosphate buffer with and without the addition 
of 1% sodium lauryl sulphate. All the powder samples were loaded into gelatin capsules 
to eliminate powders floating on the surface of the dissolution media. Drug release was 
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complete within 20 min (in the presence of 1% SDS) for both PA/AC complex and 
IBU/AC complex and exhibited faster initial release compared to the pure drug, which 
could be attributed to the presence of amorphous drug and a higher surface that is in 
contact with the dissolution media. The release rate of both PA/AC and IBU/AC 
complexes was found to be diffusion controlled with an initial burst followed by slow 
release and the rate constant was dependant on the characteristics of the drug.  Also, IBU 
release from the complex was found to be independent of pH of the dissolution medium 
which could be due to the higher influence of properties of the carrier; however, further 
studies are needed to confirm this effect and will be discussed in chapter-5. Cytotoxicity 
studies revealed that Caco-2 cells incubated with media containing 800 µg/mL of 
activated carbon (particle size of 0.45- 87.5µm) showed cell survival rate above 80%, 
suggesting the low toxicity of these particles. The low toxicity, high drug loading capacity 
and ability to stabilise amorphous drug supports the potential of activated carbon as an 
amorphous drug carrier. 
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 -Towards development of activated carbon as a drug carrier: 
optimisation of drug loading method 
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4.1.  Introduction 
Drug loading into porous carriers has shown to improve the dissolution rate of the drug, 
since the loaded drug is shown to exhibit an amorphous nature. However, the loading 
method and loading parameters can affect the diffusion of the drug into the pores of the 
carrier, thereby affecting the loading efficiency, solid state characteristics and drug 
release kinetics (Ahern et al. 2013); therefore, it is important to investigate the influence 
of loading factors on the performance of activated carbon (AC) as a drug carrier.  
Solution impregnation (solution adsorption) and solvent evaporation are the most 
commonly used drug loading methods, due to their simplicity and relatively low cost (Lai 
et al. 2017; Preisig et al. 2014). Solution impregnation involves immersion of the carrier 
in a saturated drug solution to allow the drug molecules to diffuse into the pores of the 
carrier, whereby the drug-loaded carrier particles are then collected by filtration or 
centrifugation. Solvent evaporation involves the addition of a carrier to a drug solution 
and evaporation of the solvent by rotary evaporation to obtain drug-loaded carrier 
particles. In this study, loading methods will be compared to understand the subsequent 
impact on the properties of drug/AC complex. 
In addition to the loading method, initial drug concentration can also affect the drug 
loading efficiency and solid state characteristics of the loaded drug (Kinnari et al. 2011). 
High concentrations of drug in the loading solution acts as the driving force for the 
diffusion of the drug into the pores of the carrier, therefore a high concentration of the 
drug is required to achieve maximum drug loading (Lai et al. 2017). However, a high 
concentration of drug in the loading solution can also lead to crystallisation on the surface 
of the carrier particles or as separate crystals. Indeed, as seen in the previous chapter, it 
was shown that paracetamol (PA) loaded into AC was completely amorphous, with a 
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loading efficiency of 20.7%, whereas ibuprofen (IBU) loaded AC was found to contain 
19% crystallinity, with a loading efficiency of 44.4%. Therefore, in order to obtain 
PA/AC complex with higher loading and IBU/AC complex without crystallinity, the 
optimum concentration of drug in the loading solution needs to be determined. In 
addition, these results can also demonstrate how the nature of the drug itself may further 
impact on loading efficiency and solid state characteristics since chemical nature of the 
drug affects the drug-carrier interactions thereby affecting the drug loading process.  
Also, loading parameters such as contact time, temperature, and carrier dose can also 
have an effect on the loading efficiency and investigating the effects of these factors is 
essential for design and operation of experiments for drug loading into activated carbon 
(Lai et al. 2017; Yi et al. 2016).  
4.2.  Aims and objectives 
The aim of this current chapter is to investigate the effects of loading parameters, namely 
loading method, contact time, loading temperature, and carrier dose on drug loading and 
release. To achieve this, the main objectives of this study were to: 
1) Compare the characteristics of the loaded drug in the drug/carrier complexes 
obtained using three different solvent based loading methods.  
2) Investigate the effects of contact time, temperature and carrier dose on loading 
efficiency.  
3) Determine the optimum initial drug concentration in the loading solution to achieve 
drug loading without any crystallinity.  
4) Identify the interactions between drug and carrier in complexes with different 
loadings. 
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4.3. Results and Discussion 
4.3.1. Effect of drug loading method on loading efficiency and solid state 
characteristics 
In the previous chapter, solution adsorption followed by centrifugation (SA-C) was used 
to prepare drug/carrier complex to investigate the potential of AC as a porous carrier. In 
this study, to understand the effect of loading method on loading efficiency and solid 
state characteristics, drug/carrier complex was prepared using three different solvent 
based loading methods namely rotary evaporation (RE), solution adsorption -filtration 
(SA-F) and solution adsorption -centrifugation (SA-C) as described in section-2.4.2. The 
quantity of drug in the complex was determined by UV spectroscopy and drug loading 
efficiency was calculated, as described in section-2.8. Percentage drug crystallinity in the 
complex was determined by comparing the melting enthalpy with that of a physical 
mixture containing an equivalent quantity of drug, as described in section-2.9.  
Table 4-1: Comparison of loading efficiencies and solid state characteristics of drug/carrier complexes 
prepared by three different methods (stirring speed: 100 rpm, temperature: 25 oC; initial PA and IBU 
concentration: 165 and 970 mg/mL of ethanol respectively; solution volume: 10 mL; AC dose: 1000 mg; 
contact time: 1 hour). 
Method % Drug loading   Melting enthalpy, J/g (Melting 
point , °C) 
% Crystallinity 
PA IBU PA IBU PA IBU 
RE 60.3 ± 1.7 88.5 ± 1.2 45 ± 4 (168) 77 ± 4.2 (74.2) 46.3 ± 4.1 62.1 ± 3.4 
SA-F 23.4 ± 5.2 54.5 ± 7.1 9 ± 2 (168) 30.45 ± 3 (69.8) 30 ± 6.7 37.7 ± 3.8 
SA-C 18 ± 3.4 48.4 ± 4.7 - 15.23 ± 3.8 
(72.3) 
- 22.1 ± 5.4 
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Statistically significant difference was found in the loadings (p<0.0001, one-way 
ANOVA) obtained from three different methods (Table 4-1). Also a post hoc test showed 
that there was no significant difference (p>0.5, one-way ANOVA followed by Tukey’s 
test) in the loading between SA-F and SA-C methods and could be due to the fact that 
the loading methods are very similar except with the post loading collection process, 
however, the complex prepared by SA-C method showed lower crystallinity (Figure 4-1 
and Figure 4-2)  and could be due to slower evaporation of solvent from the sediment 
obtained after centrifugation, allowing enough time for the surface adsorbed drug to 
diffuse into the pores of AC. Whereas, in the case of the SA-F method, vacuum filtration 
could have led to the crystallisation of the drug due to the rapid removal of the solvent. 
 The drug/AC complex prepared by RE method showed the highest loading (Table 4-1), 
since this method involves removal of loading solvent by evaporation leaving behind all 
the drug added. However, the complex obtained from this method also showed the highest 
amount of crystallinity and is attributed to the rapid evaporation of solvent leading to less 
contact time for the drug to diffuse into the pores, thereby resulting in the crystallisation 
of the drug (Runt & Rim 1982).  
Also, SA-F exhibited lower crystallinity due to the efficiency of separation of unbound 
drug by filtration compared to RE which removed the solvent alone by evaporation. With 
increase in drug loading, % crystallinity was found to increase and could be due to the 
saturation of the carrier at some point, indicating that increasing the loading above its 
capacity will lead to crystallisation of the drug. 
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Figure 4-1: DSC curves of paracetamol loaded activated carbon samples (PA/AC complex) prepared by 
three different methods. No melting peak was found in PA/AC complex prepared by Solution adsorption-
Centrifugation method indicating that the drug loaded is completely amorphous. Note that the heat flow 
scale is arbitrary. 
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Figure 4-2: DSC curves of ibuprofen-loaded activated carbon samples (IBU/AC complex) prepared by 
three different methods. Melting peaks were found in the complex obtained from all three methods 
indicating the presence of crystallinity. Note that the heat flow scale is arbitrary. 
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Also, melting temperatures were found to be different (Figure 4-2) for IBU/AC 
complexes obtained from different methods, which could be attributed to the difference 
in the rate of evaporation of ethanol leading to changes in the crystal habit. For e.g. rapid 
evaporation of solvent leads to formation of cavities during the crystal growth process 
(Viseras et al. 1995; Zhang et al. 2015; Lee et al. 2007). Also, higher loading in IBU/AC 
complex compared to PA/AC complex prepared from all three methods could be 
attributed to the higher concentration of IBU in the loading solution due to its higher 
maximum solubility in ethanol compared to PA. Although all three methods resulted in 
crystallisation of drug, the complex prepared by the SA-C method exhibited the least 
crystallinity, therefore all subsequent loadings were performed using this method. 
 
4.3.2. Investigating the effect of contact time between drug and carrier on the 
loading efficiency 
Diffusion of drug molecules into the pores of the carrier depends on the contact time 
between the drug and the carrier, therefore allowing enough time for maximum drug 
loading is crucial (Thomas 1983). To determine the contact time required for maximum 
loading, drug loading was performed at different stirring times as described in section-
2.4.3.  
Results from both PA and IBU loading (Figure 4-3) showed a statistically significant 
difference in the drug loading between complexes obtained at different contact times (p 
< 0.05, one-way ANOVA). A post hoc test showed that loading increased significantly 
with an increase in contact time up to 4 hours (p < 0.05, one way ANOVA followed by 
Tukey’s test) and there was no statistically significant difference (p > 0.05, Tukey’s 
multiple comparison test) in the drug loading of complexes obtained at contact time of 4-
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24 hours, suggesting that equilibrium was reached at 4 hours. Therefore, all subsequent 
loadings were performed for 4 hours. Also, a high drug loading (16.4% and 35% for PA 
and IBU, respectively) was achieved within 1 hour of stirring and could be attributed to 
the rapid adsorption of the drug due to large concentration gradient and ease of 
accessibility of adsorption sites in the superficial pores. The contact time required to 
reach an equilibrium depends on various factors such as porosity of the carrier, 
solute/adsorbate and solvent and therefore needs to be determined based on the loading 
conditions (Yi et al. 2016). 
n s
C o n t a c t  t im e  ( h o u r s )
%
 D
r
u
g
 L
o
a
d
in
g
0 5 1 0 1 5 2 0 2 5
0
1 0
2 0
3 0
4 0
5 0
P a r a c e t a m o l
Ib u p r o fe n
*
* n s
 
Figure 4-3: Effect of contact time on loading efficiency (stirring speed: 100 rpm; temperature: 20 oC; initial 
PA and IBU concentration: 150 and 698 mg/mL of ethanol respectively; solution volume: 10 mL; AC dose: 
1000 mg). Results are the mean of triplicate experiments ± SD. Statistically significant differences are 
noted for p < 0.05 (*p < 0.05; ns-no significance; one-way ANOVA and Tukey’s multiple comparison 
test). 
 
4.3.3. Effect of Temperature on loading efficiency  
Temperature affects the interactions between the drug (solute) and the solvent, thereby 
affecting the adsorption of the drug by the porous carrier (Garzón et al. 2004). Therefore, 
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to understand the effect of temperature on drug loading, drug loading was performed at 
four different temperatures as described in section-2.4.4. 
With the increase in temperature, a statistically significant difference was found in the 
drug loading (p < 0.05, one-way ANOVA), suggesting that drug loading was temperature 
dependent. Loading efficiency decreased with increase in the temperature (Figure 4-4) 
and is similar to the results obtained from previous research. Reduction of drug loading 
at higher temperatures is due to reduced adsorption of molecules that tend to stay in the 
solution due to higher energy. Also, the decrease in the loading was found to be higher 
in the case of IBU than PA, suggesting that the influence of chemical characteristics of 
the drug due to drug-solvent interactions (Chen et al. 2011; Yi et al. 2016).  
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Figure 4-4: Effect of temperature on loading efficiency (stirring speed: 100 rpm; initial PA and IBU 
concentration: 150 and 698 mg/mL of ethanol respectively; contact time: 4 hours; solution volume: 10 mL; 
AC dose: 1000 mg). Results are the mean of triplicate experiments ± SD. Statistically significant 
differences are noted for p < 0.05 (*p < 0.05, one-way ANOVA and Tukey’s multiple comparison test). 
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4.3.4. Investigating the effect of initial drug concentration in the loading solution 
on loading efficiency and solid state characteristics 
To determine the effect of concentration of drug in the loading solution on the loading 
efficiency, drug loadings were performed by SA-C method using four different drug 
concentrations as described in section-2.4.5. UV results indicated that, with the increase 
in the drug concentration, a statistically significant difference was found in the drug 
loading (p < 0.01, one-way ANOVA). Drug loading reached a maximum when the drug 
concentration in the loading solution reached the saturation point (Figure 4-5), indicating 
that drug loading increases with increase in the initial concentration of drug in the loading 
solution. However previous research found that high drug loading achieved was 
associated with high amounts of crystallinity indicating the disadvantages of using high 
initial drug concentration for loading (Lai et al. 2017).  
Solid state analysis was performed on drug/carrier complex with different loadings and 
lower drug loading was found to be advantageous in the case of IBU/AC complex, since 
thermal studies revealed that crystallinity decreased with a decrease in the drug loading 
(Table 4-2), whereby IBU/AC complex with a loading of 30.2% was completely 
amorphous. These results indicate that IBU/AC complex with complete amorphous drug 
loading could be achieved when the initial drug concentration in the loading solution was 
350 mg/mL. These results might also suggest that the maximum IBU loading that could 
be achieved without any crystallinity is less than 34.6%, since crystallinity was found in 
the IBU/AC complex with a loading ≥ 34.6 %, which is slightly less than the maximum 
IBU loading (39%) estimated from the previous chapter.  
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Figure 4-5: Effect of initial drug concentration on loading efficiency (stirring speed: 100 rpm; temperature: 
20 oC; solution volume: 10 mL; AC dose: 1000 mg; contact time: 4 hours). Results are the mean of triplicate 
experiments ± SD. Statistically significant differences are noted for p < 0.05 (*** p < 0.001, one-way 
ANOVA and Tukey’s multiple comparison test). 
 
Table 4-2: Effect of initial drug concentration on loading efficiency and solid state characteristics of 
IBU/AC complexes (stirring speed: 100 rpm; temperature: 20 oC; solution volume: 10 mL; AC dose: 1000 
mg; contact time: 4 hours). 
Initial drug concentration 
(mg/mL of ethanol) 
% Drug loading % Crystallinity 
350 30.2 ± 2.2 - 
450 34.6 ± 3 6 ± 1.5 
550 37.5 ± 2.6 10 ± 3.4 
698 (saturation point) 45 ± 3.7 19 ± 2.8 
 
No crystallinity was found in the case of PA/AC complex obtained at all four drug 
concentrations, with the highest drug loading achieved being 20.7%, when the initial drug 
concentration used was 150 mg/mL, indicating that higher loading could be achieved if 
the initial PA concertation in the loading solution is further increased; however, this is 
the maximum concentration (150 mg/mL) that could be achieved at 20 oC. Therefore, 
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saturated PA solutions at four different temperatures were used for loading as described 
in section-2.4.6, to determine the maximum PA loading that could be achieved without 
any crystallisation.  
Results indicated that PA loading increased with an increase in the initial drug 
concentration (Table 4-3), reaching a maximum of 26.8% when the initial PA 
concentration in the loading solution was 199 mg/mL at 35 ºC. Also, it has to be noted 
that this higher temperature could have reduced the drug loading since drug loading 
decreased with increase in the temperature in the previous study and the true loading at a 
concentration of 199mg/mL could have been higher than 26.8% if a lower temperature 
(25 ºC) was used; however, it is not possible to reduce the temperature since this will 
result in reduced solubility of the drug.   
Further, PA was found to be loaded in a completely amorphous state in all the samples, 
indicating that drug loading higher than 26.8% could be achieved without leading to 
crystallisation of drug. Therefore, loading of at least 26.8% for PA and 30.2% for IBU 
could be achieved without any crystallisation, when an initial drug concentration of 199 
mg/mL and 350 mg/mL was used for loading PA and IBU, respectively. The difference 
in the optimum required concentration between PA and IBU could be attributed to the 
higher melting point of PA compared to IBU since drugs with higher melting point 
readily undergo crystallisation (Brent 2015). 
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Table 4-3: Effect of initial drug concentration on loading efficiency (stirring speed: 100 rpm; solution 
volume: 10 mL; AC dose: 1000 mg; contact time: 4 hours). 
Temperature (ºC) Drug concentration 
(mg/mL of ethanol)  
% Drug loading   
20 150 20.7 ± 1 
25 165 22 ± 1.8 
30 183 24.6 ± 2 
35 199 26.8 ± 2 
 
4.3.4.1. Effect of loading efficiency on the interactions between drug and carrier 
To understand the effect of loading efficiency on drug-carrier interactions, FTIR 
spectroscopy was used to study drug/carrier complexes. FTIR spectrum of drug/AC 
complex with different loadings were compared with that of pure drug (Figure 4-6 and 
Figure 4-7). 
FTIR spectra of  PA/AC complex with 26.8% drug loading showed a peak at 3310 cm-1, 
a broad peak at 3200 cm-1, and a sharp peak at 1645 cm-1, corresponding to secondary 
amide N-H stretching, phenol O-H stretching, and carbonyl C=O stretching, respectively, 
similar to that of pure PA. In the case of PA/AC complex with 24.6% loading, peaks 
corresponding to N-H and O-H stretching could not be identified, although the peak 
corresponding C=O stretching could be observed. There could be three reasons for this:  
(1) Lower intensity of N-H and O-H peaks compared to C=O peak; (2) the presence of 
the drug in the deeper pores in the complex. The depth of penetration of IR increases with 
a decrease in the wavenumber, therefore, drug located in the deeper pores could be 
identified better at lower wavenumbers (Oelichmann 1989; Kazarian & Chan 2013); (3) 
Lower drug loading leading to reduced intensity of the peaks, since no FTIR peaks could 
be identified in the PA/AC complex with a drug loading of 20.7% (section 3.4.4). 
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Both IBU/AC complexes with loading 30.2% and 44.4% showed a sharp peak, 
corresponding to carboxylic acid (C=O) stretching at 1710 cm-1, and characteristic three 
peaks between 2960-2860cm-1, corresponding to C-H stretching, similar to that of pure 
IBU (Lai et al. 2017). However, the intensity of the peaks was found to decrease with a 
decrease in the drug loading. 
Nevertheless, spectra of drug/AC complex was found to be similar to that of pure drug in 
both PA and IBU. No significant shift in the position of existing peaks was found and no 
new peaks were found, indicating the absence of any chemical bonding between 
functional groups and AC since chemisorption can result in drug potency in some cases 
and can also lead to irreversible drug adsorption or slower drug release which can be 
disadvantageous when immediate release is preferred (Guo et al. 2013; Choudhari et al. 
2014). Also, the presence or absence of peaks in the FTIR spectra doesn’t seem to indicate 
the presence of crystalline drug on the surface of AC, since peaks could be seen in the 
FTIR spectra of PA/AC complexes with no crystallinity.  
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Figure 4-6: FTIR spectra of paracetamol (PA), paracetamol-loaded activated carbon (PA/AC complex) 
with different loadings, showing peaks corresponding to amide, phenol and carbonyl groups of PA. No 
chemical interactions could be detected between PA and AC. Note that the transmittance scale is arbitrary. 
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Figure 4-7: FTIR spectra of ibuprofen (IBU), ibuprofen-loaded activated carbon (IBU/AC complex) with 
different loadings, showing peaks corresponding to methyl and carboxylic acid groups of IBU. No chemical 
interactions could be detected between IBU and AC. Note that the transmittance scale is arbitrary. 
 
4.3.5. Effect of carrier dose on loading efficiency 
Previous studies suggest that the quantity of carrier can affect the drug loading, thereby 
affecting the release rate (Lai et al. 2017). Therefore, to investigate the effect of quantity 
of carrier on drug loading efficiency, drug loading was performed using varying amounts 
of carrier as described in section-2.4.7.  
Drug loading results (Figure 4-8 and Figure 4-9) showed a statistically significant 
difference in the total quantity of drug loaded (p < 0.001, one-way ANOVA) and loading 
efficiency (p < 0.05, one-way ANOVA) between complexes prepared using different 
carrier doses.  A post hoc test showed that total quantity of drug loaded increased 
significantly for PA (p < 0.01, Tukey’s multiple comparison test) and IBU (p < 0.05, 
Tukey’s multiple comparison test) with an increase in the carrier dose from 500 to 1000 
mg (per 10 mL drug solution); however, no significant difference (p > 0.05, Tukey’s 
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multiple comparison test) was found when the carrier dose was increased from 1000 to 
1500 mg (per 10 mL drug solution) for both PA and IBU. 
Although the total amount of drug loaded increased, loading efficiency decreased 
significantly (p<0.001, one way ANOVA) due to an increase in the quantity of the carrier 
in complex and was in agreement with previous reports (Lai et al. 2017). Also it can be 
suggested that the drug loading results were influenced by the quantity of the carrier 
alone, since the initial drug concentration was kept constant (no changes in the drug-
solvent interactions).  
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Figure 4-8: Effect of carrier quantity on PA loading efficiency (stirring speed: 100 rpm; initial PA 
concentration: 150 mg/mL of ethanol respectively; contact time: 4 hours; solution volume: 10 mL; 
temperature: 20 oC). Results are the mean of triplicate experiments ± SD. Statistically significant 
differences are noted for p < 0.05 (** p < 0.01; one-way ANOVA and Tukey’s multiple comparison test). 
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Figure 4-9: Effect of carrier quantity on IBU loading efficiency (stirring speed: 100 rpm; initial IBU 
concentration: 698 mg/mL of ethanol respectively; contact time: 4 hours; solution volume: 10 mL; 
temperature: 20 oC). Results are the mean of triplicate experiments ± SD. Statistically significant 
differences are noted for p < 0.05 (*p < 0.05; one-way ANOVA and Tukey’s multiple comparison test). 
 
4.4. Conclusions   
The work in this chapter showed that the loading efficiency and solid state characteristics 
of the drug loaded into activated carbon are influenced by a range of factors, such as the 
loading method, the concentration of drug in the loading solution, temperature, contact 
time and carrier dose. Three different loading methods were compared and it was found 
that high drug loading could be achieved with solvent evaporation, although this method 
also showed a very high drug crystallinity (46.3% for PA and 62.1% for IBU). Complexes 
prepared by solution adsorption-centrifugation method showed the lowest crystallinity 
and was used for all subsequent drug loadings. Initial drug concentration was also found 
to affect solid state characteristics, with results indicating that drug/carrier complex 
without any crystallinity could be achieved by adjusting the drug concentration in the 
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loading solution; the optimum concentration to achieve a complex without crystalline 
drug was found to be 199 mg/mL and 350 mg/mL for PA and IBU, respectively, and the 
loading achieved was 26.8% for PA and 30.2 % for IBU.  Also, no chemical interactions 
could be detected between the drug and the carrier even at higher drug loading, supporting 
the physical adsorption of the drug. 
Drug loading into activated carbon was found to reach an equilibrium in 4 hours, 
indicating that stirring time of 4 hours would be sufficient to achieve maximum loading. 
Also, drug loading decreased with increase in the temperature and could be due to 
increase in drug-solvent interactions at a higher temperature. Drug loading was found to 
increase with an increase in the quantity of AC up to 1000 mg per 10 mL of drug solution, 
after which no significant increase in drug loading could be seen. Overall, these studies 
have demonstrated that successful optimisation of drug loading into activated carbon 
must consider several factors to achieve maximum loading without any crystallisation. 
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 -Effect of surface chemistry and porosity of activated carbon 
on drug loading and release 
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5.1. Introduction 
When employing a porous carrier, such as activated carbon, in the realm of drug delivery, 
the key properties of surface chemistry and porosity are important characteristics, since, 
amongst other aspects, they may affect the drug loading and release profiles (Lai et al. 
2017; Limnell et al. 2007). Results from previous chapters have shown the potential of 
activated carbon as a drug carrier with a high drug loading capacity and with an ability 
to inhibit crystallisation of loaded drug; however, complete drug release could not be 
achieved in the absence of SDS and was attributed to the poor wettability of AC, leading 
to inaccessibility of the dissolution medium to the deeper micropores. Activated carbon 
is generally hydrophobic and has poor wettability, due to its preparation method 
involving high-temperature treatment, resulting in the loss of functional groups (Liu et 
al. 2008). However, several oxygen-containing groups, such as phenol, carboxyl, and 
lactone, might still be present in low quantities at the edges of the micropores, due to the 
presence of free valence carbon atoms at these sites. The quantity of such oxygen-
containing groups on the surface can affect the polarity of AC, thereby affecting 
interaction with water (Ahnert  H. A.; Pinto, N. G. 2009). Oxygen groups on the surface 
of AC can interact with water molecules through hydrogen bonding, thereby increasing 
the hydrophilicity of AC, which, in turn, may affect the drug loading and release (Hayati 
& Mahmoodi 2012; Yin et al. 2007). Several modification techniques, such as acidic 
treatment, basic treatment, heat treatment and impregnation with surfactants have been 
studied previously to increase oxygen-containing groups on AC surface (Table 5-1). 
However, such modifications also resulted in some disadvantages, such as reduction in 
surface area, reduction in adsorption capacity and release of SO2 or NO2 gases (Yin et al. 
2007; Ahnert  H. A.; Pinto, N. G. 2009; Li et al. 2002). 
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Table 5-1: Types of treatments used for modification of surface chemistry of carbon based materials 
Treatment Effect on surface chemistry and 
porosity of carbon based materials 
Reference 
Boiled in HNO3 (5N) 
solution for 10 hours under 
a reflux.  
Total acidic groups of AC increased by 6 
times and BET surface area decreased 
from 604 m2/g to 399 m2/g. 
(Jaramillo et al. 
2010) 
Treated with H2SO4/HNO3 
(3:1) at room temperature 
for 3 hours. 
The increase in the carboxylic and 
hydroxyl groups in carbon nanotubes. 
(Li et al. 2005) 
Immersed in HNO3/H2SO4 
mixture at 100 ºC under N2 
atmosphere for 24 hours. 
Hydroxyl and epoxy groups increased 
from 1.58 to 10.08% in graphite. 
(Shin et al. 2013) 
Boiled in HNO3 (4M) 
solution for 1 hour. 
Total acidic groups of AC (mmol/g) 
increased by 22.8 times and total basic 
groups (mmol/g) decreased by 4.6 times. 
(Ahnert  H. A.; 
Pinto, N. G. 2009) 
Heated with conc H2SO4 for 
3 hours at 80 ºC. 
Total acidic groups of AC (mmol/g) 
increased by 2.2 times and BET surface 
area increased from 991 to 1113 m2/g. 
(Terzyk & 
Rychlicki 2000) 
Treated with  HNO3 (6N) 
solution for 5 hours at room 
temperature 
BET surface of AC decreased from 1136 
to 1088 m2/g and carboxyl groups 
increased from 2 to 29 mmol/100g. 
(Li et al. 2003) 
Treated with 1-5 N NaOH 
for 24 hours at room 
temperature 
The total surface oxygen-containing 
groups of AC (meq/g) increased by 1.86 
times when treated with 2N and 4N 
NaOH. 
(Chiang et al. 
2002) 
Treated with 35% NaOH 
solution for 24 hours 
BET surface area in AC decreased from 
1013 to 807 m2/g and base value 
increased from 173 to 420 meq/g.  
(Park & Jang 
2002) 
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In addition to surface chemistry, the porosity of the carrier might also affect drug loading 
and release. Carriers with smaller pore size and longer pore channel were found to exhibit 
slower drug release (Zhang et al. 2010; Horcajada et al. 2004), indicating that carriers 
with a high fraction of micro porosity and large particle size could be disadvantageous in 
achieving faster release.  
5.2. Aim and objectives 
The aim of this current chapter, therefore, is to investigate the effects of carrier 
characteristics, namely surface chemistry and porosity, on drug loading and release. To 
achieve this, the main objectives of this study were to: 
1. Modify the surface chemistry of AC (G60 type) by three different surface 
treatment methods. 
2. Investigate the surface chemistry and porosity of surface treated AC, using XPS, 
FTIR, and nitrogen sorption techniques. 
3. Evaluate the effect of surface treatment of AC on drug loading and release. 
4. Evaluate the effect of porosity on drug loading and release using four different 
types of AC.  
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5.3. Results and Discussion 
5.3.1 Effect of surface chemistry of activated carbon on drug loading and release 
To consider the effects of the surface chemistry of the carrier on drug loading and release, 
AC was treated to modify its surface chemistry with HNO3, NaOH and a mixture of 
H2SO4/HNO3 separately, as described in section 2.7. The treated ACs were referred to as 
AC- HNO3 and AC-NaOH, respectively. Treatment with strong acids, such as nitric acid, 
is the most commonly used method to incorporate oxygen groups, where the extent of 
oxidation was found to depend on the concentration and temperature of the oxidant 
(Jaramillo et al. 2010). Furthermore, nitric acid in the presence of sulphuric acid is a 
stronger oxidant and can penetrate the deeper layers of carbon structure, potentially 
enabling more extensive oxidation of the carrier surfaces (Shin et al. 2013). Basic 
treatment has also been employed to modify the surface chemistry of AC and was found 
to improve the adsorption of organic compounds; during treatment with NaOH, hydroxyl 
ions might react with the surface functional groups of AC, resulting in an increase in the 
number of lactone, carboxylic and phenolic functional groups (Chiang et al. 2002).  
5.3.1.1. Characterisation of surface chemistry of modified activated carbon  
The surface chemistry of AC before and after surface treatment was examined using XPS 
analysis. XPS spectra of all samples (Figure 5-1) showed two peaks corresponding to 
carbon (C 1s) and oxygen (O 1s), marked at 284 eV and 532 eV, respectively, while 
spectra of AC-H2SO4/HNO3 and AC-HNO3 showed an additional peak corresponding to 
nitrogen (N 1s), marked at 400 eV. Peaks corresponding to tin (Sn 2p) and silver (Ag 3d), 
marked at 495 eV and 377 eV, respectively (Daniel et al. 2013), were also found in AC-
H2SO4/HNO3 could have originated from the internal structure of AC as a result of 
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opening of some pores during treatment with the mixture of H2SO4 and HNO3 or could 
be from contamination during analysis (Terzyk 2001).  
Relative atomic contents (Table 5-2) were calculated from the peak areas and results 
indicated that, post treatment, the atomic percentage of carbon decreased while the atomic 
percentage of nitrogen and oxygen increased, indicating the increase in the number of 
oxygen containing groups. AC treated with a mixture of H2SO4 and HNO3 exhibited the 
highest percentage of surface oxygen content compared to HNO3 and NaOH treatments 
and could be due to the stronger oxidising nature of nitric acid in the presence of sulphuric 
acid (Shin et al. 2013). 
Table 5-2: The relative atomic contents of carbon, oxygen, and nitrogen of activated carbon before and 
after surface treatment determined from XPS analysis. 
Sample 
 
Relative atomic contents 
C (%) O (%) N (%) 
AC 95.69 4.31 -- 
AC-NaOH 93.96 6.04 -- 
AC- HNO3 91.09 8.16 0.75 
AC-H2SO4/HNO3 70.17 27.78 2.06 
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Figure 5-1: XPS spectra of pristine activated carbon (AC) and surface treated activated carbon (AC- HNO3,  
AC- NaOH, and AC- H2SO4/HNO3). The major peaks are marked for Carbon (C 1s), Nitrogen (N 1s) and 
Oxygen (O 1s) present on the surface. Note that the intensity scale is arbitrary. 
 
 
FTIR was employed to further confirm the presence of surface oxygen groups and to 
identify the types of functional groups present on the surface of treated AC. No significant 
difference was found in the FTIR spectra of AC, AC-NaOH, and AC-HNO3, since there 
was only a slight increase in the oxygen content post treatment (Table 5-2).   However, 
AC-H2SO4/HNO3 exhibited a broad band between 2600 and 3500 cm
-1, which can be 
attributed to O-H stretch, and a strong absorption band at 1717 cm-1, which can be 
assigned to C=O groups, indicating the presence of carboxylic acid groups. The peak at 
1560 cm-1 is attributed to carboxylate anion stretch mode (Atieh et al. 2010; Rios et al. 
2003). FTIR studies suggested that AC treated with a mixture of H2SO4 and HNO3 is an 
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effective method to incorporate oxygen groups compared to treating with NaOH or HNO3 
supporting the results from XPS. 
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Figure 5-2: FTIR analysis of pristine activated carbon (AC) and surface treated activated carbon.  AC 
treated with a mixture of H2SO4 and HNO3 (AC-H2SO4/HNO3) exhibited peaks corresponding to carboxylic 
acid groups. Note that the transmittance scale is arbitrary. 
 
5.3.1.2. Characterisation of porosity of modified activated carbon 
The porosity of AC before and after surface treatment was studied using nitrogen sorption 
analysis. The adsorption/desorption isotherms (Figure 5-3) of AC- HNO3 and AC- NaOH 
was found to be very similar to that of pristine AC, indicating that there was no significant 
change in the porosity due to surface treatment with HNO3 and NaOH; however, a 
significant reduction in the absorption was found in the adsorption/desorption isotherm 
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of AC-H2SO4/HNO3, indicating a reduction in the porosity due to treatment with mixture 
of H2SO4 and HNO3 solution. Similar results were found in previous reports where the 
porosity reduced by 34% (Bhatnagar et al. 2013) and could be due to the penetration of 
acid through breaking of the graphitic layers (Shin et al. 2013). 
Specific surface area and pore volume were determined using BET and NLDFT theory 
and revealed that surface area and pore volume were reduced by 5.3 and 6.2 times, 
respectively, in AC-treated with AC-H2SO4/HNO3 (Table 5-3). Nevertheless, although 
pore volume reduced significantly for AC-H2SO4/HNO3, the pore size distribution was 
found to be similar to that of pristine AC indicating that reduction in the surface area and 
pore volume is due to the destruction of significant amount of pores and not due to the 
narrowing of pores by surface oxygen groups.  Conversely, for AC-HNO3, although there 
was no significant difference in the surface area and pore volume compared to pristine 
AC, pore size distribution curves (Figure 5-4) revealed that pore size distribution became 
broader in the range of 5-14 nm and shifted towards lower pore size, which could be due 
to the increase in surface oxygen groups resulting in narrowed pores (Strelko & Malik 
2002). 
No difference in the pore size distribution could be seen in the case of AC-NaOH and 
could be due to the lower amount of surface oxygen content compared to other samples  
Porosity analysis suggested that treatment with a mixture of H2SO4 and HNO3 solution 
is disadvantageous despite the increase in surface oxygen content, due to the reduction in 
the porosity.  
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Figure 5-3: Nitrogen adsorption/desorption isotherms at 77 K of pristine activated carbon and surface 
treated activated carbon. Significant reduction in the adsorption was observed in the activated carbon 
treated with a mixture of H2SO4 and HNO3 (AC-H2SO4/HNO3). 
 
 
Table 5-3: Surface area and pore characteristics determined from nitrogen sorption analysis of pristine 
activated carbon and surface treated activated carbon. Significant reduction in the surface area and pore 
volume was observed in the activated carbon (AC-H2SO4/HNO3) when treated with a mixture of H2SO4 
and HNO3 solution. 
Sample Specific surface areaa 
(m2/g) 
Total pore volumeb  
(cm3/g) 
Micropore volumeb 
(cm3/g) 
AC 1027.4 0.81 0.33 
AC- HNO3 1008.8 0.83 0.33 
AC-NaOH 1021.7 0.79 0.32 
AC-H2SO4/HNO3 193.7 0.13 0.066 
aCalculated using Brunauer-Emmett-Teller (BET) theory  
bDetermined by NLDFT theory assuming slit-shaped pores. 
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Figure 5-4: Pore size distribution (2-14nm) calculated using NLDFT slit-shaped pore model of pristine 
activated carbon (AC) and surface treated activated carbon. Despite significant reduction in the pore 
volume, pore size distribution of AC-H2SO4/HNO3 was found to be similar to that of pristine AC. 
 
5.3.1.3. Drug loading and release from modified activated carbon 
To determine the effect of surface chemistry on drug loading and release, PA was loaded 
into AC, AC-HNO3, AC-NaOH, and AC-H2SO4/HNO3 using the previously optimised 
solution adsorption-centrifugation method. 1000 mg of AC was added to 10 mL of 
saturated PA solution (150 mg/mL of ethanol) and was allowed to undergo stirring (100 
rpm) at 20 oC for 4 hours.  
Statistically significant differences (p < 0.001, one-way ANOVA) in the drug loading 
was observed for AC before and after surface treatment (Figure 5-5). Also, a post hoc test 
showed that there was no statistically significant difference (p > 0.05, Dunnett’s multiple 
comparison test) in the drug loading for AC- HNO3 and AC-NaOH compared to that of 
pristine AC, and the difference in the drug loading was only in the case of AC-
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H2SO4/HNO3. To determine whether the difference in the drug loading was due to the 
porosity or surface oxygen content of AC, a Pearson’s r test was used. A stronger and a 
more significant positive correlation (r =0.999, p <0.001) was found between the surface 
area of AC and % drug loading compared to the surface oxygen content of AC, indicating 
that the lower drug loading in the case of AC-H2SO4/HNO3 was due to the reduction in 
the porosity, since drug loading decreases with decrease in the porosity; effect of porosity 
on drug loading will be discussed in the later parts of this chapter. 
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Figure 5-5: Drug (paracetamol) loading efficiency of pristine activated carbon (AC) and surface treated 
activated carbon (AC-NaOH, AC-HNO3, and AC-H2SO4/HNO3). Statistically significant differences 
compared to control (AC) are noted for p < 0.05 (** p < 0.01, one-way ANOVA and Dunnett’s multiple 
comparison test). Results are the mean of triplicate experiments ± SD. 
 
To study the effect of surface treatment on drug release, 50 mg of drug/carrier complex 
was added to 100 mL of phosphate buffer (pH 5.8) and was allowed to undergo stirring 
for 24 hours. Statistically significant differences (p < 0.0001, one-way ANOVA) in the 
drug release were observed for AC before and after surface treatment (Figure 5-6). Also, 
a post hoc test showed that there was no statistically significant difference (p > 0.05, 
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Dunnett’s multiple comparison test) in the drug release between AC-NaOH compared to 
that of pristine AC, indicating that treatment with NaOH was ineffective in improving 
the drug release.  
To determine whether the difference in the drug release was due to the porosity or the 
surface oxygen content of AC, a Pearson’s r test was used. In contrast to drug loading, a 
stronger and a more significant positive correlation (r =0.991, p <0.01) was found 
between the surface oxygen content of AC and % drug release compared to the surface 
area of AC. Also, a complete drug release was achieved in the case of AC-H2SO4/HNO3 
and could be attributed to increased wettability due to surface oxygen groups, thereby 
leading to increased accessibility of dissolution medium to the pores. However, complete 
drug release could be due to the adsorption of drug in the superficial mesopores and 
macropores since most of the microporosity is lost during the treatment.  
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Figure 5-6: Effect of the surface oxygen content of pristine and surface treated activated carbon on drug 
(paracetamol) release. Drug release was determined in phosphate buffer post stirring for 24 hours. 
Statistically significant differences compared to control (AC) are noted for p < 0.05 (* p < 0.05; **** p < 
0.0001, one-way ANOVA and Dunnett’s multiple comparison test). Results are the mean of triplicate 
experiments ± SD. 
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5.3.2. Effect of porosity of activated carbon on drug loading and release 
5.3.2.1. Particle size and porosity analysis of activated carbon 
To determine the effect of porosity on loading and release, different types of AC were 
purchased and drug loading was performed using PA as a model drug. Prior to drug 
loading, AC samples were characterised for particle size and porosity. AC used in the 
previous chapters is also used in this particular study and will be referred to as AC-G60 
In addition, three other types of AC obtained under different manufacturing conditions 
were also used and will be referred to as AC-KB, AC-USP, and AC-C9157.  
Laser diffraction studies revealed that all the samples have a broad particle size (Figure 
5-7 and Table 5-4). The average particle size of AC-G60, AC-USP, and AC- C9157 is 
very similar and is in the range of 29-35 µm, whereas the particle size of AC-KB is much 
lower, with an average size of 19.82 µm.   
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Figure 5-7: Particle volume size distribution of four different types of activated carbon obtained from laser 
diffraction analysis. All samples have a broad particle size distribution in the range of 0.5 to 100 µm. 
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Table 5-4: Particle size characteristics of four different types of activated carbon obtained from laser 
diffraction analysis.  
Material X90a (µm) X50b (µm) X10c (µm) Volume mean 
diameter (µm) 
Span 
AC-G60 40.59 ± 0.53 12.62 ± 0.09 3.92 ± 0.02 17.85 ± 0.15 2.91 ± 0.02 
AC-KB 37.25 ± 0.31 17.83 ± 0.22 5.53 ± 0.14 19.82 ± 0.21 1.78 ± 0.02 
AC-C9157 63.34 ± 1.55 23.46 ± 0.76 7.19 ± 0.23 29.92 ± 0.86 2.39 ± 0.03 
AC-USP 68.43 ± 0.12 29.41 ± 0.16 7.91 ± 0.1 34.33 ± 0.09 2.06 ± 0.01 
aParticle dimension corresponding to 90% of the cumulative undersize distribution 
bMedian particle dimension  
cParticle dimension corresponding to 10% of the cumulative undersize distribution 
 
Porous characteristics of the four types of AC were studied using nitrogen sorption 
analysis. The adsorption/desorption isotherm (Figure 5-8) of all four types of AC 
exhibited a typical type IV isotherm and a hysteresis loop at relative pressure (P/Po) equal 
to 0.45, characteristic of microporous materials with significant mesoporosity (Chen et 
al. 2010). AC-KB exhibited a sharp increase in the adsorption, indicating a more uniform 
pore size compared to other types of AC (Izquierdo-Barba et al. 2005), in line with the 
results from laser diffraction analysis. Specific surface area was determined from 
adsorption/desorption isotherms using the BET model, which revealed that AC-KB has 
the highest surface area of 1386.9 m2/g, while AC-USP has the lowest surface area of 
888.6 m2/g, out of the four samples (Table 5-5). Pore volume and pore size results were 
determined using non-local density functional theory (NLDFT) model assuming slit-
shaped pores and revealed that all the AC samples exhibited a broad distribution in the 
range of 2-14 nm, with AC-G60 and AC-USP showing very similar pore size distribution 
  
140 
 
(Figure 5-9) whereas AC-KB was found to have a broader pore size distribution 
compared to other types of AC since it was manufactured using chemical activation; 
Chemical activation was found to result in higher porosity compared to steam activation 
(Maciá-agulló & Linares-solano 2004). 
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Figure 5-8: Nitrogen adsorption/desorption isotherms at 77 K of four types of activated carbon. All samples 
exhibited a typical type IV isotherm and a hysteresis loop at relative pressure (P/Po) equal to 0.45, 
characteristic of microporous materials with significant mesoporosity.  
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Table 5-5: Surface areas and pore volumes of four different types of activated carbon 
 
Sample Specific surface 
areaa (m2/g) 
Total pore 
volume b (cm3/g) 
Micropore 
volume b (cm3/g) 
Micropore 
volume fraction 
AC-G60 1027.4 0.81 0.33 0.407 
AC-KB 1386.9 1.07 0.44 0.411 
AC-USP 888.6 0.61 0.29 0.475 
AC-C9157 1007.4 0.48 0.36 0.75 
 
aCalculated using Brunauer-Emmett-Teller (BET) theory 
bDetermined by NLDFT theory assuming slit-shaped pores. 
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Figure 5-9: Pore size distribution (2-14nm) determined using NLDFT slit-shaped pore model, of four 
different types of activated carbon. AC-G60 and AC-USP have a very similar pore size distribution and 
AC-KB has a wider range of pores compared to other types of AC. 
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5.3.2.2. Drug Loading 
To determine the effect of porosity on drug loading efficiency, PA was loaded into four 
different types of activated carbon (AC-G60, AC-KB, AC-USP, and AC-C9157) using 
solution adsorption-centrifugation method. 1000 mg of AC was added to 10 mL of 
saturated PA solution (150 mg/mL of ethanol) and was allowed to undergo stirring (100 
rpm) at 20 oC for 4 hours.  
Drug loadings obtained for different ACs were compared with corresponding total pore 
volume (Figure 5-10). There was a statistically significant difference in the drug loading 
(p<0.001, one way ANOVA) between different types of AC. To assess the relationship 
between porosity (surface area, total pore volume and micropore volume) and drug 
loading, a Pearson’s r test was used and there was a positive correlation (r =0.96, p <0.05) 
between total pore volume and % drug loading, indicating that carriers with high total 
pore volume could be advantageous to achieve high drug loading as seen in previous 
reports (Yu et al. 2014). 
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Figure 5-10: Drug loading efficiency of four different types of activated carbon. Drug loading was found 
to increase with increase in the total pore volume. Statistically significant differences are noted for P < 0.05 
(** p ≤ 0.01; one-way ANOVA and Tukey’s multiple comparison test). Results are the mean of triplicate 
experiments ± SD 
 
5.3.2.3. Drug Release 
To investigate the effect of porosity on the drug release of drug/carrier complex, 50 mg 
of drug/carrier complex was added to 100 mL of phosphate buffer at pH 5.8 and was 
allowed to undergo stirring for 24 hours and the quantity of drug in the buffer was 
determined by UV analysis.  
There was a statistically significant difference in the % drug release (p <0.001, one way 
ANOVA) between different types of AC (Figure 5-11). To assess the relationship 
between porosity (surface area, total pore volume, and micropore volume) and drug 
release, a Pearson’s r test was used. No correlation was found between surface area and 
total pore volume; however, there was a negative correlation (r = -0.97, p <0.05) between 
micropore volume fraction and % drug release, indicating that application of carriers with 
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less microporosity could be advantageous in achieving complete drug release. Also, a 
post hoc test showed that there was no statistically significant difference (p > 0.05, 
Tukey’s multiple comparison test) in the % drug release between AC-KB and AC-USP, 
even though there is a difference in the micropore volume fraction, indicating that there 
is an influence of some other factors, such as surface chemistry of carrier, on the drug 
release.  
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Figure 5-11: Drug release from four different types of activated carbon determined in phosphate buffer post 
stirring for 24 hours. Drug release was found to decrease with increase in the micropore volume fraction. 
Statistically significant differences are noted for P < 0.05 (* p < 0.05; **** p < 0.0001; one-way ANOVA 
and Tukey’s multiple comparison test). Results are the mean of triplicate experiments ± SD 
 
5.4. Conclusion 
The work in this chapter showed that drug loading and release are affected by the 
characteristics of AC, such as porosity and surface chemistry. Drug release from AC was 
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incomplete (56%) in the absence of SDS and was attributed to the inaccessibility of 
dissolution to micropores, due to the poor wettability of AC. Therefore, to achieve 
complete drug release and to understand the effects of the surface chemistry of AC on 
drug loading and release, AC was subjected to three different surface modification 
techniques. High surface oxygen content was achieved when AC was treated with a 
mixture of H2SO4 and HNO3 (AC-H2SO4/HNO3); however, porosity was reduced 
significantly, leading to reduced PA loading (8%). Drug release studies indicated that 
percentage drug release increased with increase in the surface oxygen content and a 
complete drug release (93%) was achieved in AC- H2SO4/HNO3. AC treated with HNO3 
(AC- HNO3) and AC treated with NaOH (AC-NaOH) showed a drug release of 60 and 
67%, respectively, indicating that treatment with NaOH and HNO3 is ineffective to 
achieve complete drug release. Although AC- H2SO4/HNO3 resulted in complete drug 
release, drug loading was reduced significantly, suggesting that an optimum surface 
treatment needs to be determined to achieve complete drug release without reducing the 
drug loading capacity. 
In addition to surface chemistry, porosity was also found to affect the drug loading and 
release. Paracetamol was loaded into four different types of activated carbon with 
different porosity characteristics and drug loading was found to increase with an increase 
in the total pore volume. However, drug release was found to decrease with an increase 
in the micropore volume fraction, indicating that total drug release could be improved 
when AC with low microporosity is used. 
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 -Synthesis of carbon onion for drug delivery applications 
 
 
 
 
 
 
 
 
Some of the results presented in this chapter have been presented in the paper:  
Miriyala, N., Kirby, D., Pazaras, I., Bo, Y., Ouyang, D., Ye, H (2017), “Synthesis and 
application of carbon onion for drug delivery” (in preparation) 
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6.1. Introduction 
Carbon onion (OLC) has attracted great interest for various electronic, tribological and 
biological applications and can be produced via thermal annealing of ND under vacuum 
or inert gas atmosphere (Costa et al. 2014; Bartelmess & Giordani 2014). 
ND used in the production of OLC are produced from detonation and consists of an sp3 
hybridised diamond core surrounded by sp2 hybridised amorphous carbon fragments, 
stabilised by nitrogen and oxygen containing functional groups. The presence of 
functional groups and sp2 carbon fragments in the ND structure results in the formation 
of tight aggregates reaching up to hundreds of nanometres in size which could only be 
disaggregated by functionalisation and this aggregation leads to the development of 
aggregate created porosity containing both open and closed pores. These primary 
aggregates form agglomerates up to several micrometres in size due to the presence of 
van der Waals interactions and can be broken down mechanically (Shenderova et al. 
2002). Thermal annealing of these agglomerates of ND results in the formation of 
aggregates of OLC of several micrometres in size.  
The particle size of OLC depends on the particle size of the ND used for the synthesis; 
the typical particle size of ND used for the synthesis of OLC is less than 10 nm, since 
smaller size NDs enable the graphitisation at lower temperatures compared to larger 
crystals (Joly-Pottuz et al. 2008; Terrones & Terrones 2003; Qian et al. 2004).  
The transformation of ND to OLC involves graphitisation from the surface to the core; 
as the temperature increases, the surface functional groups of ND decompose between 
200 and 700oC, undergoes a phase transformation from sp3 to sp2 hybridisation between 
700  and 1100 oC in order to reduce the surface energy and finally forms completely 
merged graphitised carbon shells between 1100 and 1300 oC (Zeiger, Jackel, et al. 2015). 
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The merging of graphite shells causes a significant decrease in the surface energy for the 
graphitised particles, which could be the driving force for the formation of spherical OLC. 
Formation of OLC from ND varies depending on the annealing conditions, such as 
annealing time, temperature and atmosphere, as shown in Table 6-1.  
Table 6-1:  Synthesis of carbon onion from nanodiamond at different annealing conditions 
Annealing 
temperature (°C) 
Annealing time 
(Atmosphere) 
Results Reference 
900-1400 1 hour (Argon) Carbon onions begin to form in the 
range of 1100–1200 °C with a 
diamond core. Complete 
transformation occurs at 1400 °C. 
(Qiao et al. 
2006a)  
1400 2 hours (Argon) 
 
Carbon onions formed initially are 
converted into graphitic ribbons. 
(Qiao et al. 
2006b)  
RT to 1150 1 hour (Argon) 
 
Graphitisation starts at 670 °C and 
ends at 1100 °C. 
(Xu et al. 
2002)  
1866 1 hour (Argon ) 
 
Graphitic ribbon structures are 
formed due to carbon redistribution. 
(Kuznetsov 
et al. 2004)  
700-1100 --(Vacuum)  
 
ND surface reconstructs below 900 °C 
and is progressively graphitised after 
900 °C. 
(Petit et al. 
2011)  
800-1700 1, 3 or 10 hours 
(Argon) 
At 1700 °C, polyhedral graphite 
crystals can be formed. Surface area 
increases until 1300 °C and then 
remains constant before decreasing. 
(Zeiger, 
Jäckel, et 
al. 2015)  
1600 13 minutes 
(Vacuum ) 
 
Carbon onion with graphitic shell and 
diamond core of 8 nm. 
(Joly-
Pottuz et al. 
2008)  
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6.2. Aims and Objectives 
 
The aim of this current chapter, therefore, is to perform thermal annealing of 
nanodiamonds at three different temperatures and study the effect of annealing 
temperature on the physicochemical characteristics. To achieve this, the main objectives 
of this study were to: 
1. Perform thermal annealing of nanodiamonds at 900, 1000 and 1100 ºC, under 
flowing nitrogen atmosphere. 
2. Investigate the effect of annealing temperature on the surface morphology, using 
SEM, and analyse the structural transformation, using Raman spectroscopy, XRD 
and TEM techniques. 
3. Study the effect of annealing temperature on the surface chemistry, using XPS 
and FTIR techniques, and to study the porosity using nitrogen sorption analysis. 
 
6.3. Results and discussion 
6.3.1. Surface morphology 
Pristine nanodiamonds appear to have a light greyish colour and with the increase in the 
annealing temperature from 900 to 1100 °C, ND powders transform from light grey to 
dark grey and finally to dark black at 1100 °C. SEM pictures also reveal a significant 
difference in the morphology of ND-1100 compared to pristine nanodiamonds, ND-900 
and ND-1000, as shown in Figure 6-1. ND-1100 showed tightly bound aggregates 
reaching up to 2 µm in size compared to other samples showing loosely bound 
agglomerates. During annealing ND undergoes a process of agglomeration and forms 
microparticles since ND particles have high agglomerating character, due to the surface 
  
150 
 
functional groups (El-Say 2011) resulting in the formation of OLC aggregates thereby 
leading to aggregate created porosity. 
 
Figure 6-1: Scanning electron microscope pictures showing the morphology of (A) pristine nanodiamond 
and nanodiamonds annealed at temperatures (B) 900, (C) 1000 and (D) 1100 °C. 
6.3.2. Structural characterisation 
Raman spectra of the nanodiamond samples before and after annealing are shown in 
Figure 6-2. The peak positions and peak full width at half maximum (FWHM) were 
determined by fitting spectra with a Gaussian line shape using Origin software and are 
shown in Table 6-2. 
The spectrum of pristine nanodiamonds (ND) showed two dominant peaks: one at 1325 
cm-1, corresponding to the sp3 diamond bonds (F2g) with  a small background of sp2 
disorder peak (D band), and the second at 1595 cm-1, corresponding to sp2 dimer bonds 
(G band), indicating the presence of amorphous carbon fragments characteristics of ND 
produced from detonation process (Qiao et al. 2006b; Xie et al. 2010).  
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Post annealing, spectra of samples consists of a broad D band in the region 1332-1350 
cm-1, attributed to increase in the sp2 disorder with a background of sp3 diamond. With 
the increase in temperature, the intensity of this D band increased, suggesting the 
transformation of sp3 to sp2 configuration (Chu & Li 2006).  
Also, with an increase in the annealing temperature, G band shifts downwards from 1594 
to 1568 cm-1 which could be due to the removal of functional groups and then shifts 
upwards to 1587 cm-1 which could be due to tensile strain induced from graphene planes 
becoming spherical. The FWHM of G band decreases after annealing to 1000 and 1100 
ºC, suggesting the increase in the long-range order of graphitic carbon. The G band of 
ND-1100 has the lowest FWHM, suggesting the high quality of graphitic shells around 
the diamond core. (Roy et al. 2003; Wang et al. 2005; Mochalin et al. 2013). The relative 
intensity of D and G bands (ID/IG) gives the degree of graphitisation during annealing, 
which is seen to gradually increase from 900 to 1100°C, suggesting the transformation 
from sp3 to sp2 configuration (Zeiger, Jäckel, et al. 2015). 
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Figure 6-2: Raman spectra of ND, ND-900, ND-1000 and ND-1100 (bottom to top) showing the F2g peak 
corresponding to the sp3 diamond at 1325 cm-1,  D band and G band corresponding to sp2 configuration at 
~ 1330 cm-1 and  ~1570 cm-1, respectively. Note that the intensity scale is arbitrary. 
 
Table 6-2:  Raman shifts, areal intensities and peak widths obtained from the spectra of pristine 
nanodiamonds and nanodiamonds annealed at different temperatures determined by fitting spectra with a 
Gaussian line shape using Origin software. 
Sample Peak position 
(cm-1) 
FWHMa 
(cm-1) 
Peak Assignment Areal intensity 
ratiob (ID/IG) 
ND 1325 
1594 
189.7 
116.4 
Diamond 
G- sp2 dimers  
- 
ND-900 1343 
1568 
215.85 
134.14 
D-sp2 disorder  
G-sp2 clusters 
1.4 
ND-1000 1345 
1588 
175.6 
97.5 
D-Graphite  
G-Graphite 
1.9 
ND-1100 1343 
1587 
204.7 
89 
D-Graphite  
G Graphite 
2.3 
a Peak Full width at half maximum 
b Relative intensity of D and G bands 
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The peak corresponding to diamond should still be present in the Raman spectra of ND-
1100, but could be masked by the intensive D peak. Hence, X-ray diffraction was used 
to investigate the presence of diamond core in ND-1100, using Miller indices {hkl} to 
identify different planes of atoms.  
The XRD pattern of ND (Figure 6-3) shows three diffraction peaks at 2θ: 43o {111}, 75o 
{220}, and 91o {311}, corresponding to diamond, and a peak at 29o {002}, corresponding 
to the sp2 carbon, (Tomita et al. 2002) suggesting the presence of amorphous carbon and 
supporting the results from the previous Raman data.  
The lattice spacing of various planes and intensities of peaks were compared between ND 
and ND-1100; in ND-1100, the peak at 43o has lower intensity (Table 6-3) compared to 
unannealed ND, suggesting a decrease in the diamond carbon.  
The FWHM of the diamond peak also increases after annealing, indicating the decrease 
in the crystallite size of ND (Xu et al. 2002). Since diffraction scattering corresponding 
to sp3 diamond phase is more intense and can often mask the sp2 signal, XRD data cannot 
be used to monitor the formation of sp2 carbon but can only be used to monitor changes 
in the diamond phase.  
Raman studies suggest that annealing of NDs resulted in the formation of sp2 carbon from 
sp3 carbon, whilst XRD studies suggest that sp3 diamond phase was still present post 
annealing NDs to 1100 °C. The interpretation of these results is to assume that ND-1100 
sample consists of particles with a diamond core surrounded by graphitic shells. 
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Figure 6-3: XRD patterns of ND and ND-1100 showing the diffractions of diamond and graphite planes 
showing peaks corresponding to diamond (d) planes at 2θ:  43o {111}, 75o {220} and 91o {311}, peaks 
corresponding to graphitic (g) planes at 29o {002}. Note that the intensity scale is arbitrary. 
 
Table 6-3: Summary of results obtained from XRD analysis of ND and ND-1100.  
Sample Miller indices 
{hkl} 
2θ (degrees) d Value (Å)a FWHM % Relative 
intensityb 
ND 002 29.87 2.99 5.66 12 
111 43.54 2.08 2.03 100 
220 75.17 1.26 2.02 13 
311 91.15 1.08 2.33 6 
ND-1100 002 29.61 3.01 6.25 20.9 
111 43.4 2.08 2.06 51.6 
220 75.11 1.26 1.93 6.2 
311 91.37 1.08 1.79 2.8 
aLattice spacing 
bRelative intensity is calculated by dividing the absolute intensity of each peak by absolute intensity of 
the most intense peak.  
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HRTEM was used to further confirm the presence of graphitic shells surrounding the 
diamond core in ND-1100. TEM images (Figure 6-4) of ND show a diamond core with 
a typical lattice spacing of ~ 2 Å {111} (Xiao et al. 2014), surrounded by amorphous 
carbon. TEM images of ND-1100 show diamond core surrounded by 3-5 graphitic shells, 
with a typical lattice spacing of ~ 3 Å {002} (Duffy et al. 2015) further supporting the 
data from Raman and XRD studies. 
      
 
Figure 6-4: Transmission electron micrographs of pristine nanodiamond (A, B) showing the lattice spacing 
of 2.06 Å corresponding to the plane {111} and nanodiamond annealed at 1100 °C (C, D)  showing the 
lattice spacing of 3.06 Å  corresponding to the plane {002}. 
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6.3.3. Chemical characterisation 
The surface chemistry of nanodiamonds before and after annealing was examined using 
XPS and FTIR techniques. XPS spectra (Figure 6-5) of ND contained an intense carbon 
(C 1s) peak and two weak peaks, corresponding to nitrogen (N 1s) and oxygen (O 1s), 
marked at 284, 400, and 532 eV, respectively. Also, a  series of CKLL Auger peaks 
appear between 1200 and 1240 eV that can provide information about the chemical 
bonding (Wu & Pendleton 2001; Titantah & Lamoen 2005). The atomic percentage of 
carbon increased while the atomic percentage of nitrogen and oxygen decreased as the 
annealing temperature increases (Table 6-4), which could be due to the reduction in the 
surface dangling bonds, such as –C-H and –C-O- bonds, at high temperatures (Xie et al. 
2010).  
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Figure 6-5: XPS spectra of pristine nanodiamonds (ND) and nanodiamonds annealed at different 
temperatures (ND-900, ND-1000 and ND-1100) . The major peaks are marked for Carbon (C 1s), Nitrogen 
(N 1s) and Oxygen (O 1s) present on the surface. Note that the intensity scale is arbitrary. 
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The relative contents of sp3 and sp2 carbon in the samples were determined by analysing 
the C-KLL X-ray excited Auger spectra (Table 6-4 and Figure 6-6) with the method used 
by Jones et al. (Jones & Ojeda 2012). The KLL spectrum was smoothened by Savitzy-
Golay with 15 points and differentiated with 9 points (Kaciulis 2012). The distance 
(energy ‘D’) between the maximum of positive excursion and the minimum of negative 
excursion of the first differential was determined.  
Post-annealing, D value was found to increase, indicating an increase in the content of 
sp2 carbon (Xie et al. 2010), consistent with the results from Raman spectroscopy. 
Relative contents of sp3 and sp2 carbon were determined from the linear interpolation of 
D value of 13 eV for diamond (100%- sp3) and 22 eV for graphite (100%- sp2). D value 
of ND was found to be 13 eV despite the presence of sp2 carbon as indicated from Raman 
and XRD data, and the exact reason for this is not clear. Sp2 content was found to increase 
to 13% post annealing to 900 ºC. Annealing to 1000 ºC significantly increased the sp2 
content to 63% which was found nearly four times to that seen in ND-900. The rate of 
increase of sp2 content decreased after 1000 ºC with ND-1100 showing sp2 content of 
68% indicating the successful conversion of sp3 diamond to sp2 graphite during 
annealing.  ND-1100 sample also contains 32% of sp3 carbon, indicating the presence of 
diamond core, consistent with the results from XRD and HRTEM analysis. 
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Figure 6-6: XPS C KLL Auger Spectra (Top) and their first derivatives (Bottom) as compared with pristine 
nanodiamonds (ND) and nanodiamonds annealed at different temperatures (ND-900, ND-1000 and ND-
1100). D parameter represents the width between maximum and minimum excursions of the derivative of 
Auger spectra. Note that the intensity scale is arbitrary.  
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Table 6-4: The relative atomic contents of carbon, oxygen, and nitrogen, and the relative atomic contents 
of different chemical states of carbon determined from XPS analysis. 
Sample C (%) O (%) N (%) C KLL Auger spectra 
Da ( eV) Sp2 (%) Sp3 (%) 
ND 93.8 3.9 1.9 13 0 100 
ND-900 95.6 2.7 1.7 14.2 13 87 
ND-1000 96.0 2.8 1.2 18.7 63 37 
ND-1100 97.1 1.6 1.0 19.1 68 32 
aD parameter represents the width between maximum and minimum excursions of the derivative of Auger 
spectra 
 
FTIR spectra of nanodiamonds before and after annealing are shown in Figure 6-7. The 
broad band between 3000 and 3600 cm-1 can be attributed to O-H and N-H vibrations, 
indicating the presence of amino groups and acid groups or adsorbed water, and the 
intensity of this band has significantly reduced after thermal treatment since these groups 
are unstable at high temperatures. Peaks around 2900 cm-1 could be assigned to aliphatic 
–C-H- vibrations of amorphous carbon fragments and are present in all the samples and 
have reduced in intensity after thermal treatment and could be due to the graphitisation 
of carbon. The peak at 2300 cm-1 is assigned to the CO2 from the ambient air (Jarre et al. 
2014). The band at 1690 cm-1 can be assigned to C=O group, indicating the presence of 
acid groups, which reduced significantly after thermal annealing. The multiple peaks 
between 1100 and 1500 cm-1 can be attributed to C-N and C-O groups, which have also 
reduced in intensity post annealing.  
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Figure 6-7: FTIR spectrum of pristine nanodiamonds and nanodiamonds annealed at different temperatures. 
Annealing nanodiamonds removed adsorbed water. *peak assigned to CO2 from ambient air. Note that the 
transmittance scale is arbitrary. 
 
The FTIR transmittance of various functional groups after thermal annealing is much 
smaller compared to pristine nanodiamonds, suggesting the reduction in surface dangling 
bonds, consistent with the results from XPS analysis. However, the functional groups 
were not completely removed and the presence of these functional groups on carbon 
onion surface results in higher stability and higher aggregation ability, due to 
intermolecular bonds between the functional groups, compared to carbon onions free of 
functional groups (Costa et al. 2014). 
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6.3.4. Porosity analysis 
N2 sorption analysis was performed to understand the changes in the porosity of ND 
before and after annealing since results from previous chapters indicated the infleunce of 
porosity on drug loading and release. N2 isotherms of all samples showed a type II 
isotherm and H3 hysteresis loop (Figure 6-8), corresponding to particles with aggregate 
created porosity (Jackel et al. 2014). The presence of hysteresis loop indicates the 
presence of capillary condensation, due to mesopores characteristic of ND aggregates and 
OLC aggregates produced from thermal annealing. The lower closure point of the 
hysteresis loop at high pressure (P/Po ~ 0.75) suggests that the mesopores were wide in 
size, since pore size affects the location of the capillary condensation (Monson 2012; 
Duffy et al. 2015). 
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Figure 6-8: N2 Sorption analysis as compared with ND and ND-1100. Nitrogen sorption isotherms showing 
Type II isotherm with a H3 hysteresis loop. Data for ND-900 and ND-1000 is not shown for clarity. 
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Pore size distribution curves (Figure 6-9) were determined using non-local density 
functional theory (NLDFT) model assuming slit-shaped pores. Pore size distribution 
curves of ND and ND-1100 samples in the diameter range of 3-30 nm are similar 
indicating that the agglomerate created porosity in the ND lead to the formation of intra 
aggregate porosity (Zeiger, Jäckel, et al. 2015). 
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Figure 6-9: Pore size distribution in the range 2-14 nm for ND and ND-1100 determined using non-local 
density functional theory model. Data for ND-900 and ND-1000 is not shown for clarity. 
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BET surface area was determined from the nitrogen adsorption isotherm and surface area 
was found to increase with increase in the annealing temperature (Table 6-5) and could 
be due to the changes in the density due to loss of functional groups, transformation from 
sp3 to sp2 carbon and change in the particle size.  The total pore volume and micropore 
volume in ND-1100 was also found to be slightly higher than ND and could be due to the 
opening of some closed pores (Zeiger, Jäckel, et al. 2015). The surface area of ND-1100 
is significantly less than that of AC and could be due to the absence of significant 
microporosity in ND-1100, however, pore volume was found to be higher than and could 
be due to the higher amount of mesopores present in the aggregates of ND-1100.  
Also when compared to the high surface area AC (1000 m2/g), ND-1100 with a surface 
area of 293.3 m2/g, could be disadvantageous as a carrier for drug loading, since drug 
loading capacity depends on the porosity of the carrier. 
 
 
Table 6-5: Surface area and pore characteristics calculated from nitrogen sorption analysis. 
Sample Specific surface 
area a (m2/g) 
Total pore volume b  
(cm3/g) 
Micropore volume b  (cm3/g) 
ND 256.7 1.16 0.018 
ND-900 259.2 1.13 0.018 
ND-1000 264.5 1.1 0.018 
ND-1100 293.3 1.2 0.027 
a BET specific surface area 
b Total volume in pores determined by NLDFT theory assuming slit-shaped pores 
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6.4. Conclusion 
In summary, nanodiamonds were annealed to three different temperatures (900, 1000 and 
1100 oC). Results from Raman and XPS analysis indicated an increase in sp2 carbon 
content with an increase in the annealing temperature. XRD and HRTEM studies 
suggested the presence of a diamond (sp3) core surrounded by graphitic (sp2) shells in 
nanodiamonds annealed at 1100 oC (ND-1100), suggesting that the transformation from 
sp3 carbon to sp2 carbon occurred in the direction of the outer layer to the core.  XPS and 
FTIR studies also indicated the presence of various oxygen and nitrogen containing 
functional groups on the surface of ND before and after annealing. The number of 
functional groups decreased with an increase in the annealing temperature, however were 
still present even after annealing the ND to 1100 oC. N2 sorption studies suggested a slight 
increase in the surface area after annealing to 1100 oC, which could be attributed to a 
change in the density, while the pore volume and pore size distribution remained almost 
constant. Post annealed ND-1100 will subsequently be referred to as carbon onion and 
its application in drug delivery will be investigated in chapter-7. 
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 - Application of carbon onion aggregates as a carrier for 
amorphous drug delivery 
 
 
 
 
 
 
 
 
 
 
Some of the results presented in this chapter have been presented in the paper:  
Miriyala, N., Kirby, D., Pazaras, I., Bo, Y., Ouyang, D., Ye, H (2017), “Synthesis and 
application of carbon onion for drug delivery” (in preparation) 
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7.1. Introduction 
Recently, carbon based materials with aggregate created porosity such as nanodiamond 
(ND), fullerenes, and carbon nanotubes (CNT) have been studied as potential drug 
carriers via physical adsorption (Lim et al. 2016; Zhu et al. 2012; Cui et al. 2016); 
however, the application of these materials in drug delivery is often associated with 
limitations, such as: 1) requirement of incorporating functional groups in ND to improve 
the interaction between the drug and carrier (Lim et al. 2016; El-Say 2011; Shenderova 
et al. 2002),  2) complicated synthesis of fullerenes with very low purity and yield (Mojica 
et al. 2013; Kyesmen et al. 2016), and 3) toxicity concerns of CNT (Bergin & Witzmann 
2013).  
Carbon onion or onion-like carbon (OLC) can overcome the aforementioned limitations 
by its ability to facilitate stronger pi-pi interactions between the aromatic groups of the 
drug and the graphene rings of OLC (Bielicka et al. 2013; Terrones & Terrones 2003; 
Costa et al. 2014), without the need of functionalisation. In addition, OLC can be prepared 
in large quantities via annealing of  nanodiamonds (ND) as described in chapter-6 and 
there are no reports indicating any significant toxicity of OLC (Zeiger, Jäckel, et al. 2015; 
Pakhira et al. 2016; Bartelmess & Giordani 2014). Also, OLC undergoes aggregation 
resulting in aggregate created mesoporosity with some microporosity, but compared to 
AC, OLC exhibits a relatively low surface area which could be disadvantageous since 
drug loading efficiency is proportional to the surface area of the carrier (Zeiger, Jäckel, 
et al. 2015). However, OLC can exhibit much stronger drug adsorption compared to AC 
due to the possible pi-pi interactions between the drug and spherical graphene layers of 
OLC (Bielicka et al. 2013). 
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The porosity of OLC aggregates and the possible pi-pi interactions can be advantageous 
for drug adsorption; therefore, exploring the potential of carbon onion in adsorption and 
release of drugs is of interest in this study.  
Results in the previous chapter demonstrated that annealing of nanodiamonds at 1100 ºC 
resulted in a sample (ND-1100) with the highest content of sp2 carbon, with onion-like 
graphene shells surrounding a diamond core (Chapter 6); hence, this sample was studied 
for drug loading and is referred to as OLC in this chapter. Paracetamol and Ibuprofen 
were used as model drugs to investigate the adsorption of drugs onto OLC. Adsorption 
of the drug onto OLC and release of the drug is schematically represented in Figure 7-1. 
 
 
Figure 7-1: Schematic illustration of drug loading and release from carbon onion aggregates. 
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7.2. Aims and Objectives 
The aim of this chapter is to investigate the application of carbon onion aggregates as a 
vehicle for drug delivery, using paracetamol and ibuprofen as model drugs. To achieve 
this, the main objectives were to: 
1. Investigate the particle size of carbon onion or onion-like carbon (OLC) and study 
the cytotoxicity of OLC using Caco-2 cells. 
2. Perform drug loading using solution adsorption method and study the effect of 
contact time on the drug loading efficiency. 
3. Study the effect of drug characteristics (solubility and loading concentration) on 
the drug loading efficiency and solid state characteristics using DSC and XRD 
techniques. 
4. Investigate the interactions between drugs and OLC and to understand if the drug 
loading was due to physical adsorption or chemical interaction using FTIR 
analysis.  
5. To study the drug release from the drug/OLC complex and analyse the porosity 
of OLC before and after drug loading using nitrogen sorption analysis. 
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7.3. Results and Discussion 
7.3.1. Characterisation of carbon onion 
The primary particle size of OLC depends on the primary particle size of ND used; 
however, the aggregate size depends on various factors, such as annealing temperature 
and aggregate size of ND used for the synthesis (Moseenkov et al. 2014). Detonation ND 
usually has a primary particle size of less than 10 nm; however, to reduce the surface 
energy, these primary particles often form tight aggregates of size 20-30 nm, and these 
primary aggregates form secondary aggregates of 100 nm to a few micrometres in size. 
The functional groups that are present on the surface of each ND facilitate the formation 
of such aggregates. In addition, the presence of van der Waals interactions between these 
aggregates often leads to the formation of agglomerates (Shenderova et al. 2002). 
Application of these agglomerates of ND as a starting material in the synthesis of OLC 
results in the production of aggregates of OLC bonded by graphitic layers (Moseenkov 
et al. 2014). 
OLC used in this study has an aggregate size in the range of 0.45- 21.5 µm (Figure 7-2 
and Table 7-1), with nearly 90% of the particles ≤ 10 µm in size. Toxicity studies of these 
OLC aggregates were performed on Caco-2 cells to determine the feasibility of 
application of OLC in oral drug formulations. The efficiency of uptake of microparticles 
is much lower compared to nanoparticles, therefore the risk of toxicity associated with 
these OLC aggregates can be much lower. However, studies have shown uptake of 
microparticles of size up to 10 µm by intestinal epithelium, with particles of size < 5 µm 
transported through lymphatics and particles of size > 5 µm retained in the Peyer’s 
patches (Desai et al. 1996), suggesting the importance of considering the toxicity of 
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microparticles. Hence, toxicity of OLC aggregates on Caco-2 cells was investigated by 
MTT assay. 
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Figure 7-2: Particle volume size distribution of carbon onion obtained from laser diffraction analysis. All 
samples have a broad particle size distribution in the range of 0.5 to 21.5 µm. 
 
 
Table 7-1: Particle size characteristics of four different types of carbon onion obtained from laser 
diffraction analysis. 
Material X10a (µm) X50b (µm) X90c (µm) Volume mean 
diameter (µm) 
Span 
Carbon 
onion 
0.88 ± 0.0 2.2 ± 0.0 7.45 ± 0.02 3.37 ± 0.01 2.99 ± 0.01 
a Particle dimension corresponding to 10% of the cumulative undersize distribution 
b Median particle dimension 
c Particle dimension corresponding to 90% of the cumulative undersize distribution 
 
OLC showed a significant effect (P<0.0001, one-way ANOVA) on the survival of Caco-
2 cells, with cell survival reduced when exposed to media containing OLC concentrations 
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≥ 400 µg/mL; however, the cell viability was still over 75% (Figure 7-3), suggesting OLC 
is a safe drug carrier for oral drug delivery. Cell uptake studies are necessary to determine 
the exact reasons behind the slight toxicity at high concentrations and also to investigate 
if the particles are being taken up by the cells. Also, producing OLC aggregates of particle 
size > 10 µm can eliminate the risk of internalisation by cells. 
Additionally, 10% of the OLC used in this study exhibited particle size < 1 µm. Although 
the objective was to use OLC for oral drug delivery, it is also important to consider the 
toxicity of inhalation of these particles.  Microparticles of size < 1 µm can deposit in the 
alveoli, where these particles can be taken by macrophages; however, most of the 
insoluble particles of this size are either exhaled or retained in the lungs (Luckey & 
Venugopal 1977). Since OLC aggregates are insoluble, the chance of internalisation is 
low, although synthesis conditions need to be optimised to eliminate the production of 
aggregates of size < 1 µm, to avoid the possibility of inhalation toxicity.  
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Figure 7-3: Cytotoxicity of carbon onion against Caco-2 cells. MTT assay was used to analyse the survival 
rate of Caco-2 cells incubated with different concentrations of carbon onion. Statistically significant 
differences compared to control (0 µg/mL) are noted for P < 0.05 (*P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** 
P ≤ 0.0001, one-way ANOVA and Dunnett’s multiple comparison test). Results are the mean of triplicate 
experiments ± SD. 
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7.3.2. Effect of contact time on adsorption of drugs onto carbon onion 
Diffusion of drug molecules into the pores of the carrier depends on the contact time 
between the drug and the carrier (Thomas 1983), as evidenced in chapter-4; therefore, to 
determine the contact time required for maximum loading, drug loading was performed 
as described in section-2.7.1. 
Results from both PA and IBU loading (Figure 7-4) showed a statistically significant 
difference in the drug loading of complexes obtained at different contact times (p < 0.05 
for PA and p < 0.001 for IBU; one-way ANOVA). A post hoc test showed that loading 
increased significantly with an increase in contact time up to 1 hour (p < 0.05 for PA and 
p < 0.001 for IBU; one way ANOVA followed by Tukey’s test) and there was no 
statistically significant difference (p > 0.05, Tukey’s multiple comparison test) in the drug 
loading of complexes obtained at contact time of 1-4 hours, suggesting that equilibrium 
was reached at 1 hour and could be attributed to the saturation of adsorption sites after 1 
hour of contact time. Therefore, all subsequent loadings were performed for 1 hour. The 
maximum drug loading efficiency was found to be 15.5% and 36.6% for PA and IBU, 
respectively. Higher drug loading of IBU is attributed to the higher concentration of IBU 
present in the loading solution similar to the results obtained with activated carbon 
(chapter 3) and the loadings achieved for OLC are only slightly less than AC (20.7% for 
PA and 44.4% for IBU) despite the huge difference in the surface area (surface area of 
OLC-293.3 and AC-1027.4 m2/g) and it could be attributed to the higher pore volume of 
OLC compared to AC (Total pore volume of OLC and AC is 1.2 and  0.81 cm3/g 
respectively).  
Also, the time taken to reach equilibrium is faster for OLC (1 hour) compared to AC (4 
hours) which could be attributed to the significant amount of micro porosity in AC 
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compared to OLC (micropore volume of AC and OLC is 0.33 and 0.03 cm3/g 
respectively)  requiring longer time for diffusion due to steric hindrance.  
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Figure 7-4: Effect of contact time on loading efficiency (stirring speed: 100 rpm; temperature: 20 oC; initial 
PA and IBU concentration: 150 and 698 mg/mL of ethanol respectively; solution volume: 5 mL; OLC dose: 
500 mg). Results are the mean of triplicate experiments ± SD. Statistically significant differences are noted 
for p < 0.05 (*p < 0.05, *** p < 0.001; ns-no significance; one-way ANOVA and Tukey’s multiple 
comparison test). 
 
7.3.3. Effect of initial concentration of drug on loading efficiency and solid state 
properties 
To determine the effect of concentration of drug in the loading solution on the loading 
efficiency, drug loading was performed as described in section-2.7.2. UV results 
indicated that, with the increase in the drug concentration, a statistically significant 
difference was found in the drug loading (p < 0.05 for PA and p < 0.01 for IBU; one-way 
ANOVA). Drug loading reached a maximum when the drug concentration in the loading 
solution reached the saturation point (Figure 7-5), indicating that drug loading can be 
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increased by increasing the initial concentration of drug in the loading solution similar to 
the results obtained with activated carbon (chapter-4).   
Thermal analysis results of PA/OLC complex with different drug loadings were 
compared. In the case of PA/OLC complex, complex with a drug loading of 15.5% 
exhibited a melting peak at 169 °C, suggesting the presence of crystallinity; however, 
complex with drug loading ≤ 11.5% did not show any crystallinity (Figure 7-6), which 
could indicate that saturation has been reached and any loading higher than 11.5% results 
in crystallisation of paracetamol which is less than the drug loading achieved with AC 
(26.8%) without any crystallisation.  
D r u g  C o n c e n t r a t io n  ( m g / m L  o f  e t h a n o l)
%
 D
r
u
g
 L
o
a
d
in
g
0 1 0 0 2 0 0 3 0 0 4 0 0 5 0 0 6 0 0 7 0 0
0
1 0
2 0
3 0
4 0
P a r a c e ta m o l
Ib u p r o fe n
*
**
 
Figure 7-5: Effect of initial drug concentration on loading efficiency (stirring speed: 100 rpm; temperature: 
20 oC; solution volume: 5 mL; OLC dose: 500 mg; contact time: 1 hour). Results are the mean of triplicate 
experiments ± SD. Statistically significant differences are noted for p < 0.05 (* p < 0.05, ** p < 0.01, one-
way ANOVA and Tukey’s multiple comparison test). 
 
Solid state characteristics of IBU/OLC complex with different drug loadings were also 
compared and complex with a drug loading of 31.6% and 36.6% exhibited a melting peak 
  
175 
 
at 74.8 °C, suggesting the presence of crystallinity; however, complex with loading 
20.7%, did not show any crystallinity (Figure 7-7), which could indicate that saturation 
has been reached and any loading higher than 20.7% results in crystallisation of 
ibuprofen, which is less than the drug loading achieved with AC (30.2%) without any 
crystallisation. The ability of AC to load more drug without crystallisation could be 
attributed to the higher fraction of microporosity in AC (40.7 %) compared to OLC 
(2.5%), since micropores can only accommodate a single layer of drug, unlike the 
mesopores that can allow multilayer drug adsorption thereby leading to crystallisation of 
the drug loaded. 
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Figure 7-6: DSC curves of carbon onion (OLC) and paracetamol loaded carbon onion (PA/OLC complex) 
with different drug loadings. Complex with drug loading ≤ 11.5% did not exhibit a melting peak indicating 
that the drug loaded was completely amorphous. Note that the heat flow scale is arbitrary. 
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Figure 7-7: DSC curves of carbon onion (OLC) and ibuprofen-loaded carbon onion (IBU/OLC complex) 
with different drug loadings. Complex with drug loading of 20.7% did not exhibit a melting peak indicating 
that the drug loaded was completely amorphous. Note that the heat flow scale is arbitrary. 
 
The results from DSC were confirmed by X-ray diffraction studies (Figure 7-8). XRD 
patterns of PA/OLC complex-11.5% did not show any peaks corresponding to crystalline 
PA, suggesting that the drug was completely present in an amorphous form. Similarly, 
IBU/OLC complex-20.7% did not show any diffraction pattern corresponding to 
crystalline IBU. Therefore, all subsequent studies were performed on PA/OLC complex-
11.5% and IBU/OLC complex-20.7% only, which showed no crystallinity in the sample. 
Results from DSC and XRD studies suggest that the optimum initial drug concentration 
to achieve drug/carrier complex without any crystallisation of drug is 100 mg/mL and 
300 mg/mL, for PA and IBU, respectively, to achieve a drug loading of 11.5% and 20.7% 
respectively, indicating the effect of initial drug concentration on the loading efficiency 
and solid state characteristics.  
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Similar to AC, loading achieved in the case of OLC for PA is lower than that achieved 
for IBU and could be due to the higher melting point of PA compared to IBU since drugs 
with higher melting point readily undergo crystallisation (Brent 2015). Possible 
hydrophobic interactions between IBU and OLC could also be responsible for the higher 
stability of the loaded IBU compared to PA. 
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Figure 7-8: XRD patterns of carbon onion (OLC) paracetamol-loaded carbon onion (PA/OLC complex) 
and ibuprofen-loaded carbon onion (IBU/OLC complex) with different drug loadings. Note that the 
intensity cale is arbitrary. 
 
7.3.4. Drug-carrier interactions 
FTIR studies suggested that ND contained functional groups such as C=O, O-H, and N-
H (Chapter-6). Post-annealing in OLC (ND-1100), these functional groups are still 
present, but have reduced in intensity. Therefore, it is important to consider possible 
chemical interactions between drugs and OLC, since these interactions can affect the 
chemical nature and stability of drugs. FTIR spectra of PA/OLC complex -11.5%  and 
PA/OLC phy mix containing an equivalent amount of drug as that of the complex (Figure 
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7-9) showed peaks corresponding to an NH amide band stretch at 3320 cm-1 and a broad 
phenolic OH stretch at 3129 cm-1, similar to that of Pure PA. Spectra of PA/OLC complex 
did not show any significant shift in the existing peaks or new peaks, confirming physical 
adsorption of PA. Also, spectra of IBU/OLC complex-20.7% and IBU/OLC phy mix 
containing an equivalent amount of drug as complex showed peaks corresponding to 
carbonyl CO stretch at 1694 cm-1, similar to pure IBU, and no new peaks were found, 
indicating the absence of any chemical interactions (Figure 7-10).  
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Figure 7-9: FTIR spectra of paracetamol (PA), carbon onion (OLC), paracetamol-loaded carbon onion 
(PA/OLC complex) and physical mixture of paracetamol and carbon onion (PA/AC phy mix). No chemical 
interactions could be detected between PA and OLC. Note that the transmittance scale is arbitrary. 
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Figure 7-10: FTIR spectra of ibuprofen (IBU), carbon onion (OLC), ibuprofen-loaded carbon onion 
(IBU/OLC complex) and physical mixture of ibuprofen and carbon onion (IBU/OLC phy mix). No 
chemical interactions could be detected between IBU and OLC. Note that the transmittance scale is 
arbitrary. 
 
7.3.5. In vitro drug release studies 
Release profiles of pure drug and drug/OLC complex are shown in Figure 7-11 and 
Figure 7-12. Drug release from PA/OLC complex in the absence of SDS was incomplete, 
with only 11.4 % release in 10 min and could be due to poor wettability of carbon onion 
(particles were found to sticking to the surface of the vessel). Similar to PA/OLC 
complex, drug release from IBU/OLC complex in the absence of SDS was incomplete; 
however, this was slightly higher, with 17.4% release in 10 min and could be attributed 
to higher drug loading in IBU/OLC complex.  In the presence of SDS, drug release from 
PA/OLC complex was complete in 15 min, and was significantly faster (p<0.0001, two-
way ANOVA) compared to pure PA. Similarly, drug release of IBU/OLC complex was 
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complete in 30 min and significantly higher (p<0.0001) compared to pure crystalline IBU 
in the presence of SDS.  
Compared to the pure drug, faster release in drug/OLC complex could be attributed to the 
amorphous nature of the drug loaded in complex and higher surface area that is in contact 
with the dissolution media, supporting the advantage of using OLC in amorphous drug 
delivery. 
Drug release profiles obtained in the presence of SDS for PA and IBU were fitted with 
simplified Higuchi model based on Fick’s law of diffusion which describes drug release 
from an insoluble matrix (Costa et al. 2001; Izquierdo-Barba et al. 2005).Higuchi square 
root of time plots for both drug loaded complexes in Figure 7-13, display a two-step 
release with an initial burst effect which could be attributed to the drug release from 
superficial pores followed by a slow release which could be attributed to the drug release 
from deeper micropores. Rate constants also suggest that drug release from OLC was 
slightly slower than that of AC and could be due to stronger adsorption between drug and 
OLC (Table 7-2).  
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Figure 7-11: Dissolution profiles of paracetamol (PA) and paracetamol-loaded carbon onion (PA/OLC 
complex) determined at pH 5.8. Curves PA-SDS and PA/OLC complex-SDS represent dissolution profiles 
determined in media containing 1% SDS. Statistically significant differences are noted for P < 0.05 (*P < 
0.05; **** P < 0.0001, two-way ANOVA and Bonferroni’s multiple comparison test).  Results are the mean 
of triplicate experiments ± SD.     
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Figure 7-12:  Dissolution profiles of ibuprofen (IBU) and ibuprofen-loaded carbon onion (IBU/OLC 
complex) determined at pH 5.5. Curves IBU-SDS and IBU/OLC complex-SDS represent dissolution 
profiles determined in media containing 1% SDS. Statistically significant differences are noted for P < 0.05 
(*P < 0.05; *** P < 0.001; **** P < 0.0001, two-way ANOVA and Bonferroni’s multiple comparison test). 
Results are the mean of triplicate experiments ± SD. 
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Figure 7-13: Two step regression linear utilising Higuchi’s square root of time plot for drug release from 
complex in the presence of SDS. In brackets pH of the dissolution medium. Each point represents the mean 
of n=3 determinations. 
 
 
Table 7-2: Kinetic parameters of drug release from paracetamol and ibuprofen loaded carbon onion 
Sample Higuchi diffusion two step 
Duration Rate constant Linear regression 
coefficient 
PA/OLC complex 
at pH 5.8 
3-10 min 
10-20 min 
46.34 
16.91 
0.999 
0.797 
IBU/OLC 
complex at pH 5.5 
3-10 min 
10-20 min 
48.07 
13.87 
0.94 
0.916 
 
 
7.3.6. Porosity analysis of carrier before and after drug loading 
Adsorption isotherms and pore size distribution curves of OLC before and after drug 
loading are shown in Figure 7-14 and Figure 7-15, with the data from N2 sorption studies 
summarised in Table 7-3. The adsorption/desorption isotherm of OLC exhibited a typical 
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type II isotherm and H3 hysteresis loop, corresponding to aggregate created porosity. The 
pore size distribution of pure OLC shows the presence of pores in the range of 2-14 nm. 
For PA/OLC physical mixture, a reduction in surface area and pore volume was observed, 
but the pore size distribution was similar to that of OLC, indicating that there was no drug 
present in the pores of OLC. However, for IBU/OLC physical mixture, pores in the range 
of 2-5 nm completely disappeared and the exact reason is not clear but could be due to 
the adsorption of IBU on OLC due to hydrophobic interactions resulting in some pores 
being blocked. Post loading, in PA/OLC complex, a reduction in the pore size was 
observed in pores in the range of 10-14 nm and the pore size distribution broadens in the 
range of 7.5-10.5 nm, suggesting the adsorption of PA into the pores of OLC. In the case 
of IBU/OLC complex, pores in the range of 2-5 nm completely disappeared and the pore 
size distribution broadens for pores in the range of 5-14 nm, which could be due to the 
reduction of pore size from drug loading. Also, the reduction in pore volume and surface 
area from IBU loading is much higher than that for PA loading indicating the higher 
affinity of IBU towards AC possibly due to hydrophobic interactions. 
Table 7-3: Surface areas and pore volumes obtained from Nitrogen sorption of carbon onion (OLC), 
ibuprofen-loaded carbon onion (IBU/OLC complex) and paracetamol loaded carbon onion (PA/OLC 
complex)  
Sample Specific surface 
areaa (m2/g) 
Total pore 
volume (cm3/g) 
Micro pore 
volumeb (cm3/g) 
OLC 293.3 1.2 0.03 
PA/OLC complex-11.5% 138.4 0.73 0.002 
PA/OLC phy mix-11.5% 210.1 0.86 0.015 
IBU/OLC complex-20.7% 46.1 0.27 0 
IBU/OLC phy mix-20.7% 65.4 0.38 0 
a Calculated  by BET method 
b Calculated by NLDFT method  
 
  
184 
 
 
O L C
R e la t iv e  p r e s s u r e  ( P / P o )
Q
u
a
n
ti
ty
 A
d
s
o
r
b
e
d
 (
c
m
³
/
g
 S
T
P
)
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
0
2 0 0
4 0 0
6 0 0
8 0 0
P A / O L C  c o m p le x - 1 1 .5 %
P A / O L C  p h y  m ix - 1 1 .5 %
( a )
 
R e la t iv e  p r e s s u r e  ( P / P o )
Q
u
a
n
ti
ty
 a
d
s
o
r
b
e
d
 (
c
m
³
/
g
 S
T
P
)
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
0
2 0 0
4 0 0
6 0 0
8 0 0
I B U / O L C  c o m p le x - 2 0 .7 %
O L C
I B U / O L C  p h y  m ix - 2 0 .7 %
( b )
 
Figure 7-14: Nitrogen adsorption/desorption isotherms at 77 K of carbon onion (OLC) before and after 
drug loading showing, (a) paracetamol loaded carbon onion (PA/OLC complex) and physical mixture of 
paracetamol and carbon onion (PA/OLC phy mix); (b) ibuprofen-loaded carbon onion (IBU/OLC complex) 
and physical mixture of ibuprofen and carbon onion (IBU/OLC phy mix). 
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Figure 7-15: Pore size distribution (2-14nm) calculated using NLDFT slit-shaped pore model of carbon 
onion (OLC) before and after drug loading showing- (a) paracetamol-loaded carbon onion (PA/OLC 
complex) and physical mixture of paracetamol and carbon onion (PA/OLC phy mix); (b) ibuprofen-loaded 
carbon onion (IBU/OLC complex) and physical mixture of ibuprofen and carbon onion (IBU/OLC phy 
mix). 
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7.4. Conclusions 
The current study investigated the application of carbon onion (OLC) aggregates as drug 
carriers using paracetamol and ibuprofen as model drugs. OLC aggregate microparticles 
exhibited very low cytotoxicity on Caco-2 cells with cell viability over 80% at all the 
concentrations tested (10–800 µg/mL). The solution adsorption method was employed 
for drug loading, as with activated carbon in previous chapters, and the results 
demonstrated that loading efficiency increased with an increase in the contact time, 
reaching a maximum loading (15.5% for PA and 36.6% for IBU) after one hour for both 
drugs and no further increase could be observed even after 4 hours, suggesting that 
equilibrium has been achieved after one hour. 
To understand the effect of initial drug concentration on the loading efficiency, drug 
solutions of varying concentrations were used for loading at a constant temperature. 
These studies have shown, that with an increase in initial drug concentration, loading 
efficiency increased reaching maximum when the initial drug concentration reached the 
saturation point. 
Results from thermal analysis and diffraction studies suggested that both PA/OLC 
complex and IBU/OLC complex with the highest loading showed crystallinity. The drug 
was found to be completely amorphous in PA/OLC complex and IBU/OLC complex with 
the loading of 11.5% and 20.7%, respectively, indicating that the concentration of drug 
in the loading solution needs to be optimised, to achieve complex without any crystalline 
drug. Furthermore, these maximum levels for amorphous drug loading were less than 
those seen with AC (26.8% and 30.2% for PA and IBU respectively) and could be due to 
lower surface area of OLC compared to AC, however the drug loading achieved for OLC 
were relatively high and could be due to higher pore volume of OLC compared to AC. 
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Drug release kinetics were studied using USP II dissolution method in sodium phosphate 
buffer with and without SDS. About 11.4% and 17.1% of the total loaded PA and IBU, 
respectively, was released; however, this was incomplete due to poor wettability of OLC 
in the absence of SDS. Complete drug release was achieved in the presence of SDS and 
dissolution rate was higher than that of the pure crystalline drug, establishing that drug 
loading was reversible and also faster due to amorphous nature of the drug loaded into 
OLC, suggesting that these results are promising for the development of carbon onion 
based drug delivery systems. 
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 -General discussion and conclusions 
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Drug solubility and dissolution play a crucial role in the development of drug delivery 
systems in order to achieve optimum bioavailability. Conversion of crystalline forms of 
drugs to the amorphous form has previously been found to improve the solubility and 
dissolution profile of drugs, due to the structural disorder and higher internal energy of 
amorphous forms. However, amorphous forms have poor stability and tend to convert 
into crystalline forms (Fasinu et al. 2011; Hancock & Parks 2000). Drug loading into 
porous materials has shown great potential in stabilising the amorphous form of drugs 
due to the restricted pore space and drug-carrier interactions; however, porous materials 
that have been investigated so far are associated with limitations, such as high cost of 
production, poor stability, high toxicity, and low loading capacity (Salonen, Laitinen, et 
al. 2005; Heikkilä et al. 2010; Ng et al. 2013). Therefore, it is important to explore porous 
materials that can overcome the aforementioned limitations. 
Recently, several porous carbon materials have been studied as carriers for drug delivery 
applications due to their high surface area, chemical inertness, and high chemical and 
thermal stability (X. Wang et al. 2011; Chen et al. 2016). Amongst those carbon 
materials, activated carbon (AC) was found to be inexpensive, commercially available 
with high surface area to volume ratio and with clinical applications as an antidote, which 
can favour the development of an efficient, cost-effective and safe carrier for oral drug 
delivery. AC has been previously investigated as a drug carrier for lymphatic targeting 
(Guo et al. 2011); however, there is no information on the drug loading efficiency, drug 
release kinetics, and application for amorphous drug delivery. 
In addition, carbon onion (OLC) is a novel carbon material that consists of several 
spherical graphene shells, which can result in possible pi-pi interactions with aromatic 
molecules, and also exhibits aggregate created pores, which can be potential adsorption 
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sites for drug molecules (Zeiger, Jäckel, et al. 2015; Reinert et al. 2015). OLC has been 
studied for its ability to cross the blood brain barrier and for application in cellular 
imaging, due to their ability to undergo cellular internalisation (Bartelmess & Giordani 
2014; Pakhira et al. 2016). However, there is no specific research on the application of 
OLC as a drug carrier. 
Therefore, investigating the potential of activated carbon and carbon onion as amorphous 
drug carriers for oral delivery formed the basis of this thesis.  
8.1. Activated carbon: Optimisation of drug loading method and factors affecting 
drug loading and release 
Activated carbon exhibited low toxicity on Caco-2 cells, indicating its safety for 
application in drug delivery. Paracetamol (PA) and Ibuprofen (IBU) were used as model 
drugs to investigate drug loading using solution adsorption method. Saturated drug 
ethanol solution was used as loading solution; the drug loading achieved and solid state 
characteristics of the drug in the complexes were different for PA and IBU, which was 
attributed to the difference in the initial concentration of drug in the loading solution 
indicating that application of saturated drug solution is not an ideal method to achieve 
completely amorphous drug loading. Also, in vitro release revealed that drug release was 
incomplete, which is attributed to the poor wettability of AC resulting in inaccessibility 
of the dissolution medium to the deeper pores. However, drug release was complete in 
the presence of sodium dodecyl sulphate (SDS) in the dissolution medium for both 
PA/AC and IBU/AC complexes, and is attributed to the reduction in surface tension 
between AC and dissolution medium. SDS molecules in the dissolution media could also 
be displacing the adsorbed drug molecules resulting in complete drug release since 
studies have reported that small molecules are displaced by larger molecules due to 
  
191 
 
competitive and displacement adsorption (Kawaguchi et al. 1986). Also, the release was 
faster compared to the pure crystalline drug and is attributed to the amorphous nature of 
the drug loaded and a higher surface that is in contact with the dissolution media.  
To achieve completely amorphous loading and to improve the drug release from AC, 
factors affecting drug loading and release were subsequently studied. Results revealed 
that drug loading is influenced by a range of factors, such as the loading method, initial 
concentration of drug in the loading solution, temperature, contact time and carrier dose, 
indicating that these factors need to be taken into consideration to achieve reproducibility. 
Solution adsorption followed by centrifugation was found to be the optimum method to 
achieve a complex with the least drug crystallinity compared to rotary evaporation and 
solution adsorption-filtration methods. Also, drug loading without any drug crystallinity 
was achieved when the initial concentration of the drug in the loading solution was 
optimised. However, the optimum concentration was different for PA and IBU, indicating 
the influence of the chemical nature of the drug and the requirement of optimisation of 
loading method for different drugs. Also, no chemical interactions could be detected 
between the drug and AC even at higher drug loading, supporting the physical adsorption 
of the drug. 
To improve the drug release, AC was surface treated and drug release was found to 
increase with an increase in the surface oxygen content, indicating that modification of 
surface chemistry improved the wettability thereby, improving the drug release. 
However, an increase in the surface oxygen content also resulted in the decrease in 
porosity, thereby leading to reduced drug loading, indicating that the surface treatment 
needs to be optimised to achieve improved wettability without reducing the drug loading 
capacity.  
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In addition to surface chemistry, porosity was also found to affect the drug loading and 
release. PA loading into four different types of AC with different porosity characteristics 
revealed that drug loading increased with an increase in the total pore volume, whilst 
drug release decreased with an increase in the micropore volume fraction, indicating that 
total drug release could be improved when AC with low microporosity is used. 
8.2. Carbon onion: synthesis and application as carrier for amorphous drug delivery  
To synthesise carbon onion for application in drug delivery, nanodiamonds were 
annealed to three different temperatures and results showed the presence of a diamond 
core surrounded by graphitic shells when annealed at 1100 oC; this was, therefore, 
referred to as carbon onion (OLC), and its application in drug delivery was investigated. 
OLC exhibited low toxicity on Caco-2 cells, indicating its safety for application in drug 
delivery. Drug loading studies indicated the ability of OLC to achieve complete 
amorphous loading; however, drug release was incomplete in the absence of SDS, similar 
to that of AC, due to the poor wettability of OLC. Drug release was complete in the 
presence of SDS and was faster compared to the pure crystalline drug, indicating the 
potential of OLC as an amorphous drug carrier. Also, no chemical interactions could be 
detected between the drug and OLC, indicating the safety of loading into OLC without 
changing the chemical nature of the drug. 
8.3. Activated carbon vs Carbon onion as a drug carrier 
Drug loading was found to reach an equilibrium faster in the case of OLC compared to 
AC and could be due to the significant amount of micro porosity in AC, requiring a 
longertime for diffusion due to steric hindrance.  
  
193 
 
Furthermore, when drug loading was performed using saturated drug solution, drug 
loadings achieved in OLC were less than those seen with AC and could be due to the 
lower surface area of OLC compared to AC; however, the drug loadings achieved for 
OLC were relatively high, despite the huge difference in the surface area, and could be 
due to the higher pore volume of OLC compared to AC. 
Post optimisation of drug loading method, the maximum drug loading achieved without 
any crystallinity was higher in AC compared to OLC, and this ability of AC to load more 
drug without crystallisation could be attributed to the higher fraction of microporosity in 
AC compared to OLC, since micropores can only accommodate a single layer of drug, 
unlike the mesopores that can allow multilayer drug adsorption resulting in crystallisation 
of the drug loaded. However, if the microporosity of the carrier is responsible for the 
higher capacity of stabilisation of amorphous drug, reducing the microporosity of AC to 
improve drug release could be disadvantageous, indicating that modifying the surface 
chemistry of AC is the ideal method to achieve complete drug release. 
Also, drug release in the absence of SDS was much lower in the case of OLC compared 
to AC, indicating the more hydrophobic nature of OLC. However, in the presence of 
SDS, drug release from both AC and OLC was very similar and faster compared to the 
pure crystalline drug.  
Nevertheless, both AC and OLC were found to be promising materials for application as 
amorphous drug carriers, especially AC, with its loading capacity and ability to stabilise 
amorphous drug similar to that of ordered mesoporous materials such as silica despite the 
disordered porous structure of the former. Additionally, AC is inexpensive, non-toxic, 
commercially available and is clinically used indicating the feasibility for commercial 
development of porous carrier based formulations.  
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8.4. Final conclusions 
To summarise, in relation to the thesis aims and objectives, these studies have shown 
that: 
1. Activated carbon and carbon onion exhibited low cytotoxicity in Caco-2 cells, 
indicating their safety for application in oral drug delivery. 
2. PA and IBU were loaded successfully into AC and OLC using solution adsorption 
followed by centrifugation method. 
3. Maximum loadings of 26.8% (PA) and 30.2% (IBU) without any drug 
crystallinity were achieved for AC, whilst for OLC the loadings were 11.5% (PA) 
and 20.7% (IBU). 
4. Drug loading efficiency and solid state characteristics of the drug loaded in both 
carriers were influenced significantly by the initial concentration of drug in the 
loading solution and the chemical nature of the drug. 
5. Drug release from both activated carbon and carbon was completely reversible 
and faster compared to the pure crystalline drug, indicating the potential of 
activated carbon and carbon onion as porous carriers for amorphous drug 
delivery. 
 
8.5. Future work 
The wettability of AC and OLC needs to be improved to further optimise the drug release. 
Surface treatment of activated carbon with nitric acid and sulphuric acid mixture resulted 
in loss of porosity, whereas treatment with nitric acid alone at room temperature did not 
show significant difference in the drug release; boiling with nitric acid under reflux for 
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different durations could be attempted to increase the surface oxygen content, without 
resulting in loss of porosity. Also, to improve the drug loading capacity of OLC, chemical 
activation to create porosity in the shells of OLC could be performed to increase the 
porosity, which can result in an increase in the drug loading. Residual solvent content in 
the carriers, post loading needs to be determined and other non-solvent drug loading 
methods can be investigated. Also, atomic force microscopy and polarised light 
microscopy could be employed to visually identify sites of drug adsorption.  Long term 
stability studies need to be performed to understand the ability of these carriers to 
maintain the amorphous nature of the drug on storage. In order to further understand the 
toxicity of AC and OLC, cell internalisation studies need to be employed.  
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